type,count,old_types
PKB,7,pKb ; pKB ; PKB ; pkb ; PKb ; pkB ; PkB
PKA,5,Pka ; pKA ; PKa ; pKa ; pka
DELTATM,5,deltaTm ; delta Tm ; Delta TM ; DeltaTm ; Delta Tm
ACTIVITY,5,Activity ; A ctivity ; activity ; Activit y ; Activ ity
KB,4,Kb ; kb ; K B ; KB
KH,4,KH ; Kh ; K H ; kH
2XAPTT,4,2x aPTT ; 2xAPTT ; 2x APTT ; 2 x APTT
KA,4,Ka ; ka ; KA ; K A
DELTAT,4,delta T ; Delta T ; Delta t ; deltaT
KR,4,KR ; Kr ; kr ; kR
KOBS,4,Kobs ; kobs ; k_obs ; K obs
KBAPP,4,Kbapp ; K Bapp ; KB app ; Kb app
KACT,4,K ACT ; Kact ; k act ; K act
LOGKA,4,logKA ; Log Ka ; logKa ; Log KA
LOGK'W,4,Log K'w ; Log k'w ; Log K'W ; Log k' w
KIAPP,3,Ki app ; KIapp ; Ki_app
PKA2,3,PKa2 ; pKa2 ; Pka2
AUCRATIO,3,AUC_ratio ; AUC ratio ; AUC Ratio
PD'2,3,PD'2 ; pD'2 ; PD' 2
RESIDUALACTIVITY,3,Residual Activity ; Residual activity ; Residual_activity
KON,3,Kon ; k_on ; kon
PALPHA,3,Palpha ; pAlpha ; p alpha
K12,3,k12 ; K1/2 ; K12
LOGPAPP,3,logPapp ; LogPapp ; LogP app
LOGKW,3,Log kw ; logKw ; Log Kw
PLASMAINSULIN,3,Plasma_insulin ; Plasma Insulin ; Plasma insulin
KCAT,3,k cat ; Kcat ; K cat
KREL,3,Krel ; K rel ; krel
LOGIC50,3,logIC50 ; Log IC50 ; LogIC50
PC,3,pC ; PC ; Pc
LOGD50,3,Log d50 ; LogD5.0 ; Log D50
TI,3,TI ; T.I. ; Ti
TC,3,T/C ; Tc ; TC
INCREASEINDPDTMAX,3,Increase in dP/dt max ; Increase in dP/dtmax ; Increase in dP/dTmax
KS,3,KS ; ks ; Ks
KINACT,3,K inact ; Kinact ; kinact
KIKI,3,ki/Ki ; Ki/ki ; Ki/KI
MAXACTIVATION,3,Max. activation ; Max activation ; max activation
KCATKM,3,Kcat/Km ; k cat/Km ; K cat/Km
RI,3,R.I ; Ri ; RI
-LOGKB,3,-Log KB ; -Log Kb ; -Log K B
CT,3,Ct ; C/T ; CT
KINACTKI,3,K inact/Ki ; kinact/Ki ; Kinact/Ki
LOGK,3,Log k ; log K ; Log K
EMAX,3,EMax ; E max ; Emax
KHOX,3,K HOX ; KHOX ; kHOX
K2,3,k2 ; k_2 ; K2
KOFF,3,koff ; k_off ; Koff
KOX,3,KOX ; kOX ; K OX
K2KI,3,k2 / Ki ; k2/KI ; k2/Ki
SI,3,SI ; S.I ; Si
KE,3,KE ; Ke ; ke
LOGT12,2,logt1/2 ; Log t1/2
VR,2,VR ; Vr
CV,2,CV ; c.v
POTENCYRATIO,2,Potency Ratio ; Potency ratio
NT,2,N/T ; NT
C8H,2,C 8 h ; C8h
GINDEX,2,G Index ; G index
PD50,2,PD50 ; PD 50
DRUGEXCRETION,2,Drugexcretion ; Drug excretion
MFI,2,MfI ; MFI
PM,2,Pm ; pM
DELTABP,2,Delta BP ; DeltaBP
%REMAINING,2,% remaining ; %Remaining
K-2,2,k-2 ; K-2
KOH,2,kOH ; KOH
FIC50,2,fIC50 ; FIC50
KD',2,Kd' ; KD'
WEIGHT,2,WEIGHT ; Weight
2XPT,2,2x PT ; 2X PT
PLADM,2,pLADm ; pLADM
PKA1,2,pKa1 ; PKa1
DELTARM,2,Delta RM ; deltaRm
KEQ,2,Keq ; keq
RELATIVEGROWTH,2,Relative growth ; Relative Growth
KDMPC,2,K DMPC ; KDMPC
PVALUE,2,P value ; p value
KIN,2,Kin ; kin
ABSORBANCE,2,absorbance ; Absorbance
C90,2,C90 ; c90
K',2,K' ; k'
DPDT,2,dP/dt ; dp/dt
KF,2,KF ; Kf
TMAX,2,Tmax ; T max
EC15,2,EC1.5 ; EC15
IDGTISSUE,2,I.D./g tissue ; ID/g tissue
QTCINTERVAL,2,QTc interval ; QTc Interval
FLUORESCENCE,2,fluorescence ; Fluorescence
KEFF,2,K eff ; k eff
NOOFAXONALBRANCHPOINTSCELL,2,No. of axonal branch points/cell ; No. of axonal branchpoints/cell
COMPOUNDRECOVERY,2,Compound Recovery ; Compound recovery
ACTIVITYINDEX,2,Activity_index ; Activity index
DTM,2,dTM ; dTm
AVERAGEPEAKCONCN,2,Average peak Concn ; Average peak Concn.
PT,2,Pt ; PT
PERMEABILITY,2,Permeability ; permeability
M2M1INDEX,2,M2/M1 index ; M2/M1 Index
PD,2,pD ; P/D
K-1,2,K-1 ; k-1
IAR,2,IAr ; IAR
TCMAX,2,tCmax ; T/C max
INHIBITIONOFCONTROL,2,inhibition of control ; Inhibition of control
KD,2,KD ; Kd
INHIBITIONINDEX,2,Inhibition index ; Inhibition_index
KDS,2,KDs ; Kds
LOGLD50,2,Log LD50 ; logLD50
FCMAX,2,fc max ; fCmax
FOLDREDUCTION,2,Fold_reduction ; Fold reduction
LOG(1C),2,log(1/C) ; Log (1/C)
GROWTHRATE,2,Growth Rate ; Growth rate
ALT,2,ALT ; ALT.
CHOLESTEROLLEVEL,2,cholesterol level ; Cholesterol level
DOSE,2,DOSE ; Dose
ED50,2,ED 50 ; ED50
I90,2,I90 ; I 90
ANTICONVULSANTACTIVITY,2,Anticonvulsant activity ; Anticonvulsant Activity
APOPTOTICACTIVITY,2,Apoptotic activity ; Apoptotic Activity
ST,2,ST ; S/T
HILLSLOPE,2,Hill slope ; HILLSLOPE
BSI,2,BSI ; BsI
LAMBDA-Z,2,lambda-z ; Lambda-z
GDPACTIVITY,2,GDP activity ; GDPactivity
LOGRA,2,Log RA ; logRA
KP,2,Kp ; kp
MAD,2,MAD ; M.A.D
AC,2,Ac ; AC
ED50RATIO,2,ED50 Ratio ; ED50 ratio
PARTITIONRATIO,2,Partition ratio ; partition_ratio
T,2,t ; T
CPM,2,CPM ; cpm
BWC,2,BWC ; bwc
APTT,2,APTT ; aPTT
K+2,2,k+2 ; K+2
RIC50,2,rIC50 ; RIC50
CSS,2,C ss ; Css
LOGKD,2,logKd ; Log Kd
IC,2,IC ; I/C
AESCORE,2,AE Score ; AE score
CLT,2,ClT ; CLT
N,2,N ; n
VMAXKM,2,Vmax/Km ; Vmax / Km
ALPHAKI,2,Alpha Ki ; alphaKi
PINHIBITION,2,pInhibition ; pinhibition
10E2K1,2,10E2 k1 ; 10E2 K1
IE,2,I/E ; IE
KIC,2,Ki.c ; Kic
ODCACTIVITY,2,ODC activity ; ODC Activity
KNBP,2,K NBP ; KNBP
CP,2,Cp ; C/P
PROTECTIVEINDEX,2,Protective Index ; Protective index
ND,2,ND ; N/D
CLP,2,CLp ; Clp
CR,2,Cr ; CR
RM,2,Rm ; RM
CONCENTRATIONPLASMA,2,Concentration_plasma ; Concentration_Plasma
ULCERINDEX,2,Ulcer Index ; Ulcer index
KC,2,Kc ; kc
ANALGESICACTIVITY,2,Analgesicactivity ; Analgesic activity
DP,2,DP ; D/P
LOGS,2,log S ; Log S
DELTAPH,2,deltapH ; Delta pH
T12,2,T1/2 ; t1/2
BEHAVIORALOBSERVATION,2,Behavioral observation ; behavioral observation
LOG1IC50,2,log1/IC50 ; Log 1/IC50
RETENTIONTIME,2,Retention time ; Retention_time
PXC50,2,PXC50 ; pXC50
GTP-GAMMASINDEX,2,GTP-gammaS Index ; GTP-gammaS index
K3K1,2,k3/k1 ; k3/K1
K05,2,K 0.5 ; K0.5
CURES@40MGKG,2,Cures@ 40 mg/kg ; Cures@ 40mg/kg
30DAYSURVIVALTOTAL,2,30 day survival/total ; 30 day survival / total
LOGK',2,Log k' ; Log K'
LOGP,2,logP ; LogP
K1,2,k1 ; K1
KI50,2,Ki50 ; KI50
BP,2,B/P ; BP
TT,2,TT ; Tt
ILSMAX,2,ILS max ; ILSmax
E12,2,E 1/2 ; E1/2
CFC20,2,CF C20 ; CFC20
IONIZATION,2,Ionization ; ionization
LOGKOW,2,log KOW ; Log Ko/w
PD2,2,pD2 ; PD2
INHIBITIONZONE,2,Inhibition zone ; Inhibition Zone
SCAVENGINGACTIVITY,2,Scavenging activity ; Scavenging Activity
CELLSURVIVAL,2,Cell survival ; Cell Survival
MORTALITY,2,Mortality ; mortality
KT,2,KT ; Kt
CMINSS,2,Cmin ss ; Cminss
CO,2,Co ; CO
KD1,2,Kd1 ; KD1
XI50,2,XI50 ; Xi50
CELLVIABILITY,2,Cell viability ; Cell Viability
DURATIONOFACTION,2,duration of action ; Duration of action
KD2,2,KD2 ; Kd2
PA2-PA10,2,pA2 - pA10 ; pA2-pA10
KIS,2,KIs ; Kis
FLUORESCENCEINTENSITY,2,Fluorescence Intensity ; Fluorescence intensity
GTPSHIFT,2,GTPshift ; GTP shift
LOGBB,2,logBB ; Log BB
FCMAXMIC,2,fc max/MIC ; fCmax/MIC
SELECTIVITY,2,Selectivity ; selectivity
-LOGMIC,2,-logMIC ; -Log MIC
PKP,2,pKP ; pKp
FOODINTAKE,2,Food intake ; food intake
LVDPDT,2,LV dP/dt ; LV dp/dt
KM,2,K m ; Km
PROTECTEDTESTED,2,Protected/tested ; Protected/Tested
KL,2,K L ; KL
AC50,2,Ac50 ; AC50
%ACTIVITYREMAINING,2,% activity remaining ; % Activity remaining
PLASMALEVEL,2,Plasma Level ; Plasma level
LOGI50,2,Log I50 ; logI50
PLASMAGLUCOSE,2,Plasma glucose ; Plasma_glucose
PRATIO,2,P ratio ; pRatio
BLOODPRESSURE,2,Blood Pressure ; Blood pressure
EA,2,Ea ; EA
KOBS1,2,k obs / 1 ; K obs / 1
KI',2,KI' ; Ki'
DELTAG,2,Delta G ; deltaG
LOG1GI50,2,Log 1/GI50 ; log1/GI50
TIME,2,Time ; TIME
-LOGKA,2,-Log KA ; -logKa
[3H]THYMIDINECPMDISH,2,[3H] thymidine cpm/dish ; [3H] thymidinecpm/dish
FOLDINCREASE,2,Fold increase ; Fold_increase
DELTAPEC50,2,Delta pEC50 ; deltapEC50
LOGD,2,LogD ; logD
CLM,2,CLm ; ClM
FA,2,Fa ; FA
KINX,2,Kin x ; KinX
FOLDSELECTIVITY,2,fold selectivity ; Fold selectivity
PA,2,PA ; Pa
K21,2,K21 ; k21
AE,2,AE ; Ae
GROWTHINHIBITION,2,Growth inhibition ; Growth Inhibition
CL,2,Cl ; CL
DELTALOGP,2,delta Log P ; delta logP
LOGEC50,2,logEC50 ; Log EC50
ED15,2,ED1.5 ; ED15
INHIBITION,2,Inhibition ; INHIBITION
DELTAPKI,2,Delta pKi ; deltapKi
IP,2,Ip ; IP
FM,2,Fm ; fm
LOGKI,2,Log Ki ; logKi
MAXINHIBITION,2,max inhibition ; Max inhibition
KMAX,2,Kmax ; kmax
REDUCTIONINRESPIRATORYVOLUME,2,Reduction in respiratory volume ; Reduction in respiratoryvolume
P50EP50C,2,P50e/P50c ; P50e / P50c
K,2,K ; k
LOGKILL,2,Log Kill ; Log kill
COMPLEXFORMATION,2,Complex formation ; Complex_formation
MAXPOTENTIATION,2,Max potentiation ; Max. potentiation
VM,2,Vm ; VM
TR,2,TR ; tR
PI,2,pI ; PI
DELTAVMAX,2,Delta Vmax ; delta Vmax
NOOFCULTURESACTIVETOTAL,2,No. of cultures active/total ; No. of culturesactive/total
KEL,2,Kel ; kel
PLASMACONCENTRATION,2,Plasma concentration ; Plasmaconcentration
K3,2,k3 ; K3
ECMAX,2,ECmax ; ECMax
KDAPP,2,Kdapp ; KD app
RF,2,Rf ; RF
P50C,2,P50C ; P50c
RELATIVEPOTENCY,2,Relative Potency ; Relative potency
PLADY,2,pLADy ; pLADY
LOGED50,2,logED50 ; Log ED50
EFFECT,2,effect ; Effect
BEHAVIOR,2,behavior ; Behavior
KDISS,2,Kdiss ; K diss
IDG,2,I.D./g ; ID/g
PKD,2,pKd ; pKD
TP,2,Tp ; TP
CLB,2,ClB ; CLb
KBIND,2,K Bind ; K bind
GRAFTSURVIVAL,2,graft survival ; Graft survival
LOGKB,2,logKb ; Log KB
MAXSTIMULATION,2,Max.stimulation ; Max stimulation
RATIOEC50,2,Ratio EC50 ; Ratio_EC50
LOGPI,2,Log PI ; logPi
RELATIVEBIOAVAILABILITY,2,Relative Bioavailability ; Relative bioavailability
KII,2,KII ; Kii
LOGGI50,2,logGI50 ; Log GI50
CI,2,CI ; C/I
RATIOKI,2,Ratio ki ; Ratio Ki
D50,2,d50 ; D50
GROWTHINDEX,2,Growth_index ; Growth Index
K3KI,2,k3/ki ; k3/Ki
EC5X,2,EC5X ; EC5x
SELECTIVITYINDEX,2,Selectivity index ; Selectivity Index
LOGK-IAMEX,2,LogK-IAMex ; logK-IAMex
KAPP,2,K app ; Kapp
PTD50,2,PTD50 ; pTD50
PLASMACHOLESTEROL,2,Plasma_cholesterol ; Plasma cholesterol
DELTATC,2,DeltaTC ; Delta TC
PMAX,2,pMax ; Pmax
CPMAX,2,CPmax ; Cp max
BA,2,BA ; Ba
LOG10CFU,2,log10cfu ; Log10 cfu
KO,2,Ko ; ko
%INHIBITION,2,% Inhibition ; % inhibition
SOLUBILITY,2,Solubility ; solubility
KN,2,kn ; Kn
LOGPE,2,log Pe ; Log Pe
PKABZ,2,pKa BZ ; pKabz
PLASMAGLUCOSELEVEL,1,Plasma glucose level
MDS,1,MDS
AMOUNTOFTXB2FORMATION,1,Amount of TXB2 formation
TOTAL,1,Total
KIK'I,1,Ki/K'i
DELTAPCA50,1,Delta pCa50
88Y-SERUM,1,88Y-serum
ANTIMICROBIALACTIVITY,1,Antimicrobial activity
CPSS,1,Cpss
TRABECULARTHICKNESS,1,Trabecular thickness
CARDIACOUTPUT,1,Cardiac output
LOG(RATIOKI),1,log(ratioKi)
KCATKUNCAT,1,k cat/Kuncat
DEGRADATIONRATECONSTANT,1,Degradation rate constant
RELK,1,rel k
[I],1,[I]
MESED50,1,MES ED50
CCH,1,CCh
MBEC90,1,MBEC90
ANTIBIOTICRESISTANCE,1,Antibiotic resistance
TOTALEXCRETION,1,Total excretion
DNAFRACTION,1,DNA fraction
MCC,1,MCC
FUNCTIONALPROFILE,1,Functional profile
DAUTILIZATION,1,DA utilization
TURNS1ST,1,Turns/1st
CTE,1,CTE
ACCUMULATEDCOUNTS30,1,Accumulated counts/30
PH12,1,pH1/2
BODYTEMPERATURE,1,Body temperature
CLRATIO,1,CL_Ratio
KIDNEYVDR,1,Kidney VDR
NOEFFECTIVENOTESTED,1,No effective/ no. tested
EMR,1,EMR
%RESIDUALACTIVITYWITHSKEPINONE-L,1,% Residual activity with Skepinone-L
AC3,1,AC3
DLSCONCENTRATION,1,DLS Concentration
MEINCREASE,1,ME increase
MELANOTROPICPOTENCY,1,Melanotropic potency
ANTICONULSANTACTIVITY,1,Anticonulsant activity
LESIONINDEX,1,Lesion index
CNSACTIVITY,1,CNS activity
PAPPE-6,1,Papp e-6
MAXDECREASEINHEARTRATE,1,Max decrease in heart rate
LUNGWEIGHT,1,Lung weight
CYTOCHROMELOSS,1,Cytochrome loss
VENTRICULARTACHYCARDIA,1,Ventricular tachycardia
C175,1,C175
ED2SEC,1,ED2sec
MET,1,MET
RATEOFTURBIDITYCHANGE,1,Rate of turbidity change
VIRUCIDAL,1,Virucidal
POSTDRUGBLOODPRESSURE,1,Post drug blood pressure
FEREMOVED,1,Fe removed
ACUTETOLERABILITY,1,Acute tolerability
TONIC-CLONICSEIZURE,1,Tonic-clonic seizure
ACTIVITYEC50,1,Activity EC50
AFFINITY,1,Affinity
MEANEFFECT,1,Mean effect
CC50IC50,1,CC50/IC50
LOGKGSH(S-1),1,Log k GSH (s-1)
NOOFCURES,1,No. of cures
MIC80,1,MIC80
VDSSDOSE,1,Vdss/dose
RELATIVESEMINALVESICLEWEIGHT,1,Relative seminal vesicle weight
TREATED,1,Treated
PEAKEFFECT,1,Peak effect
FIRSTADVERSEEFFECT,1,First adverse effect
KM(UNBOUND),1,Km(unbound)
LOGKMEMB,1,Log Kmemb
LED,1,LED
MBC999,1,MBC99.9
STIMULATORYEFFECT,1,Stimulatory effect
ROLIPRAMACTIVITY,1,Rolipram activity
ANIMALSWITHPALPABLETUMOR,1,Animals with palpable tumor
DENSITY,1,Density
SGOTINCREASE-ACTIVITYSCORE,1,SGOT Increase - Activity Score
RSRATIO,1,R/S ratio
SLEEPINGTIME,1,Sleeping time
ONSETSEIZURE,1,Onset seizure
ILSDAYS,1,ILS days
CHANGEINMEANAORTICFLOW,1,Change in mean aortic flow
CELLVIABILITYRATIO,1,Cell Viability Ratio
KIMICROM,1,KI_MICROM
INCREASES,1,Increases
GRADE,1,grade
CONTROLDMSOMITOCHONDRIADIFFERENT-PHENOTYPECELLS(%),1,Control DMSO Mitochondria Different-Phenotype Cells (%)
AQ,1,AQ
ETOPICBEATS,1,Etopic beats
DRF,1,DRF
RATEOFO2CONSUMPTION,1,Rate of O2 consumption
%CTRL,1,% Ctrl
BLOCKTIME,1,Block time
CHANGEINRESPIRATORYFREQUENCY,1,Change in respiratory frequency
TMSHIFTDEGREEC,1,Tm shift degreeC
DISTRIBUTIONOFEXCRETEDFE,1,Distribution of excreted Fe
PK3,1,pK3
CMAXUNBOUND,1,Cmax_unbound
SRR,1,SRR
NEUTSG,1,NEUTSG
EC59,1,EC59
WALKINGBEHAVIOUR,1,Walking behaviour
HYDROLYSISRATE,1,Hydrolysis rate
RELATIVELIPOPHILICITY,1,Relative lipophilicity
NEA,1,NEA
ID80,1,ID80
RELKO,1,rel ko
RBCNUC,1,RBCNUC
"KCS,APP",1,"KCS, APP"
CLC95,1,ClC95
SIGMAL,1,sigmaL
DARESPONSE,1,DA response
MCT,1,MCT
MPR,1,MPR
POSSIBLERESPONSE,1,Possible response
CHANGEINCHOLESTEROL,1,Change in cholesterol
EQUILIBRIUM,1,Equilibrium
CDYN,1,Cdyn
FCMAXDOSE,1,fCmax/dose
D2DURATION,1,D2 duration
DELTALOGP50,1,delta Log P50
MIC90,1,MIC90
DIAZEPAMANTAGONISM,1,Diazepam antagonism
PSI,1,pSI
HEPSEHEPATOMEGALY,1,HepSE_hepatomegaly
MISSTC,1,MISS T/C
SERUMT4,1,Serum T4
REDUCINGACTIVITY,1,Reducing activity
HR(DELTA),1,HR(delta)
SVT,1,SVT
AR,1,AR
BMAX2,1,Bmax2
C0(UNBOUND),1,C0(unbound)
DELTAFMAX,1,Delta Fmax
CONTROLDMSOTOTALCELLS,1,Control DMSO Total Cells
GENERALIZATION,1,Generalization
MAXAPD90(DELTA),1,Max APD90 (delta)
CELLSINMETAPHASE,1,Cells in metaphase
CATALYPTICACTION,1,Catalyptic action
MIC=>90,1,MIC=>90
NA+K+,1,Na+/K+
LD50X120,1,LD50 x 1/20
ABORTION,1,Abortion
LYSISAREA,1,Lysis area
P(EI),1,P (Ei)
ACTIVITYREGAINED,1,Activity regained
FOC,1,FOC
FMEAN,1,Fmean
LOG(RATIO),1,log(ratio)
AUCFIRSTTREATMENT,1,AUC first treatment
CHANGEINIOP,1,Change in IOP
TUMORAREA,1,Tumor area
TWI,1,TWI
BULLATACININDEX,1,Bullatacin index
NOCHANGE,1,No change
CELLPROLIFERATIONEC70,1,Cell Proliferation EC70
DCMAX,1,DCmax
I5,1,I5
CHANGEINSPERMATOGENESIS,1,Change in spermatogenesis
REDUCTIONOFHEARTRATE,1,Reduction of heart rate
PEC20,1,pEC20
RD500,1,RD500
CROPYIELD,1,Crop_yield
PLEURALVOLUME,1,Pleural volume
ACCUMULATEDCOUNTS30MIN,1,Accumulated counts/30 min
PUPILSIZE,1,Pupil size
CLF,1,CL/F
LOGCDGH,1,Log CDGH
MFED,1,MFED
CHANGEINHEMATOLOGY,1,Change in hematology
LNK,1,lnK
CONTROLDMSOTUBULINPHENOTYPEDIFFERENTCELLS(%),1,Control DMSO Tubulin Phenotype Different Cells (%)
%INHIBITIONINBONE-MARROW,1,% inhibition in bone-marrow
RELATIVEAFFINITY,1,Relative affinity
MLC50,1,MLC50
HC30,1,HC30
RLU,1,RLU
LOG1M,1,Log 1/M
PG,1,PG
CPCC,1,CPCC
MOLEFRACTION,1,Mole fraction
PROLACTINCONTROL,1,Prolactin control
ISOMETRICCONTRACTION,1,Isometric contraction
TOTALRELEASE,1,Total release
DIURETICEFFECTS,1,Diuretic effects
KIACT,1,Kiact
LOG2(RATIO),1,log2(ratio)
RELATIVECHANGE,1,Relative change
LBF,1,LBF
INHIBITIONAT10NM,1,Inhibition at 10nM
MESTEST,1,MES/TEST
CELLPLATINGEFFICIENCY,1,Cell plating efficiency
T999%,1,T99.9%
EC14,1,EC14
DELTAMEANSURVIVALTIME,1,Delta mean survival time
LOG1MMIC,1,Log 1/MMIC
I50M,1,I50 M
DRUGCONC(SERUM),1,Drug Conc (serum)
NOEC,1,NOEC
LOGPEFF,1,logPeff
MEANIC70,1,Mean IC70
RELATIVERATEMETABOLISM,1,Relative rate metabolism
MEANEXCRETIONOFCL-,1,Mean excretion of Cl-
GROWTH,1,Growth
AUCUNITS,1,AUC units
TISSUESEVERITYSCORE,1,Tissue Severity Score
RATIOPA2,1,Ratio pA2
LOCOMOTOR,1,Locomotor
TOXICEFFECT,1,Toxic effect
MEAIBUPTAKE,1,MeAIB uptake
KINETICCONSTANT,1,Kinetic constant
NOOFCUREDMICE,1,No. of cured mice
LOG(KINETICSOLUBILITY),1,log(Kinetic_solubility)
BMAX,1,Bmax
VINACT,1,Vinact
FICINDEX,1,FIC index
CP(F)SS,1,Cp(f)ss
[CA2+]INCREASE,1,[Ca2+] increase
RELATIVECYTOTOXICACTIVITY,1,Relative cytotoxic activity
MEANTIMETODEATH,1,Mean time to death
NOL,1,NOL
RELATIVESUBSTRATEVELOCITY,1,Relative substrate velocity
HDT,1,HDT
AUCCYTOTOXICITY,1,AUC cytotoxicity
LOGAP,1,Log AP
C,1,C
NOOFMALESCOHABITED,1,No. of males cohabited
DELTAGSOLV,1,Delta Gsolv
CYTOSTATICCONCENTRATION,1,Cytostatic concentration
GROWTHRESPONSE,1,Growth response
BEHAVIORALSCORE,1,Behavioral score
CELLSPOSITIVE,1,Cells positive
SALINECONTROL,1,Saline control
IC50L,1,IC50L
C16,1,C1.6
LOG,1,Log
MED100,1,MED100
TCID50,1,TCID50
I,1,I
FOLDRESISTANCE,1,Fold resistance
CYTOPLASMICVACUOLIZATION,1,Cytoplasmic vacuolization
%INHIB(MEAN),1,%Inhib (Mean)
LEFTATRIALPRESSURE,1,Left atrial pressure
TC(SURVIVAL),1,T/C (survival)
ANIMALSPROTECTED,1,Animals protected
AC200,1,AC200
POT,1,POT
F%T>MIC,1,f %t > MIC
TDI,1,TDI
PLASMACONTENT,1,Plasma content
UNBOUNDPLASMA,1,Unbound plasma
PHOTOSENSITIZATION,1,Photosensitization
LOG1B5,1,Log 1/B.5
INFUSIONRATE,1,Infusion rate
MEANREACTION,1,Mean reaction
LOGSP,1,Log SP
NORMALWEIGHTGAIN,1,Normal weight gain
POTENTATION,1,Potentation
ALLOSTEICENHANER(AE),1,Alloste ic enhan er (AE)
RANGEOFSURVIVALDAYS,1,Range of survival days
RELATIVESUSCEPTIBILITY,1,Relative susceptibility
(KCATKM)KUNCAT,1,(kcat/KM)/kuncat
NOOFERRORS,1,No. of errors
VMAXK,1,Vmax / K
OPTIMALCONCENTRATION,1,Optimal concentration
ED5,1,ED5
CHANGEINDENSITYOFUTERINEGLAND,1,Change in density of uterine gland
HF2,1,HF2
PA1,1,pA1
CONTROLPERIOD,1,Control period
LC50,1,LC50
POSTJUNCTIONALAGONISTPOTENCY,1,Postjunctional agonist potency
PROLONGATIONEFFECT,1,Prolongation effect
OPTIMALDOSAGE,1,Optimal dosage
FSCRECOVERY,1,FSC recovery
NOOFESCAPEFAILURES,1,No. of escape failures
T4,1,T4
FIC90,1,fIC90
ADI,1,ADI
ID100,1,ID100
EDRATIO,1,ED ratio
RELATIVEINHIBITIONINDEX,1,Relative inhibition index
EFFECTIVEDOSE,1,Effective dose
LC30,1,LC30
ALPHAC,1,Alpha c
TOCED50,1,TOC ED50
INTENSITYOFERYTHEMIA,1,Intensity of erythemia
SELECTIVETOXICITY,1,Selective toxicity
HISTAMINERELEASE,1,Histamine release
FS-SIF,1,FS-SIF
IRONCHANGE,1,Iron change
ALPHAT12,1,alphat1/2
JSS,1,Jss
RELATIVEABILITY,1,Relative ability
CELLSSICKLED,1,Cells sickled
TD50ED50,1,TD50/ED50
GR80,1,GR80
CMIN(80HR),1,Cmin(80hr)
SPEEDOFPERFORMANCE,1,Speed of performance
KAH,1,kAH
BLOCKAGEACTIVITY,1,Blockage activity
AVERAGESCORE,1,Average score
MEANHEMAGGLUTINATIONTITERS,1,Mean hemagglutination titers
SECONDARYRESPONSE,1,Secondary response
SPONTACTIVITY,1,Spont activity
TRIG,1,TRIG
TUMORUPTAKE,1,Tumor uptake
KINA,1,Kina
TUMORSIZE,1,Tumor size
AC30,1,AC30
CYTOTOXICITYINDEX,1,Cytotoxicity index
NOOFSCRATCHES,1,No. of scratches
ACTIVETOTAL,1,Active/total
CHANGETC,1,Change TC
VENTRICULARRATE,1,Ventricular rate
RADIOACTIVITYINURINE,1,Radioactivity in urine
STOMACH,1,Stomach
ANTIBODYSTIMULATION,1,Antibody stimulation
MAXIMALDECREASEINIOP,1,Maximal decrease in IOP
LOGP16,1,Log P16
MEANURINEVOLUME,1,Mean urine volume
[GSH],1,[GSH]
MAXCONTRACTILITY,1,Max contractility
MIC>80,1,MIC>80
DRUGMOLBASEPAIR,1,Drug mol/base pair
NOOFMOUSEPROTECTED,1,No. of mouse protected
IDGFEMUR,1,ID/g femur
LDL-C,1,LDL-C
IOPLOWERING,1,IOP lowering
DURATIONOFBLOCK,1,Duration of block
HC20,1,HC20
SKINSCALING,1,Skin scaling
RELATIVEHYDROLYSISRATE,1,Relative hydrolysis rate
DOSEORGAN,1,Dose/organ
1KM,1,1/Km
VMAX(APP),1,Vmax(app)
TM(APP),1,Tm(app)
%CELLDEATH,1,% Cell Death
MTD8,1,MTD/8
AUCMETAUCP,1,AUCmet/AUCp
CL-,1,Cl-
EF200,1,EF200
LOGCFUG,1,Log cfu/g
RESIDUALSECRETION,1,Residual secretion
IC>80,1,IC>80
X1(50),1,X1(50)
CHRONICTI,1,Chronic TI
BSR,1,BSR
UPTAKEBINDINGRATIO,1,Uptake/Binding ratio
RELEASE,1,Release
TPR,1,TPR
REP,1,REP
MABP,1,MABP
EICOSANOIDPRODUCTION,1,Eicosanoid production
INITIALAVERAGETUMORWEIGHT,1,Initial average tumor weight
AVERAGENOOFMETASTASIS,1,Average No. of metastasis
[I]05,1,[I] 0.5
FOLDINDUCTION,1,Fold induction
DASTIM,1,DA stim
MONOAMINELEVEL,1,Monoamine level
GTP-GAMMA35SBOUND,1,GTP-gamma35S bound
SWO,1,SWo
AUCLAST,1,AUClast
BIOLOGICALEVALUATION,1,Biological evaluation
3DPSA,1,3D PSA
MES,1,MES
NOOFCROSSES,1,No. of crosses
NOPOSITIVECASESTESTED,1,No. positive cases/tested
POTVIGILANCE,1,POT vigilance
MAXIMUMRESPONSE,1,Maximum response
DRUG,1,Drug
PROOFOFPRINCIPLE,1,proof of principle
MEANINCREASEDLIFESPAN,1,Mean increased life span
INCIDENCEOFOCCLUSION,1,Incidence of occlusion
PROLACTINRELEASE,1,Prolactin release
AFLCL,1,AFLCl
TOPICALDOSAGE,1,Topical dosage
RATFERTILITY,1,Rat fertility
BBC,1,BBC
IC0,1,IC0
ASTROCYTEREVERSAL,1,Astrocyte reversal
LOGLC50,1,Log LC50
LATENCYTIME,1,Latency time
MAXFALLINMAP,1,Max fall in MAP
PHOSPHORYLATION,1,Phosphorylation
RELATIVEIONOTROPICACTIVITY,1,Relative ionotropic activity
PARASITES,1,Parasites
AB,1,AB
GASTRICLESIONSCORE,1,Gastric lesion score
CELLAGGREGATES,1,Cell aggregates
DECREASEINEXITLATENCY,1,Decrease in exit latency
RECOVERYTIME,1,Recovery time
POLYAMINEPOOLS,1,Polyamine pools
LVDRXHR,1,LV DRxHR
REVERSIBILITY,1,Reversibility
CHANGEOFWEIGHT,1,Change of weight
BLOCKOFACTIVITY,1,Block of activity
CONDUCTION,1,Conduction
P50D,1,P50d
HEARTRATE,1,Heart rate
INCREASEINBLOODPRESSURE,1,Increase in blood pressure
MUTAGENICITY,1,Mutagenicity
COMPETITION,1,Competition
PCOCT,1,PCoct
PCASHIFT,1,PCA shift
LOG(1C50),1,log(1/C50)
LOGINHIBITION,1,Log inhibition
HUMANPOTENCY,1,Human potency
ANEUPLOIDYACTIVTY,1,Aneuploidy activty
RELATIVEUTERINEWEIGHT,1,Relative uterine weight
LYSISTIME,1,Lysis time
RELATIVEENZYMEACTIVITY,1,Relative enzyme activity
[3H]-UPTAKE,1,[3H]-uptake
GSTCPACTIVITY,1,GSTCP activity
RELATIVEUTERUSWEIGHT,1,Relative uterus weight
CYSTEINEREACTION,1,Cysteine reaction
ED40,1,ED40
MUDELTARATIO,1,Mu/delta ratio
CELLCYCLE,1,Cell cycle
HEPATOTOXICITY(COMMENT),1,Hepatotoxicity (comment)
LOG1K,1,Log 1/K
MIC75,1,MIC75
EXTENSION,1,Extension
RECOVERYATOB(MEAN),1,Recovery A to B (mean)
NEURITEBEARINGCELLSTOTALCELLS,1,Neurite bearing cells/total cells
LOG1MEC,1,Log 1/MEC
DECREASEINMEANARTERIALPRESSURE,1,Decrease in mean arterial pressure
PLASMAGHRELEASE,1,Plasma GH release
STAINING,1,Staining
ED125,1,ED125
KIX,1,Kix
XL50,1,XL50
BACTERIALCOUNTS,1,Bacterial counts
DEADTOTAL,1,Dead/total
RESIDUALINSULINRELEASE,1,Residual insulin release
KML,1,KmL
MCCD,1,MCCD
BEATSMIN,1,Beats/min
DELTAOD,1,deltaOD
EOSINOPHILS,1,Eosinophils
CYTOTOXICIY,1,Cytotoxiciy
LZ,1,LZ
I28,1,I28
NOOFSPIKES,1,No. of spikes
PHOSPHORYLATINGACTIVITY,1,Phosphorylating activity
PROTECTEDMICE,1,Protected mice
BORONINCORPORATION,1,Boron incorporation
DAMAGESCORE,1,Damage score
AUMC,1,AUMC
NOOFLUNGCOLONIES,1,No. of lung colonies
SYNERGYWITHMETHICILLIN,1,Synergy with methicillin
LOGPOCTZ,1,Log Poct Z
RELATIVERATE,1,Relative rate
COI,1,COI
%OFNORELEASE,1,% of NO release
HYPNOSISDURATION,1,Hypnosis duration
ENANTIOSELECTIVITYCOEFFICIENT,1,Enantioselectivity coefficient
MPORELEASE,1,MPO release
AUCSS(TAU)NORMALISED,1,AUCss(tau) normalised
LC60,1,LC60
%R,1,%R
MAXDELTAFC,1,Max delta FC
BRDUPOSITIVE,1,Brdu positive
DISTRIBUTIONOFRADIOACTIVITY,1,Distribution of radioactivity
CCTD50,1,CCTD50
I30,1,I30
LOGA50,1,Log A50
CHANGEINNOOFTROPHOZOITESX10E-5,1,Change in No. of trophozoites x 10E-5
SBPDECREASE,1,SBP decrease
WRITHES,1,Writhes
ACCCOUNTS,1,Acc. counts
MINIMUMTMAX,1,Minimum Tmax
LOGBETA3,1,Log beta3
C10AIR,1,C10 air
DELTALOG10CCID50,1,deltalog10CCID50
DEGREESCENTIGRADE,1,Degrees Centigrade
APD60,1,APD60
LOGOFINHIBITORYZONE,1,Log of inhibitory zone
NBTREDUCTION,1,NBT reduction
RADIOACTIVITYREMAINED,1,Radioactivity remained
CPEINDEX,1,CPE index
RATEOFDECOMPOSITION,1,Rate of decomposition
OFTUMORS,1,Of tumors
REPOLARIZATIONTIME,1,Repolarization time
DFMBMD,1,DFMBMD
DELTACP,1,DeltaCp
TUMORINHIBITION,1,Tumor inhibition
ADVERSEEFFECT,1,Adverse effect
GH,1,GH
AUCNOM,1,AUC nom
%OFCONTROLAGONISTRESPONSE,1,% of Control Agonist Response
CC,1,CC
ED37,1,ED37
GLUCOSETRANSPORT,1,Glucose transport
%REDUCTION,1,% reduction
ED10HR,1,ED10 HR
GROWTHOFCELLS,1,Growth of cells
MTD50,1,MTD50
NSVT,1,NSVT
VDAPP,1,Vd app
ANTICANCERACTIVITY,1,Anticancer activity
ESTROGENICPOTENCY,1,Estrogenic potency
NKA,1,nKa
ALPACTIVITY,1,ALP activity
ABSAC30UM,1,AbsAC30_uM
RIS,1,RIS
VELREM,1,Vel rem
INHIBITORYDIAMETER,1,Inhibitory diameter
%INHIBITIONOFCONTROLSPECIFICBINDING(MEANN=2),1,% Inhibition of Control Specific Binding (Mean n=2)
PIC50(CALC),1,pIC50(calc)
EYETOXICITY,1,Eye toxicity
CELLNODISHX10E5,1,Cell no./dish x10E5
PEC200,1,pEC200
DOSEBPBP,1,dose BP/BP
MEANINJECTEDDOSEG,1,Mean injected dose/g
IM,1,IM
STOICHIOMETRY,1,Stoichiometry
RELATIVEAMOUNT,1,Relative amount
MITOTICINDEX,1,Mitotic index
LC15,1,LC15
MEANAUC,1,Mean AUC
BACTERIALBIOTRANSFORMATION,1,Bacterial Biotransformation
EFFLUXCL,1,efflux_CL
ACTIVITYRATING,1,Activity rating
LOG1LD50(MMKG-1),1,Log 1/LD50 (mM kg-1)
PR,1,PR
CONCENTRATIONOFMAXRESPONSE,1,Concentration of max response
REVERSALTYPE,1,Reversal type
M-AGONISTINDEX,1,M-agonist index
HD10,1,HD10
HHP,1,HHP
LOG1KL,1,Log 1/KL
LOGKL,1,Log KL
LOG1CONC(MMMIN-1L-1),1,Log 1/conc (mM min-1 L-1)
HOURSABOVEEC90,1,Hours above EC90
KCAT(APP),1,Kcat(app)
IP+SCSCORE,1,IP+SC score
STABILITYOFBSR,1,Stability of BSR
TGD,1,TGD
INSULINLOWERINGEFFECT,1,Insulin lowering effect
AGONIST,1,Agonist
CMEDIA,1,Cmedia
MEANNOOFLUNGCOLONIES,1,Mean no. of lung colonies
ROTORODINDEX,1,Rotorod index
LOGPR,1,Log PR
ID99,1,ID99
DELTAPIC50,1,deltapIC50
HEMOLYTICACTIVITY,1,Hemolytic activity
FRACTIONOFACCUMULATED86RBREMAINING,1,Fraction of accumulated 86Rb remaining.
DAQ,1,Daq
ERP1,1,ERP1
CAIACTIVITY,1,CAI activity
CR2,1,CR2
-LOG(RATIOIC50),1,-log(RatioIC50)
NEGATIVEIONOTROPICACTIVITY,1,Negative ionotropic activity
SPAV3,1,SPAV3
SUBSTRATEACTIVITY,1,Substrate activity
RELATIVEJC-1ACCUMULATION,1,Relative JC-1 accumulation
TIMECONSTANTT3,1,Time constant T3
CRITICALMICELLECONCENTRATION,1,Critical micelle concentration
DELYSE,1,Delyse
NOOFDEPOLARIZATIONS,1,No. of depolarizations
AHV,1,AHV
TLAST,1,Tlast
TRIGLYCERIDECORRECTION,1,Triglyceride correction
CHANGEINCORPORALUTEA,1,Change in corpora lutea
RESOWING,1,Resowing
DAMAGEDAREA,1,Damaged area
LOGPMIC,1,Log Pmic
CLBLOOD,1,CLblood
NOOFCANINE,1,No. of canine
QA,1,QA
PARASITEMIACLEARANCEAFTERIMMUNOSUPPRESSION,1,Parasitemia clearance after immunosuppression
VMAXKMAX100,1,Vmax / Kmax100
135,1,135
K2'',1,k2''
MBC=>999,1,MBC=>99.9
ID(PERGOFORGAN),1,ID (per g of organ)
GABASHIFT,1,GABA shift
LOGRELATIVEK',1,Log relative k'
DLBT,1,DLBT
UTERINEWETWEIGHT,1,Uterine wet weight
LOGDIAM,1,logD IAM
TISSUECONCENTRATION,1,Tissue concentration
INTENSITY,1,Intensity
BWL,1,BWL
LIVERCHLEVELS,1,Liver CH levels
APD95,1,APD95
TUMORFREESURVIVAL,1,Tumor free survival
CLD,1,CLd
RRI,1,RRI
PACTIVITY,1,PActivity
PBBB,1,pBBB
DPDTMAX,1,dP/dt max
APOPTOTICCELL,1,Apoptotic cell
AVOIDANCETIME,1,Avoidance time
CLUP,1,CLup
ANTICONVULSANTACTIVITYANTICONVULSANTACTIVITY,1,Anticonvulsant activityAnticonvulsant activity
SYMPTOMS,1,Symptoms
KILLATC50,1,Kill at C50
AI50,1,AI50
PICOEQUIVALENTSOFAMINE10E6CELLS,1,Picoequivalents of amine/10e6 cells
COMPOSITEACTIVITY-SCORE,1,Composite Activity - Score
LATENCY,1,Latency
RELATIVEINHIBITORPOTENCY,1,Relative inhibitor potency
LACTOSEPRODUCTION,1,Lactose production
FRACTIONOFLIVERBLOODFLOW,1,Fraction of Liver Blood Flow
REMAININGCOMPOUND,1,Remaining compound
RATIOPAPP,1,Ratio_Papp
LOGCR,1,Log CR
DELTAH1,1,deltaH1
CA,1,CA
VMKM,1,Vm/Km
TISSUEBLOODRATIO,1,Tissue/Blood ratio
NOOFTUMORS,1,No. of tumors
URINE,1,Urine
CFU,1,CFU
FORMATIONOFNO3-,1,Formation of NO3-
CAMPINCREASE,1,cAMP increase
PD10,1,pD10
LRR,1,LRR
RELATIVEINACTIVATION,1,Relative inactivation
PLT,1,PLT
TOTALTUMORS,1,Total tumors
ASSEMBLY,1,Assembly
SWELLING,1,Swelling
CHANGEINFVR,1,Change in FVR
%INHIBITIONOFCONTROLVALUES,1,% Inhibition of Control Values
CI75,1,CI75
MAXCHANGE,1,Max change
PHYTOTOXICITY,1,Phytotoxicity
THRESHOLDACTIVEDOSE,1,Threshold active dose
DIZ,1,DIZ
DRUGUPTAKE,1,Drug uptake
LHLEVEL,1,LH level
LOGMIC,1,logMIC
TIMETOONSET,1,Time to onset
NOOFRATSWITHLESIONS,1,No. of rats with lesions
AFFINITYSTATE2,1,Affinity state 2
OBSERVEDAT,1,Observed at
PMLD,1,pMLD
WCC999,1,WCC99.9
FOLDIC50,1,Fold IC50
APOPTOTICCELLS,1,Apoptotic cells
OFVIABILITY,1,Of viability
MORTALITYNUMBER,1,Mortality number
LOGTA98,1,Log TA98
LOGRATE,1,Log rate
EPIDERMALTHICKNESS,1,Epidermal thickness
PF,1,PF
EDEMAINHIBITION,1,Edema inhibition
TUMORSWITHCR,1,Tumors with CR
TUBULINPOLYMERIZATIONRATIO,1,Tubulin polymerization ratio
LEVELOFCGMP,1,Level of cGMP
TOTALRADIOACTIVITY,1,Total radioactivity
MAXFALLINIOP,1,Max fall in IOP
MINLETHALDOSE,1,Min lethal dose
MAXUOSM,1,Max Uosm
NTD,1,NTD
MAXDELTATM,1,Max_Delta_Tm
LOG1D40,1,Log 1/D40
KDHYDRO,1,KD hydro
TIMECONSTANTT4,1,Time constant T4
MAXINTENSITY,1,Max intensity
MAXIMALBINDING,1,Maximal binding
REGIOSPECIFICITY,1,Regiospecificity
GEOMETRICMEAN,1,Geometric mean
NOOFFERRETS,1,No. of ferrets
STELEVATION,1,ST elevation
CARBONYLGROUP,1,Carbonyl group
PANCREATICRESPONSE,1,Pancreatic response
FAUCLAST,1,fAUClast
OCCUPANCY,1,Occupancy
TOXICITYRATIO,1,Toxicity ratio
EC300,1,EC300
ARRHYTHMIASCORE,1,Arrhythmia score
PEAKTIME,1,Peak time
CONVERSIONRATE,1,Conversion rate
LIMITINGT12,1,Limiting t1/2
BODYWEIGHTCHANGE,1,Body weight change
LOG1E100,1,Log 1/E100
PEAKCURRENT,1,Peak current
GLUCURONIDATION,1,Glucuronidation
MEANRATECONSTANT,1,Mean rate constant
TRANSLATION,1,Translation
RESIDUALPEPTIDE,1,Residual peptide
TRANSPORT,1,Transport
RELPOTENCY,1,Rel potency
LOGPHEP,1,Log Phep
PAPPS,1,Papps
REMISSION,1,Remission
GRCONTROL,1,GR control
CELLPROLIFERATION,1,Cell proliferation
DIURETICEFFECT,1,Diuretic effect
TC@30MGKG,1,T/C @ 30mg/kg
STAININGPOTENTIAL,1,Staining potential
BSABINDING,1,BSA binding
SPONTANEOUSMOTORACTIVITY,1,Spontaneous motor activity
CCIC50,1,CCIC50
RESPIRATORYSYSTEMRESISTANCE,1,Respiratory system resistance
NADPHOXIDATION,1,NADPH oxidation
BRAINCONC,1,Brain conc
LOGACTIVITY,1,Log activity
RISEHR,1,Rise HR
ABSOLUTE,1,Absolute
TOPOISOMERASE-IACTIVITY,1,Topoisomerase-I activity
KI'',1,Ki''
TRANSFECTIONACTIVITY,1,Transfection activity
AMOUNTINCORPORATED,1,Amount incorporated
GR10,1,GR10
MEANLIFEEXTENSION,1,Mean life extension
KSI,1,Ks/i
BPINCREASE,1,BP increase
LH,1,LH
MEDIANDAYOFDEATH,1,Median day of death
DAYOFVAGINALOPENING,1,Day of vaginal opening
LD50X110,1,LD50 x 1/10
ME,1,ME
LC99,1,LC99
N50E,1,n50e
KMKI,1,Km/Ki
PKA5,1,pKa5
RELATIVEVMAXKM,1,Relative Vmax/Km
LOG(PB),1,log(PB)
RATIOCC50EC50,1,Ratio CC50/EC50
LOGKOH-,1,Log kOH-
MEDIANRETENSIONLATENCY,1,Median retension latency
ANTICONVULSANT,1,Anticonvulsant
LOG(%),1,log(%)
KI05,1,Ki 0.5
VOLUMEOFAIR,1,Volume of air
TFREE,1,T free
EXCLUSIONPARAMETER,1,Exclusion parameter
AV,1,av
ANTIDIURETIC,1,Antidiuretic
TUMORVOLUMEREDUCTION,1,Tumor volume reduction
MGDHGI50,1,MGDH GI50
K4,1,K4
FAPP,1,Fapp
CL-CURRENTCHANGE,1,Cl - current change
MAXSALTTOLERANCE,1,Max salt tolerance
RELBRAINEXPOSURE,1,Rel brain exposure
AMNESIAREVERSAL,1,Amnesia reversal
ACUTETOXICITY,1,Acute toxicity
GROUPPERFORMANCETIME,1,Group performance time
BILI,1,BILI
EPILEPTOGENICITY,1,Epileptogenicity
EXHALATIONOF14CO2,1,Exhalation of 14CO2
NOOFANIMALSRESPONDINGANIMALSRECEIVINGDRUG,1,No. of animals responding/animals receiving drug
PWEIGHTCHANGE,1,pWeight change
TMED,1,TMED
DELTAIC,1,Delta IC
UTERUSTOBLOODRATIO,1,Uterus to blood ratio
RANGEOFMIC,1,Range of MIC
MAXREVERSINGRATE,1,Max reversing rate
NOEFFECTDOSE,1,No effect dose
TOTALCELLS,1,Total cells
DW,1,DW
FPKI,1,fpKi
PKB(APP),1,pKb(app)
BCMSERUMCA,1,BCM serum Ca
KINX10E3,1,Kin x10e3
HEPSECHOLELITHIASIS,1,HepSE_cholelithiasis
PUNCHWEIGHTMPOACTIVITY,1,Punch weight/MPO activity
EFF+-SD,1,EFF+/-SD
RADIUSOFINHIBITIONZONE,1,Radius of inhibition zone
AHINTERVAL,1,AH interval
C5AMAX,1,C5a max
ND50,1,ND50
RELATIVEONCENTRATION,1,Relative oncentration
ERH,1,ERH
LOGPCYC,1,Log Pcyc
BP(ED50),1,BP (ED50)
TRANSACETYLATIONRATE,1,Transacetylation rate
D40,1,D40
T12HS,1,T1/2 h/s
COMPOUNDCONCENTRATI,1,Compound_Concentrati
DAMAGEREDUCTION,1,damage reduction
LAMBDA-EM,1,Lambda-em
TIMESPENT,1,Time spent
ERYTHEMAFORMATION,1,Erythema formation
FIC,1,FIC
DRYWEIGHT,1,Dry weight
RELATIVEDISSOCIATIONRATE,1,Relative dissociation rate
INFERTILITYACTIVITY,1,Infertility activity
DRUGABSORPTION,1,Drugabsorption
P50E,1,P50e
LOGITBIOAVAILABILITY,1,Logit bioavailability
TPCONTROL,1,Tp control
LD99,1,LD99
LOGPN,1,Log Pn
MAXINCREASEINCORONARYFLOW,1,Max increase in coronary flow
ANESTHETICEFFECT,1,Anesthetic effect
ABBC,1,ABBC
ABAANALOGUERATIO,1,AbA/analogue ratio
PKADECREASE,1,pKa_decrease
GROSSKILL,1,Gross kill
JMAX,1,Jmax
LD50,1,LD50
DDTMSAD,1,DDT msad
DBP-20,1,DBP-20
DECREASEINBLOODPRESSURE,1,Decrease in blood pressure
SUBLETHALDOSE,1,Sublethal dose
GMMIC,1,GMMIC
P24CONCENTRATION,1,P24 concentration
KX10E3,1,k x10e3
REVERSION,1,Reversion
INFLAMED,1,Inflamed
BINDINGDECREASE,1,Binding Decrease
AVERAGEMAX,1,Average max
BORONCONCENTRATION,1,Boron concentration
RATIOCMAXBRAINPLASMA,1,Ratio_Cmax_brain/plasma
INHIBITORYACTIVITY,1,Inhibitory activity
T12DOSE,1,t1/2/dose
VAGALRESPONSE,1,Vagal response
RELATIVETUMORGROWTH,1,Relative tumor growth
ANTIPROLIFERATIVEEFFECT,1,Antiproliferative effect
SLOPE,1,Slope
DECREASE,1,Decrease
HEPATICTRIGLYCERIDE,1,Hepatic triglyceride
EDDELTA20,1,ED delta20
RHT,1,RHT
APPARENTPKA,1,Apparent_pKa
AMAX,1,Amax
PLATELETCOUNTUL,1,Platelet count/ul
MABPCHANGE,1,MABP change
TRIGLYCERIDELEVEL,1,Triglyceride level
HEPATOTOXICITY(GRANULOMATOUSHEPATITIS),1,Hepatotoxicity (granulomatous hepatitis)
PAOACTIVITY,1,PAO activity
LOGEC50(UM),1,Log EC50(uM)
CHANGEINBODYWEIGHT,1,Change in body weight
2*APTT,1,2*APTT
MEANIC50,1,Mean IC50
LVFRP,1,LV FRP
CPMX1000,1,CPM x1000
R+V,1,R+V
K'K'+1,1,k'/k'+1
CELLDEATH,1,Cell death
BASALUPTAKE,1,Basal uptake
REMAININGACTIVITY,1,Remaining activity
TOXICDOSE,1,Toxic dose
NCC,1,NCC
TOTALBINDING,1,Total binding
TPL,1,T.P.L
MEMBRANEINTEGRITY,1,Membrane integrity
HISTAMINELEVEL,1,Histamine level
-LOG(1MKC),1,-log(1/MKC)
CMAX[GH],1,Cmax_[GH]
STROKEWORK,1,Stroke work
TC90,1,TC90
CONCENTRATION,1,Concentration
HYDROLYSISRATECONSTANT,1,Hydrolysis rate constant
BUI,1,BUI
SERUMCORTICOSTERONE,1,Serum corticosterone
LCK,1,LCK
ILA,1,ILA
PFE3+,1,pFe3+
DECREASEINMAP,1,Decrease in MAP
CLERANCE,1,Clerance
IDANIMAL,1,ID/animal
DNA,1,DNA
TREATMENT,1,Treatment
KIAPP(INACT),1,Ki app (inact)
RBA,1,RBA
CHANGEOFSIZE,1,Change of size
INHIBITORYRATE,1,Inhibitory rate
LUCIFERASEEXPRESSIONCONTROL-IC90,1,LUCIFERASE EXPRESSION CONTROL - IC90
ID25,1,ID25
MARROWAREA,1,Marrow area
INFECTIONSCORE,1,Infection score
KINETICSOLUBILITY(APP),1,Kinetic_solubility(app)
TAQINHIBITION,1,Taq inhibition
NOEL,1,NOEL
GASTRICEMPTYING,1,Gastric emptying
TID20,1,TID20
MSD,1,MSD
ACTIVITY(UMOLGOFLIVER75MIN),1,Activity (umol/g.of liver 75.min)
2XTT,1,2x TT
RECOVERY,1,Recovery
C50K,1,C50k
PC60,1,pC60
C120,1,C120
INITIALMEANARTERIALPRESSURE,1,Initial mean arterial pressure
MIC>95,1,MIC>95
ECAUC02,1,ECAUC0.2
ADJUSTEDKI,1,Adjusted Ki
PDD50,1,PDD50
RESPONSEVALUE,1,Response value
REVERSALABILITY,1,Reversal ability
-LOGC,1,-Log C
NRN,1,Nr/N
DR2,1,DR2
MAXIMALEFFECT,1,Maximal effect
ALKYLATINGACTIVITY,1,Alkylating activity
ENOYL-COAHYDRATASE,1,Enoyl-CoA hydratase
PLASMALIPIDS,1,Plasma lipids
LD70,1,LD70
%LBF,1,%LBF
REFLEX,1,Reflex
EFFLUXRATIOPLUSINHIBITOR,1,Efflux ratio plus inhibitor
RATIOGI50,1,RatioGI50
PKC,1,PKC
ACTIVETOTALCULTURES,1,Active/total cultures
TOXIC,1,Toxic
PCC50,1,pCC50
BLOCKADEEFFECT,1,Blockade effect
Z,1,Z
KASSAPP,1,K ass app
BRAINUPTAKE,1,Brain uptake
PK50,1,pK50
CELLULARUPTAKEOFBORONAT16H,1,Cellular uptake of boron at 16h
GGT,1,GGT
MNTD70,1,MNTD70
BRAINPLASMA,1,Brain/Plasma
WEIGHTATTERM,1,Weight at term
INTESTINALTOXICITY,1,Intestinal toxicity
RECOVEREDINBILE,1,Recovered in bile
MTC50,1,MTC50
CAVG,1,Cavg
REDUCTIONINEOSCOUNT,1,Reduction in EOS count
PEC5,1,pEC5
HYPOCOTYLLENGTH,1,Hypocotyl length
KID,1,Kid
STIMULATIONS,1,Stimulations
INHIBITIONRATE,1,Inhibition rate
A10,1,A10
ANTAGONISTACTIVITY,1,Antagonist activity
RBF,1,RBF
LDH,1,LDH
DEPRESSION,1,Depression
APPROXLETHALDOSE,1,Approx. lethal dose
PH50,1,pH50
HIGHESTNONTOXICDOSE,1,Highest nontoxic dose
CRLEAKAGE,1,Cr leakage
C120ED50,1,C120/ED50
POTENCY,1,Potency
ADJUVANTACTIVITY,1,Adjuvant activity
OT,1,OT
TW,1,TW
ARTERIALPRESSURE,1,Arterial pressure
SUBSTRATEMETABOLIZEDAT1HR,1,Substrate metabolized at 1hr
INACTIVATION,1,Inactivation
PROTECTIONINDEX,1,Protection index
INCORPORATED,1,Incorporated
MAXCHANGEINBLOODPRESSURE,1,Max change in blood pressure
WASHOUT,1,washout
TC(TUMORVOL),1,T/C (tumor vol)
DOPACCONCENTRATION,1,DOPAC concentration
PHOSPHOROLYSIS,1,Phosphorolysis
COUNTSOFROTATION,1,Counts of rotation
LACTONEPRODUCTION,1,Lactone production
FORMATIONOFNO2-,1,Formation of NO2-
LOG10PFUML,1,log10PFU/ml
CONTROL,1,Control
LS,1,LS
HEPATICNECROSISINSURVIVORS,1,Hepatic necrosis in survivors
PERIOSTEALMINERALAPPOSITIONRATE,1,Periosteal mineral apposition rate
PAI50,1,pAI50
KDNB,1,KDNB
PLASMASELECTIVITY,1,Plasma selectivity
MAXDROP,1,Max drop
MINORALDOSE,1,Min oral dose
RBI,1,RBI
LOW,1,Low
KSECOND,1,K second
EC95,1,EC95
DNAPEAKEXCLUSION,1,DNA peak exclusion
HC>=50,1,HC>=50
SYSTEMICEFFECT,1,Systemic effect
HEPATOTOXICITY(STEATOSIS),1,Hepatotoxicity (steatosis)
PROLONGEDVRP,1,Prolonged VRP
IC60,1,IC60
EC99,1,EC99
CAROTIDFLOWDECREASE,1,Carotid Flow Decrease
PHOSLPDCHANGE,1,PHOSLPD_CHANGE
LOG(1ID50),1,log(1/ID50)
AVERAGEDOSEPERORGAN,1,Average dose per organ
KDNONIONIC,1,KD non ionic
AMOUNTOFACOTINEUSED,1,Amount of Acotine used
VLDL,1,VLDL
GLYCEAMIAEVOLUTION,1,Glyceamia evolution
RESERPINEHYPOTHERMIA,1,Reserpine hypothermia
HXSHIFT,1,Hx shift
MED>50,1,MED>50
EDMIN,1,EDmin
DIURETICACTIVITY,1,Diuretic activity
IT50,1,IT50
P10MIC,1,p10 MIC
LOG10REDUCTION,1,Log10 reduction
KA(T4),1,Ka(T4)
DOSENORMALIZEDCLEARANCE,1,Dose normalized clearance
RELATIVEPT,1,Relative PT
POTENCYINDEX,1,Potency index
LATENCYTOSTEPTHROUGH,1,Latency to step through
CURES@20MGKG,1,Cures@ 20mg/kg
SPENTTIME,1,Spent time
BLOODFLOW,1,Blood flow
PLATELETSX10E-3,1,Platelets x10e-3
MHC,1,MHC
PTCD50,1,pTCD50
CHANGEINCELLNUMBER,1,Change in cell number
MEANDAY,1,Mean day
CAMPCONTENT,1,cAMP content
EXTAUC,1,Ext AUC
MAXDELTAHR,1,Max delta HR
REACTORSTESTGROUP,1,Reactors/Test group
DPT,1,dPT
MLD,1,MLD
DAY22-TC,1,Day 22-T/C
DELTAKAPPA,1,Delta/kappa
DRUGDEATHS,1,Drug deaths
HC50,1,HC50
MST,1,MST
SGPTINCREASE-INDEXVALUE,1,SGPT Increase - Index Value
ANALOGUELEVEL,1,Analogue level
PHOSPHOLIPIDOSISINDEX,1,Phospholipidosis_index
L-T3,1,L-T3
NRD,1,NRD
VF,1,VF
NS,1,NS
REC,1,REC
CMAXTRIPHOSPHATE,1,Cmax_triphosphate
THERMSOLUBILITY,1,Therm_solubility
DECREASEINIC50,1,Decrease in IC50
INTRAPERITONALSCORE,1,Intraperitonal score
UVAPF,1,UVAPF
MUTATIONFREQUENCY,1,Mutation frequency
FRACTIONRECOVEREDINURINE,1,Fraction Recovered in urine
FINALAVERAGETUMORWEIGHT,1,Final average tumor weight
DEPLETION,1,Depletion
RESPONDERS,1,Responders
CORPORALUTEA,1,Corpora lutea
5-HTPACCUMULATION,1,5-HTP accumulation
ANTIFERTILITYACTIVITY,1,Antifertility activity
CYCLASESTIMULATION,1,Cyclase stimulation
HYDROPHOBICITYINDEX,1,Hydrophobicity index
DOPAACCUMULATION,1,DOPA accumulation
UPTAKEATC50,1,Uptake at C50
%INHIBITIONOFCONTROLAGONISTRESPONSE(MEANN=2),1,% Inhibition of Control Agonist Response (Mean n=2)
METABOLITELEVEL,1,Metabolite level
EFFLUX,1,Efflux
T-C,1,T-C
LMA,1,LMA
MOT,1,MOT
MICEWITHLESIONS,1,Mice with lesions
LOG1KI,1,log1/Ki
BOUND,1,Bound
BLOODUREANITROGEN,1,Blood urea nitrogen
AVERAGEBILEFLOW,1,Average bile flow
NOOFSURVIVORS,1,No. of survivors
ASCRIT,1,ascrit
AUCGLU,1,AUC glu
%MAXIMUMRESPONSE,1,% maximum response
LPS,1,LPS
DNAPHOTO-CROSSLINKING,1,DNA photo-crosslinking
VI30,1,VI30
TBMIC,1,TBMIC
SURVIVALRATIO,1,Survival ratio
DELTAAPD95,1,Delta APD95
MYRISTOYLCOA,1,MyristoylCoA
HRCHOL,1,HR/chol
FRACTIONEXPERIENCINGSEIZURES,1,Fraction experiencing seizures
DOSEGTISSUE,1,Dose/g tissue
RESISTANCERATIO,1,Resistance ratio
ANALGESICRESPONSE,1,Analgesic response
ACCUMULATION,1,Accumulation
DOSEMODIFICATION,1,Dose modification
PUNISHMENTTESTMSAD,1,Punishment test msad
KINASEACTIVITY,1,Kinase activity
KONOO-,1,kONOO-
KOH-,1,kOH-
INCREASEINPLASMALIPASE,1,Increase in plasma lipase
NETBODYWEIGHTDELTA,1,Net body weight delta
DRUGRECOVERY,1,Drug recovery
RATEOF[CA+2]INCREASE,1,Rate of [Ca+2] increase
K+IONCONTENT,1,K+ Ion content
SWIMMINGACTIVITY,1,Swimming activity
ADD,1,ADD
SPB,1,SPB
BINDINGSITEFRACTION,1,Binding site fraction
COF,1,COF
ABSOPTION,1,Absoption
LD95,1,LD95
PLASMAGH,1,Plasma GH
M50,1,M50
LC20,1,LC20
PK1B,1,pK1b
CAVE,1,Cave
ALPHA-CHOLESTEROL,1,Alpha-cholesterol
REDUCTIONINVIRUSYIELD,1,Reduction in virus yield
CL(APP),1,CL(app)
T12SS,1,t1/2ss
PAWWEIGHT,1,Paw weight
SUBSTRATESPECIFICITY,1,Substrate specificity
ACTIVITYOFCONTROL,1,Activity of control
CAMPACTIVITYINDEX,1,cAMP activity index
VEHICLECONTROL,1,Vehicle control
RELATIVEINTENSITY,1,Relative intensity
POCT,1,Poct
CLRENAL,1,CL_renal
MAXIMALRELAXATION,1,Maximal relaxation
KX10E-5,1,K x10e-5
A50,1,A50
AUCED90,1,AUCED90
FALL,1,Fall
BBB,1,BBB
DNASINGLESTRANDBREAKS,1,DNA single strand breaks
DEATHDOSE,1,Death dose
ECG,1,ECG
TD90,1,TD90
PS,1,PS
REDUCTIONINARTERIALBLOODPRESSURE,1,Reduction in arterial blood pressure
IG,1,IG
CONTROLDMSOHEALTHYNUCLEI(%),1,Control DMSO Healthy Nuclei (%)
APD30,1,APD30
DEADCELLS,1,Dead cells
MAXPLASMALEVEL,1,Max plasma level
KI(APP),1,Ki(app)
PHARMACOKINETIC,1,Pharmacokinetic
T>EC99,1,T>EC99
DECREASEDTRIGLYCERIDE,1,Decreased_triglyceride
ABDOMINALFAT,1,Abdominal fat
CHANGEINMYOCARDIALCONDUCTION,1,Change in myocardial conduction
BINDINGAFFINITY,1,Binding affinity
SPECIFICBINDING,1,Specific binding
LOGMEC,1,logMEC
PKIH,1,pKiH
MI20,1,MI20
MONOCATIONSPECIES,1,Monocation species
IR,1,IR
TOPICALPOTENCY,1,Topical potency
KI(KMKCAT),1,Ki/(Km/Kcat)
LOG10CFUMLDAY,1,log10CFU/ml/day
BPDECREASE,1,BP decrease
ACETYLCHOLINELEVEL,1,Acetylcholine level
MIC+MIC-,1,MIC+/MIC-
SEROSALMUCOSALCA,1,Serosal/Mucosal Ca
ZSCORE,1,Z score
KPOL,1,Kpol
TPE,1,TPE
CONTROLS,1,Controls
BILURUBINLEVEL,1,Bilurubin Level
FEEDCONSUMPTION,1,Feed consumption
PERIOSTEALMINERALIZINGSURFACE,1,Periosteal mineralizing surface
LDLOXIDATION,1,LDL oxidation
IC50RATIO,1,IC50 ratio
UTERINEACTIVITY,1,Uterine activity
CONVULSION,1,Convulsion
PKA6,1,pKa6
LACTATEPRODUCED,1,Lactate produced
IRONMOBILIZATION,1,Iron mobilization
VASODILATORYRATE,1,Vasodilatory rate
MEANDECREASE,1,Mean decrease
VARIATION,1,Variation
LOG10ED50,1,Log10ED50
PFA,1,PFA
RATIOOFDEPOLARIZINGACTIVITY,1,Ratio of depolarizing activity
RATIOLD50ED50,1,Ratio LD50/ED50
%BINDING,1,% binding
KHYDR,1,khydr
RT,1,RT
COMPOSITEACTIVITY-ACTIVE,1,Composite Activity - Active
CBFINCREASINGACTIVITY,1,CBF increasing activity
ACUTELETHALTOXICITY,1,Acute lethal toxicity
MDD,1,MDD
PHOS,1,PHOS
KA',1,Ka'
DTH,1,DTH
CI95,1,CI95
ROR,1,ROR
VIRUSRATING,1,Virus rating
NOOFANIMALSWITHLIVERNECROSIS,1,No. of animals with liver necrosis
ANTIBIOTICACTIVITY,1,Antibiotic activity
CC30,1,CC30
F12,1,F1/2
-LOGED50,1,-Log ED50
A2,1,A2
NOOFMALESFERTILE,1,No. of males fertile
BACTERICIDAL,1,Bactericidal
FEC90,1,fEC90
COUNTS,1,Counts
MARGINBEFOREONSETOFHYPOKALEMIA,1,Margin before onset of hypokalemia
LOG1LD50,1,Log 1/LD50
RATIOIC50EC50,1,Ratio IC50/EC50
MRTINF,1,MRTinf
MBEC80,1,MBEC80
MEANAORTICBLOODPRESSURE,1,Mean aortic blood pressure
BODYTEMPCHANGE,1,Body temp change
%OFCONTROLAGONISTRESPONSE(MEANN=2),1,% of Control Agonist Response (Mean n=2)
EQUIEFFECTIVEDOSE,1,Equieffective dose
LOGK4,1,Log K4
ACQUISITIONTIME,1,Acquisition time
LOGSENSITIVITY,1,Log sensitivity
TUMORFREETOTAL,1,Tumor free/total
PHOSPHOLIPIDOSISMEC,1,Phospholipidosis_MEC
DECREASEINHEARTNOREPINEPHRINE,1,Decrease in heart norepinephrine
RATTURNING,1,Rat turning
DELTALOG10CFUML,1,deltalog10CFU/ml
RD100,1,RD100
KALIURETICACTIVITY,1,Kaliuretic activity
MORTALITYINHIBITION,1,Mortality inhibition
PC30,1,pC30
HIGHESTACTIVEDOSE,1,Highest active dose
NOOFACTIVENOOFTESTED,1,No. of active/no. of tested
LOGCMC,1,logCMC
FEVERRESPONSE,1,Fever response
NEOSTIGMINEREVERSAL,1,Neostigmine reversal
EC90MIC,1,EC90/MIC
HILLCOEFFICIENT(N50),1,Hill coefficient (n50)
MAXPROTECTION,1,Max protection
MEAN%GROWTH(N=2)FOR001ΜMPROBECONCENTRATION,1,Mean % growth (n = 2) for 0.01 µM probe concentration
APOPTOSISINDUCTION,1,Apoptosis induction
RATIOGI50EC50,1,Ratio GI50/EC50
IC50,1,IC50
RECOVEREDRADIOACTIVITY,1,Recovered radioactivity
RATIOCMAX,1,Ratio Cmax
EX-VIVOSCREENING,1,Ex-vivo screening
EXCRETED,1,Excreted
AUTOPHAGYINDUCTION,1,autophagy induction
PK1D,1,pK1d
AUPAP,1,AUPAP
ROTOROD,1,Rotorod
%BOUNDFRACTION,1,% bound fraction
C100,1,C100
FEC85,1,fEC85
SURVIVALTREATED,1,Survival treated
MI100,1,MI100
KDH,1,KdH
ED,1,ED
PROLONGEDQT,1,Prolonged QT
CD,1,CD
DBPUPRATIO,1,DBP/UP ratio
AVERAGELOGGI50,1,average log GI50
KDMPG,1,K DMPG
LOG(1CON),1,log(1/CON)
IC2X,1,IC2x
%ABSORBED,1,% absorbed
RADIOACTIVITYLEVEL,1,Radioactivity level
DIRECTLYMEASUREDTHICKNESS,1,Directly measured thickness
NOOFNONPREGNANTTREATED,1,No. of nonpregnant/treated
DEUTERIUMRETENTION,1,Deuterium retention
CHOLESTROLLEVELS,1,Cholestrol levels
BASO,1,BASO
LOWESTEFFECTIVECONCENTRATION,1,Lowest effective concentration
RELATIVETHYMUSWEIGHT,1,Relative thymus weight
C6H,1,C6h
ANTIAMNESICACTIVITY,1,Antiamnesic activity
BRAIN,1,Brain
RELATIVEADRENALWEIGHT,1,Relative adrenal weight
ANTICOCCIDIALACTIVITY,1,Anticoccidial Activity
FRE,1,FRE
CHANGEINTIDALVOLUME,1,Change in tidal volume
MAXREDUCTIONINMEANARTERIALPRESSURE,1,Max reduction in mean arterial pressure
RBARATIO,1,RBA ratio
INJECTEDDOSEG,1,Injected dose/g
LOG1KD,1,Log 1/Kd
MT,1,M/T
TERMINALT12,1,Terminal t1/2
SPREADING,1,Spreading
T>FEC50,1,T>fEC50
MRTLAST,1,MRTlast
RELATIVEINHIBITION,1,Relative inhibition
%CHANGE,1,% change
VK,1,V/K
KOBSCONCENTRATION,1,k obs / concentration
EI,1,EI
RELATIVETODA,1,Relative to DA
TASTECLASS,1,Taste class
MFC>99,1,MFC>99
DRUGMOBILITY,1,Drug mobility
IVR,1,IVR
1VMAX,1,1/Vmax
ZONEREDUCTION,1,Zone reduction
G0G1,1,G0/G1
RESPONSERATIO,1,Response ratio
SCHIZONTSIZE,1,Schizont size
SNGFR,1,SNGFR
NOPREGNANTMATED,1,No. pregnant/mated
EAUC50,1,EAUC50
AVERAGESAMPLEINTAKE,1,Average sample intake
KI1,1,Ki1
ANTIOVULATORYACTIVITY,1,Antiovulatory activity
LOG[-8],1,Log [-8]
MEANDAYOFDEATH,1,Mean day of death
POPULATIONNORMAL(%),1,Population Normal (%)
AXONALREGENERATIONRATE,1,Axonal regeneration rate
CRSECRETION,1,Cr secretion
MORTALITYRANGE,1,Mortality range
MEAN,1,Mean
PCRCURERATE,1,PCR cure rate
SURVIVORS,1,Survivors
DISSOCIATION,1,Dissociation
ONSETOFBLOCK,1,Onset of block
EC50REL,1,EC50rel
DEGRADATIONRATIO,1,Degradation ratio
BNA,1,BNa
HEPSELIVERFATTY,1,HepSE_liver fatty
WEIGHTCHANGEATNADIR,1,Weight change at nadir
ACUTETI,1,Acute TI
PERMEATED,1,Permeated
ABSOLUTETURNANGULAR3MIN,1,Absolute turn angular/3 min
ICD,1,ICD
2T11,1,2T11
PB,1,PB
INCORPORATION,1,Incorporation
LIVERTG,1,Liver TG
PMEC,1,pMEC
MCV,1,MCV
BLOODGLUCOSELEVEL,1,Blood glucose level
CC90,1,CC90
RELATIVESELECTIVITY,1,Relative Selectivity
-LOG(1AD50),1,-log(1/AD50)
MBC=>99,1,MBC=>99
TOTALNUMBEROFENTRIES,1,Total number of entries
POTENTIATION,1,Potentiation
INCREASEINCBF,1,Increase in CBF
DISPACEMENT,1,Dispacement
BLOODPLASMARATIO,1,Blood/Plasma ratio
PGC50,1,pGC50
LOGBETA,1,Log beta
P2UPTAKE,1,P2 uptake
MAXACTIVITYCONCENT,1,Max_Activity_Concent
2XAPPT,1,2x aPPT
INCREASEINVOLUME,1,Increase in volume
THYMIDINESHIFT,1,Thymidine shift
NATRIURETICACTIVITY,1,Natriuretic activity
%OFRESIDUALACTIVITY,1,% of residual activity
K+2K,1,k+2/k
VIRUSYIELD,1,Virus yield
TISSUEPLASMARATIO,1,Tissue/Plasma Ratio
CA2+BINDINGPROTEIN,1,Ca2+ binding protein
TIMETO30%BSR,1,Time to 30% BSR
MAXDELTAVMAX,1,max Delta Vmax
CELLPROTEININUNTREATEDCONTROL,1,Cell protein in untreated control
DERIVEDTRABECULARTHICKNESS,1,Derived trabecular thickness
SD90,1,SD90
FSC,1,FSC
-LOGK,1,-Log K
RATEOFHYDRIDETRANSFER,1,Rate of hydride transfer
INHIBITIONAT1UM,1,Inhibition at 1uM
MORTALITYRATIO,1,Mortality ratio
RATERESPONSE,1,Rate response
%OFSELECTIVITY,1,% of selectivity
RADIALGROWTHINHIBITIONOFFUNGI(Ā)(MM),1,Radial growth inhibition of fungi (Ā) (mm)
RESIDUALCONTRACTILEACTIVITY,1,Residual contractile activity
HEMATOCRIT,1,Hematocrit
IOGP,1,IogP
AFFINITYRATIO,1,Affinity ratio
KKIN,1,Kkin
INHIBITIONOFINCREASEINWEIGHT,1,Inhibition of increase in weight
KIAM',1,kIAM'
CONTROLGROWTH,1,Control growth
ERYTHEMAINTENSITY,1,Erythema intensity
%OFINHIBITIONORSTIMULATION,1,% of inhibition or stimulation
EFFECTIVENESS,1,Effectiveness
AVERAGESURVIVAL,1,Average survival
IOP,1,IOP
C20APD95,1,C20 APD95
EC50L,1,EC50L
MAXAGONISTRESPONSE,1,Max agonist response
MAXDELTA,1,Max delta
ONSET,1,Onset
TGI,1,TGI
K''IAM,1,K''IAM
LOG(TAUKA),1,log(Tau/KA)
SGOTACTIVITY,1,SGOT activity
UP,1,U/P
MBEC2,1,MBEC2
FPDMEASUREMENT,1,FPD measurement
EC70,1,EC70
INSULINRELEASE,1,Insulin release
NOOFMICE,1,No. of mice
T>MIC90,1,T>MIC90
IH50,1,IH50
RESPIRATORYFREQUENCY,1,Respiratory frequency
NETLOGCELLKILL,1,Net log cell kill
NUMBER,1,Number
K'',1,k''
RECOVERYBTOAPLUSINHIBITOR(MEAN),1,Recovery B to A plus inhibitor (mean)
RELATIVEMAXIMUM,1,Relative maximum
KIKM,1,Ki/Km
MEANPITSIZE,1,Mean pit size
LOG10LT50,1,log10LT50
SELECTIVITYRATIOS32,1,Selectivity ratio S3/2
PKIL,1,pKiL
ED30,1,ED30
MBIC,1,MBIC
LOGMRI,1,Log MrI
CONTROLVALUE,1,Control value
KSV,1,KSV
RELMAXFI,1,Rel Max FI
HORMONALACTIVITY,1,Hormonal activity
AFFECTEDANIMALS,1,Affected animals
PIC35,1,pIC35
RATIOIP,1,Ratio I/P
TOTALACTIVITY,1,Total activity
PERCENTEFFECT,1,Percent Effect
MODIFICATIONOFHEMOGLOBIN,1,Modification of hemoglobin
PACKEDCELLVOLUME,1,packed cell volume
HEPSELIVERDISEASE,1,HepSE_liver disease
RELATIVEESTERASESUSCEPTIBILITY,1,Relative esterase susceptibility
LED100,1,LED100
LOG%ABS,1,log%Abs
RESIDUEFRACTION,1,Residue fraction
MUSCARINICRECEPTORAFFINITY,1,Muscarinic receptor affinity
ANTI-FXAACTIVITY,1,Anti-fXa activity
EFFLUXRATIO,1,Efflux ratio
DELTAPLASMACHOLESTEROL,1,Delta plasma cholesterol
CC75,1,CC75
%INHIBITIONINLIVER,1,% inhibition in liver
DISTRIBUTION(DOSEG),1,Distribution (dose/g)
CONTROLLEVEL,1,Control level
DOSENONRENALLYCLEARED,1,Dose non renally cleared
PROTECTIVEEFFECT,1,Protective effect
CMIN(SS),1,Cmin(ss)
NOSURVIVED,1,No. survived
FOLDSELECTIVE,1,Fold selective
-LOGEC50,1,-Log EC50
APD75,1,APD75
MEANLOGLC50,1,Mean log LC50
RELATIVEEFFICACY,1,Relative efficacy
INCREASEINRFU,1,increase in RFU
VERP,1,VERP
FINALPLASMACONCENTRATION,1,Final plasma concentration
INSULINSECRETION,1,Insulin secretion
DRUGUPTAKE(FREE)DOSE,1,Druguptake(free)/dose
2TT,1,2TT
LOG10PFU,1,log10PFU
SDL,1,SDL
EC>90,1,EC>90
PEAKGH,1,Peak GH
ID30,1,ID30
CLOGP-LOGP,1,clogP-logP
TUMORGROWTHINHIBITION,1,Tumor growth inhibition
ACTIVITYINANIMALS,1,Activity in animals
SIGMASH,1,sigmaSH
STERILITY,1,Sterility
TOTALNOOFTURNS,1,Total no. of turns
BETAT12,1,beta t1/2
INITIALINHIBITION,1,Initial inhibition
DAP,1,DAP
CMIN(84HR),1,Cmin(84hr)
I50,1,I50
C24H,1,C24h
MEANTUMORATENCY,1,Mean tumor atency
AVERAGECHANGEINWEIGHT,1,Average change in weight
SELECTIVITYRATIOS31,1,Selectivity ratio S3/1
CC50EC50,1,CC50/EC50
AUCTDOSE,1,AUCt/dose
THYMUSWEIGHTCHANGE,1,Thymus weight change
BLOCKAGE,1,Blockage
%OFINHIBITION,1,% of inhibition
SYSTOLICBLOODPRESSURE,1,Systolic blood pressure
REVERTANTSPLATE,1,Revertants/plate
BASALGLUCOSE,1,Basal glucose
SURVIVORSANIMALSTESTED,1,Survivors / animals tested
IC75,1,IC75
KENALOXONE,1,Ke naloxone
RW,1,RW
EXHIBITINGTURNING,1,Exhibiting turning
TOP1CLEAVAGEACTIVITY,1,Top1 cleavage activity
T>IC50,1,T>IC50
R50,1,R50
DELTACORONARYFLOW,1,Delta coronary flow
SP,1,SP
BASISMOTILITY,1,Basis motility
LOG(1ED50),1,log(1/ED50)
GLUTATHIONELEVELS,1,Glutathione levels
VCF,1,Vc/F
LEVEL,1,Level
AGGREGATION,1,Aggregation
NITRATE,1,Nitrate
MNTD>90,1,MNTD>90
RECOVERED,1,Recovered
REDUCTIONINHEARTRATE,1,Reduction in heart rate
LOGDELTA(1T2),1,Log delta (1/T2)
DECREASEINARTERIALBLOODPRESSURE,1,Decrease in arterial blood pressure
MEANSCORE,1,Mean score
REMLATENCY,1,REM latency
CHANGEINRESPONSE,1,Change in response
CATIONINFLUX,1,Cation influx
POTENCYCLK4UM,1,Potency_Clk4_uM
KKMAX,1,Kkmax
ELIMINATION,1,Elimination
INCREASEINRESPONSE,1,increase in response
EC001,1,EC0.01
PAE,1,PAE
RBP,1,RBP
MEANSURVIVALDAYS,1,Mean survival days
KAEFFECT,1,KA effect
ACATACTIVITY,1,ACAT activity
DECREASEINAP,1,Decrease in AP
DHP-ISUSCEPTIBILITY,1,DHP-I susceptibility
TC50,1,TC50
SDS,1,SDS
TUMOUR[5-FU],1,Tumour_[5-FU]
BLOCKADE,1,Blockade
MIC98,1,MIC98
SIGNIFICANCE,1,Significance
[ALP]MAX,1,[ALP]max
%RESIDUALKINASEACTIVITY,1,% residual kinase activity
LOGPM,1,logPm
MEANNOOFSHOCKS,1,Mean no. of shocks
BGREDUCTION,1,BG reduction
FBF,1,FBF
VASOPRESSORACTIVITY,1,Vasopressor activity
DELTAMST,1,Delta MST
NOOFSHOCKSACCEPTED5MIN,1,No. of shocks accepted/5 min
LOG(1MEC),1,log(1/MEC)
%NO2-,1,% NO2-
IL-1PRODUCTION,1,IL-1 production
MAXNON-TOXICDOSE,1,Max non-toxic dose
NOOFANIMALSPROTECTEDANIMALSTESTED,1,No. of animals protected/animals tested
MORPHOLOGY,1,Morphology
DOSERATIO,1,Dose ratio
ELOGD,1,eLog D
MRT,1,MRT
33,1,3.3
MEANLAF,1,Mean LAF
AMPLITUDE,1,Amplitude
AD,1,AD
OPTICALDENSITY,1,Optical density
PLATELETAGGREGATION,1,Platelet aggregation
GI,1,GI
CK,1,CK
TENSION,1,Tension
DEGRADATION,1,Degradation
NOHA,1,NOHA
AMPAEFFECT,1,AMPA effect
OXIDATION,1,Oxidation
POLYAMINELEVEL,1,Polyamine level
EXCRETEDGLUCOSE,1,Excreted glucose
RVR,1,RVR
RELATIVEODNUPTAKE,1,Relative ODN uptake
SERUMPROLACTINLEVEL,1,Serum prolactin level
MIGRATION,1,Migration
PYROGENICEFFECT,1,Pyrogenic effect
FRACTIONCURED,1,Fraction cured
PERMEABILITYLIMITED,1,Permeability limited
MICE,1,Mice
FAUCMIC,1,fAUC/MIC
KILLED,1,Killed
LOGCONCENTRATION,1,Log concentration
SIGMAH,1,sigmaH
RELATIVERATEOFHYDROLYSIS,1,Relative rate of hydrolysis
PEAKDELTAMAP,1,Peak deltaMAP
AIRECOVERYTIME,1,AI recovery time
AGGREGATIONRATIO,1,Aggregation ratio
MPC8,1,MPC8
R%,1,R%
LOGKOBS,1,Log Kobs
MEANKD,1,Mean KD
MRF,1,MRF
BRAINLEVEL,1,Brain level
CELLCYCLEANALYSIS,1,Cell cycle analysis
NOOFRATSOVULATED,1,No. of rats ovulated
INHIBITORYZONE,1,Inhibitory zone
LONG-TERMSURVIVORS,1,Long-term survivors
REACTIONRATE,1,Reaction rate
SPEEDOFINDUCTION,1,Speed of induction
MEANMAXIMUMTEMPDROP,1,Mean maximumtemp drop
NOOFANIMALSWITHDAMAGE,1,No. of animals with damage
INTRINSICTOXICITY,1,Intrinsic Toxicity
BBR,1,BBR
DOPAMINERELEASE,1,Dopamine release
INHIBITIONOVERTIME,1,Inhibition over time
CAVERAGE,1,Caverage
MIC>99,1,MIC>99
PROTONATED,1,Protonated
BINDINGRATIO,1,Binding ratio
ED35,1,ED35
ABOLITION,1,Abolition
KIRATIO,1,Ki ratio
IRONEXCRETION,1,Iron excretion
GAG,1,GAG
BITTERTASTEINTENSITY,1,Bitter taste intensity
STIMULATIONINDEX,1,Stimulation index
DOSEPERORGAN,1,Dose per organ
DISTRIBUTIONPERCENT,1,Distribution percent
HYPOCALCEMICACTIVITY,1,Hypocalcemic activity
KAPPRATIO,1,K app ratio
FI,1,FI
TIRATING,1,TI rating
TCI,1,TCI
PAWEDEMA,1,Paw edema
ANTAGONISTPOTENCY,1,Antagonist potency
NEUROPROTECTION,1,Neuroprotection
-LOGEC20,1,-Log EC20
LOG(1MIC>90),1,log(1/MIC>90)
NETTURNSMIN,1,Net turns/min
-LOGID50,1,-Log ID50
EOS,1,EOS
LOG10TCID50,1,log10 TCID50
INHIBITIONAT5NM,1,Inhibition at 5nM
GLUCOSECORRECTION,1,Glucose correction
ATTTACKS,1,Atttacks
LOGTCID50MG,1,Log TCID50/mg
LOG(10^6IC50),1,log(10^6/IC50)
METD,1,METD
CREATININECL,1,Creatinine_CL
TC1,1,T/C 1
SERUMTG,1,Serum TG
ALKYLATION,1,Alkylation
CULTURE,1,Culture
MEANARTERIALBLOODPRESSURE,1,Mean arterial blood pressure
OD,1,OD
FL-1,1,FL-1
PEAKRADIOACTIVITYINBLOOD,1,Peak radioactivity in blood
NONRGS-EC50(UM),1,NonRGS-EC50 (uM)
DECREASEINCR,1,Decrease in CR
NOOFVOMITINGEPISODES,1,No. of vomiting episodes
CREL,1,Crel
CGMPCONTENT,1,cGMP content
INCREASEINFOOTPADTHICKNESS,1,Increase in footpad thickness
SERUMLEVEL,1,Serum level
THYLPOSITIVECELLS,1,Thylpositive cells
OCC50,1,Occ50
TV,1,T/V
NOOFINVADEDCELLS,1,No. of invaded cells
RELATIVEKD,1,Relative Kd
PCHANGE,1,pChange
SKINTHICKNESS,1,Skin thickness
PAFC50,1,pAFC50
THYMOLYSIS,1,Thymolysis
V0,1,V0
GI50EC50,1,GI50/EC50
TOXICINDEX,1,Toxic index
MEC15,1,MEC1.5
"LOGPE,MAX",1,"Log Pe,max"
CCCT,1,CCCT
RELATIVEACTIVITYOFACHE,1,Relative activity of AChE
IONOTROPICACTIVITY,1,Ionotropic activity
TINH,1,T inh
EC996,1,EC99.6
BETA-LACTAMASEINDUCTION,1,Beta-lactamase induction
RELATIVECONTRACTILEPOTENCY,1,Relative contractile potency
NAN,1,nan
"PEC05,DISS",1,"pEC0.5,diss"
HEPATOTOXICITY(SEVEREHEPATITIS),1,Hepatotoxicity (severe hepatitis)
SCEREBRATIO,1,S/Cereb Ratio
POLYMORPHONUCLEARCELLS,1,Polymorphonuclear cells
VSV,1,VSV
ANTICONFLICTACTIVITY,1,Anticonflict activity
LOG[-6],1,Log [-6]
KTM,1,K Tm
HEPATICEXTRACTION,1,Hepatic extraction
LOG(1IC50),1,log(1/IC50)
NETLOGCHANGEINTUMORBURDEN,1,Net log change in tumor burden
HDL,1,HDL
MIGRATIONINDEX,1,Migration index
CPP,1,CPP
ANTICOAGULANTACTIVITY,1,Anticoagulant activity
AMOUNTOFOUABAINUSED,1,Amount of Ouabain used
LOGKH,1,Log KH
BLOCKADEDURATION,1,Blockade duration
A05,1,A0.5
FORMALDEHYDE,1,Formaldehyde
GENERALACTIVITY,1,General activity
AMOUNTOFUNREACTEDSUBSTRATE,1,Amount of unreacted substrate
BRONCHOALVEOLARLAVAGES,1,Bronchoalveolar lavages
IO,1,IO
MINED,1,Min ED
MAXCONTRACTILEACTIVITY,1,Max contractile activity
RTP,1,RTP
LWBW,1,Lw/Bw
MPC,1,MPC
INTRAPERITONEALSCORE,1,Intraperitoneal score
MEANLOGGI50,1,Mean log GI50
TRABECULARNO,1,Trabecular no.
OVERTBEHAVOIUR,1,Overt behavoiur
HEXOBARBST,1,Hexobarb ST
GROUPTOXICITY,1,Group toxicity
TRANSPORTRATE,1,Transport rate
INJECTIONDOSEG,1,Injection dose/g
LOCOMOTORACTIVITY,1,Locomotor activity
FLAKINGSCORE,1,Flaking score
ED75,1,ED75
V12,1,V1/2
GI50,1,GI50
CARTILAGESPACE,1,Cartilage space
CHANGEINBP,1,Change in BP
NOOFRABBITSCONVULSED,1,No. of rabbits convulsed
RELATIVEIC50,1,Relative IC50
AREA,1,Area
C(24H),1,C(24h)
ICA,1,ICA
PKINACT,1,pKinact
AVBLOCK,1,AV block
AMOUNTDELIVERED,1,Amount delivered
INCREASEINHEARTRATE,1,Increase in heart rate
COMPETITIVEPROTECTION,1,Competitive protection
TOTALTURNS,1,Total turns
DELTAERP,1,Delta ERP
MNTD,1,MNTD
ULCERINCIDENCE,1,Ulcer incidence
BEHAVIORSCORE,1,Behavior score
TUMORGROWTH,1,Tumor growth
AUIC,1,AUIC
RELATIVELUCIFERASERESPONSE,1,Relative luciferase response
ANTAGONIST,1,Antagonist
FICI80,1,FICI80
EC75,1,EC75
IRRITATIONOFEYES,1,Irritation of eyes
AVERAGESKINREACTION,1,Average skin reaction
DELTABEATSMIN,1,Delta beats/min
PA50,1,pA50
AVERAGECOLONYCOUNT,1,Average colony count
IRONOUTPUT,1,Iron output
ISC,1,ISC
RATIO,1,Ratio
AEACTIVITY,1,AE activity
SHLEVEL,1,SH level
LOGPION,1,Log Pion
APPROXPKA,1,Approx. pKa
NOOFVIRUSFREEMICE,1,No. of virus free mice
TPO(MAX),1,TPO(max)
%OFACTIVITYREMAINING,1,% of activity remaining
APD50,1,APD50
POPULATIONFRAGMENTEDNUCLEI(%),1,Population Fragmented Nuclei (%)
INITIALCONCENTRATION,1,Initial concentration
BATWEIGHT,1,BAT weight
MNTD50,1,MNTD50
CUMULATIVEURINEVOLUME,1,Cumulative urine volume
([I][S]05),1,([I]/[S]0.5)
CELLNODISH,1,Cell no/dish
C10,1,C10
FEZ,1,Fez
NOOFGUINEAPIGSPROTECTED,1,No. of guinea pigs protected
WCC90,1,WCC90
AC40,1,AC40
HEPATOTOXICITY(MODERATE),1,Hepatotoxicity (moderate)
ILS(SUR),1,ILS (Sur)
INCREASECONTRACTILITY,1,Increase contractility
DAR,1,DAR
NOOFPLAQUES,1,No. of plaques
PARASITEMIA,1,Parasitemia
RATIOED50,1,Ratio ED50
CUTANEOUSTOXICOLOGYSCORE,1,Cutaneous toxicology score
DMF,1,DMF
NO2-(MOLMOL),1,NO2- (mol/mol)
ACTIVECONCENTRATIONI,1,ActiveConcentrationI
PHOSPHOLIPIDOSISAS%OFPOSITIVECONTROL,1,Phospholipidosis as % of positive control
LIPHOPHILICITY,1,Liphophilicity
EFFICIENCY,1,Efficiency
VAGUS,1,Vagus
PKA(1),1,pKa(1)
NOOFDEADANIMALS,1,No. of dead animals
IW,1,IW
EMAXL,1,EmaxL
CTF,1,CTF
SHIFT,1,Shift
DIFFERENTIATEDCELLS,1,Differentiated cells
KIOBS[I],1,Ki obs / [I]
B(DPB),1,B(DPB)
IPOL,1,IPol
LDHINCREASE-ACTIVITYSCORE,1,LDH Increase - Activity Score
NEUTLE,1,NEUTLE
BASALCONTROL,1,Basal control
HEMODYNAMICCHANGE,1,Hemodynamic change
SAFETYRATIO,1,Safety ratio
INHIBITORYBINDING,1,Inhibitory binding
DELTAERPC,1,Delta ERPc
INHIBITIONCONSTANT,1,Inhibition constant
RESCUEDNEURONS,1,Rescued neurons
CE37,1,CE37
ACETALDEHYDE,1,Acetaldehyde
NOOFMICEDEAD,1,No. of mice dead
FH,1,Fh
PKAAN,1,pKa AN
NOOFKILLEDORPARALYZED,1,No. of killed or paralyzed
HCR,1,HCR
MBIC50,1,MBIC50
OUABAINDOSE,1,Ouabain dose
RESPONDER,1,Responder
MEANBODYWEIGHT,1,Mean body weight
ERP3,1,ERP3
RPP,1,RPP
RCI,1,RCI
LOAEL,1,LOAEL
DD,1,DD
INHIBITIONCONCENTRATION,1,Inhibition concentration
WEIGHTREDUCTION,1,Weight reduction
DECREASEINSBP,1,Decrease in SBP
CHANGESINAIRWAYRESISTANCE,1,Changes in airway resistance
MACROPHAGECYTOTOXICITY,1,Macrophage cytotoxicity
GASTRICCONCENTRATION,1,Gastric concentration
SPECIFICACTIVITY,1,Specific activity
ACTIVITY(MG),1,Activity (mg)
CLOGP,1,CLogP
"CAVE,SS",1,"Cave,ss"
PERTURBATIONS,1,Perturbations
AGONISTRESPONSE,1,Agonist response
RESORPTION,1,Resorption
DELTAH,1,deltaH
SF,1,SF
LOGII50,1,Log II50
PDC,1,PDC
RATIOPKB,1,Ratio pKb
MAXRELAXATION,1,Max relaxation
AOA,1,AOA
[EOP']INFINITY[EOH]INFINITY,1,[EOP']infinity/[EOH]infinity
BIOLOGICALACTIVITY,1,Biological activity
NOOFMICESURVIVING>6MONTHS,1,No. of mice surviving >6 months
LOGD74,1,LogD7.4
DFM,1,DFM
SS,1,SS
PTC50,1,pTC50
LUCIFERASEINFECTIONASSAY-IC50,1,LUCIFERASE INFECTION ASSAY - IC50
EII50,1,EII50
K0,1,k0
TS,1,Ts
PRA1,1,pRA1
ILS(MGKG),1,ILS (mg/kg)
ANTIBODYRESPONSE,1,Antibody response
EEREF,1,E/Eref
BODYWEIGHTLOSSATNADIR,1,Body weight loss at nadir
PEAKEFFECTTIME,1,Peak effect time
MBP,1,MBP
TOXICITYINDEX,1,Toxicity index
CARNITINEACETYLTRANSFERASE,1,Carnitine acetyl transferase
2PT,1,2PT
MBC>999,1,MBC>99.9
[EA],1,[EA]
TSHCHOL,1,TSH/chol
BHIA50,1,BHIA50
LOG1B+100,1,Log 1/B+100
VELOCITYRELATIVETOATP,1,Velocity relative to ATP
KI0,1,Ki0
MAXAGGREGATION,1,Max aggregation
DUR,1,DUR
EXCRETIONRATE,1,Excretion rate
KA-,1,kA-
K'O,1,k'o
RECOVERYBTOA(MEAN),1,Recovery B to A (mean)
AMOUNTFORMED,1,Amount formed
MAXDELTABP,1,Max delta BP
LOG10CFUG,1,log10CFU/g
MAXLOWERING,1,Max lowering
REMAININGRATIO,1,Remaining ratio
DNACROSSLINKING,1,DNA crosslinking
INITIALACTIVITY,1,Initial activity
ID50RATIO,1,ID50 ratio
TETRAMER,1,Tetramer
LOGGEOMETRICMEAN,1,Log geometric mean
HYPOCHROMICSHIFT,1,Hypochromic shift
DECREASEINTONE,1,Decrease in tone
RESPONSEUNIT,1,Response unit
PC100,1,PC100
ADJUVANTEFFECT,1,Adjuvant effect
TOTALTRITIUM,1,Total tritium
LVDPDTMAX(DELTA),1,LV dP/dTmax(delta)
ROTATIONS10H,1,Rotations/10 h
NOAEL,1,NOAEL
LACTONE,1,Lactone
SURVIVINGFRACTION,1,Surviving fraction
BRAINLESION,1,Brain lesion
KDSPA,1,KdSPA
-DELTAGOBS,1,-Delta G obs
INCIDENCE,1,Incidence
HT50,1,HT50
DECREASEINMABP,1,Decrease in MABP
NOOFDEADMICE,1,No. of dead mice
MAXRELEASE,1,Max release
VASODILATION,1,Vasodilation
INTRINSICEFFICACY,1,Intrinsic efficacy
LOGPOCTC,1,Log Poct C
GTPASEACTIVITY,1,GTPase Activity
EDP,1,EDP
EC5,1,EC5
VOMITS,1,Vomits
BASALGH,1,Basal GH
IMPDHACTIVITY,1,IMPDH activity
CELOGK',1,CE logK'
LOSSOFACTIVITY,1,Loss of activity
EFTPC,1,EFTPC
POW,1,Po/w
AB50,1,AB50
CLONIC,1,Clonic
REDUCEDCIRCADIANOSCILLATION,1,Reduced_circadian_oscillation
OTHERS,1,Others
REPORT,1,Report
DIFFERENCE,1,Difference
OCC90,1,Occ90
MEANTOTALPLASMACONCENTRATION,1,Mean total plasma concentration
CMPH,1,CMpH
2APTT,1,2aPTT
EXHAL+B1718ATIONOF14CO2,1,Exhal+B1718ation of 14CO2
CURRENTS,1,Currents
INHIBITIONRATIO,1,Inhibition ratio
WEIGHTGAINORLOSS,1,Weight gain or loss
E2,1,E2
DECREASEINACTIVITY,1,Decrease in activity
MEANVESICLESCORE,1,Mean vesicle score
INHIBITORYRESPONSE,1,Inhibitory response
PHOTOLYSIS,1,Photolysis
VCRACCUMULATION,1,VCR accumulation
CARDIACDEPRESSION,1,Cardiac depression
TN,1,TN
HARELEASE,1,HA release
TAI,1,TAI
KIINACT,1,Ki inact
DPMBOUNDTOPROTEIN,1,dpm bound to protein
DTOX,1,d tox
UTERINEWEIGHTEFFECT,1,Uterine weight effect
MICEINFI,1,Mice In. / Fi.
"S20,W",1,"S20,w"
PFE3,1,pFe3
FIBERSPREPARATIONS,1,Fibers/preparations
ILS40,1,ILS40
CBRAIN,1,Cbrain
RATIOPKI,1,Ratio pKi
MAXHYPOTENSION,1,Max hypotension
GGTINCREASE-INDEXVALUE,1,GGT Increase - Index Value
MIC70,1,MIC70
PHYSICALDEPENDENCECAPACITY,1,Physical dependence capacity
NOOFSURVIVORSTOTAL,1,No. of survivors/total
TREMOROLYTICDOSE,1,Tremorolytic dose
LOG10LC50,1,Log 10 LC50
RELAXATION,1,Relaxation
RATECONSTANT,1,Rate constant
PKAAZ,1,pKa AZ
NETDRYWEIGHT,1,Net dry weight
ZONEOFSTIMULATION,1,Zone of stimulation
GASTRICDAMAGE,1,Gastric damage
LOG1DELTACA,1,Log 1/delta/Ca
SEVERITYMEAN,1,Severity mean
CLOGD74,1,CLogD7.4
KA1,1,Ka1
TAR,1,TAR
CONTRACTILITY(LVDPDT),1,Contractility (LV dP/dt)
CMP,1,CMP
ABSAC90,1,AbsAC90
INHIBITORYINDEX,1,Inhibitory index
KNA,1,KNa
GR20,1,GR20
LOGPF,1,logPF
[3H]CONCENTRATION,1,[3H] concentration
CURED,1,Cured
MDL50,1,MDL50
ESTROGENICEFFECT,1,Estrogenic effect
INHIBITORYACTIVITYRATIO,1,Inhibitory activity ratio
LOG1ID75(UML-1),1,Log 1/ID75 (uM L-1)
KREACT,1,Kreact
EGGREDUCTION,1,Egg reduction
LOG1EDMES(25),1,Log 1/EDMES(2.5)
TD100,1,TD100
LOGAC50,1,Log AC50
AUG,1,AUG
HCT,1,HCT
KIEQ,1,Kieq
DELTALOG(TAUKA),1,deltalog(Tau/KA)
S05,1,S0.5
NADHCONTENT,1,NADH content
MAXIMALACTIVATION,1,Maximal activation
PDC50,1,pDC50
RATIOOFDISTRIBUTION,1,Ratio of distribution
FLUOROSCENCE,1,Fluoroscence
IMAX,1,Imax
INJECTEDDOSE,1,Injected dose
RATIOAUC,1,Ratio AUC
BASELINESYSTOLICBP,1,Baseline systolic BP
DR10,1,DR10
NOOFPROTECTEDTESTED,1,No. of protected/tested
MOTORACTIVITY,1,Motor activity
BT,1,BT
NOOFMICEWITHOUTTUMORS,1,No. of mice without tumors
RBA1,1,RBA1
REDUCTIONINPROSTATEWEIGHT,1,Reduction in prostate weight
I10,1,I10
SENSITIZEDANIMALS,1,Sensitized animals
WETWEIGHTOFTISSUE,1,Wet weight of tissue
POSITIVECELLS,1,Positive cells
EDEMARATIO,1,Edema ratio
MOBILIZATION,1,Mobilization
ADPFORMATION,1,ADP formation
CIC90,1,CIC90
CONVULSIONS,1,Convulsions
RL,1,RL
HEPATOTOXICITY(SUCCESSFULREINTRODUCTION),1,Hepatotoxicity (successful reintroduction)
CICIC50,1,CIC IC50
ACTIVEDOSERANGE,1,Active dose range
EGGS,1,Eggs
A1SELECTIVITY,1,A1 selectivity
GOTLEVEL,1,GOT Level
CARBOHYDRATE,1,Carbohydrate
LOG[-10],1,Log [-10]
LLRMSAD,1,LLR msad
LOG[-9],1,Log [-9]
NOFORMATION,1,NO formation
PDI,1,PDI
AMOUNTOF[3H]THYMIDINE,1,Amount of [3H]thymidine
EC10,1,EC10
RANGEOFDEATH,1,Range of death
PFUML,1,PFU/ml
RTACTIVITY,1,RT activity
UNCHANGEDTRACER,1,Unchanged tracer
RETENTIONINDEX,1,Retention_index
DELTAHR50,1,Delta HR50
RELATIVEANTIANDROGENICACTIVITY,1,Relative antiandrogenic activity
LC70,1,LC70
RELATIVEANALGESICPOTENCY,1,Relative analgesic potency
PRESSURERESPONSE,1,Pressure response
ED6,1,ED6
FRACTIONIONISED,1,Fraction ionised
GGTINCREASE-NUMBEROFREPORTS,1,GGT Increase - Number of Reports
MAXFOLDINCREASE,1,Max fold increase
CHANGEOFTUMORAREA,1,Change of tumor area
REACTIONTIME,1,Reaction time
MIC50,1,MIC50
ED200,1,ED200
CC25,1,CC25
MAXDVDT,1,Max dV/dt
MEANTUMORDELAY,1,Mean tumor delay
NEUTROPHILS,1,Neutrophils
HYPO,1,HYPO
MEANEXCRETIONOFK+,1,Mean excretion of K+
HSFACTIVITYX10E2,1,HSF activity x10e2
TOXTEST,1,TOX/TEST
REACTION,1,Reaction
NITRITE,1,Nitrite
PAH50,1,pAH50
MEDIANTC,1,Median T/C
MITC95,1,MITC95
IZ,1,IZ
PROPIOALDEHYDEGENERATED,1,Propioaldehyde generated
DERIVEDTRABECULARNUMBER,1,Derived trabecular number
T>MIC,1,T>MIC
POTENTIATIONINFLECTIONPOINT,1,Potentiation inflection point
KAPS,1,K aps
NOOFCOLONYFORMINGUNITS,1,No. of Colony forming Units
PRODRUGREDUCTION,1,Prodrug reduction
KHYDROL,1,Khydrol
HEPATOTOXICITY(CHOLEOSTASIS),1,Hepatotoxicity (choleostasis)
DELTALV,1,Delta LV
ALPHAE,1,Alpha E
TOXICITY(DEATHS),1,Toxicity (deaths)
P[A50],1,p[A50]
ANALGESIA,1,Analgesia
QKD,1,qKD
PDK,1,PDK
EP22,1,Ep2/2
MNTD>75,1,MNTD>75
CTC50,1,CTC50
WETWEIGHT,1,Wet weight
LOGPALK,1,Log Palk
LOCOMOTION,1,Locomotion
ECI,1,ECI
POTENCYVSEKC,1,Potency vs EKC
CTD50,1,CTD50
RELATIVEDAUNOMYCINACCUMULATION,1,Relative daunomycin accumulation
ED100,1,ED100
LOG1LD10,1,Log 1/LD10
RELATIVELEVEL,1,Relative level
BPCHANGE,1,BP change
TRANSPORTERPRODUCTIONRATE(R),1,Transporter production rate (r)
THRUPTAKE,1,Thr uptake
AVERAGEFOODINTAKE,1,Average food intake
LDHINCREASE-INDEXVALUE,1,LDH Increase - Index Value
INCREASEINBLOODPRESSURE(PR),1,Increase in blood pressure (P/R)
TC41,1,T/C 41
RV,1,RV
CONTROLST,1,Control S/T
CA2+ANTAGONISTICACTIVITY,1,Ca2+ antagonistic activity
OUABAIN,1,Ouabain
CLBILIARY,1,CL_biliary
LOG10EID50G,1,log10EID50/g
FREEFRACTION,1,Free fraction
MEANENHANCEMENTOFBINDING,1,Mean enhancement of binding
CLTOTAL,1,CLtotal
PARASITEMIACLEARANCEAFTERTREATMENT,1,Parasitemia clearance after treatment
UB,1,UB
ANTIBODYTITER,1,Antibody titer
LC100,1,LC100
ALPHA,1,Alpha
REDUCEDSERPINE1GENEEXP,1,Reduced_Serpine1_gene_exp
ACIDOUTPUT,1,Acid output
SERUMGLUCOSE,1,Serum glucose
IC25,1,IC25
SELECTIVITYQUOTIENT,1,Selectivity quotient
LOGRATIO,1,Log ratio
MEANSURVIVALTIME,1,Mean survival time
ALTGPT,1,ALT/GPT
[LDH]MAX,1,[LDH]max
KCALC,1,K calc
HSAI,1,HSAI
CELLSARRESTED,1,Cells arrested
CONTROLOFGROWTH,1,Control of growth
INITIALRATERATIO,1,Initial rate ratio
KX10E-3,1,k x10e-3
CHOLESTEROLCONCENTRATION,1,Cholesterol Concentration
ULCEROGENICACTIVITY,1,Ulcerogenic activity
OXYGENCONSUMED,1,Oxygen consumed
"%ENZYMEACTIVITY(RELATIVETODMSOCONTROLS,AVERAGEN=2)",1,"% Enzyme Activity (relative to DMSO controls, average n=2)"
ICL50,1,ICL50
CELLSIZE,1,Cell size
SSAT,1,SSAT
FC50,1,FC50
PKM,1,pKm
IC90,1,IC90
SLI,1,SLI
PROLONGEDARP,1,Prolonged ARP
%INHIBITIONINSPLEEN,1,% inhibition in spleen
%RELEASEOFNITRICOXIDE,1,% release of nitric oxide
GR,1,GR
2-DGUPTAKESTIMULATION,1,2-DG uptake stimulation
LOGKZ,1,Log KZ
STOOLOUTPUT,1,Stool output
LOG1IC90,1,Log 1/IC90
KRELATIVE,1,Krelative
SEIZURESTAGE,1,Seizure stage
RELATIVET12,1,Relative t1/2
I05,1,I0.5
RELATIVEMOLARPOTENCY,1,Relative molar potency
DISSOCIATIONRATECONSTANT,1,Dissociation rate constant
CELLSURVIVED,1,Cell survived
APPROXIMATECOLONYFORMATIONUNIT,1,Approximate colony formation unit
MBC9999,1,MBC99.99
LUI,1,LUI
IMRATIO,1,I/M ratio
MINCONCENTRATION,1,Min concentration
ECAR,1,ECAR
ED58,1,ED58
MAXCFRESPONSE,1,Max CF response
PCA,1,PCA
CA2+ANTAGONISM,1,Ca2+ antagonism
SUPEROXIDEANION,1,Superoxide anion
MAXRESPONSE,1,Max response
CELLPERMEATION,1,Cell permeation
RELATIVEPROTECTION,1,Relative protection
BAV,1,BAV
KUNCAT,1,Kuncat
METABOLICRATE,1,Metabolic rate
ASPIRINFORMED,1,Aspirin formed
PROFILE,1,Profile
LOG1I50,1,Log 1/I50
ONCOSTATICINDEX,1,Oncostatic index
KIRR,1,kirr
FR10CONTROL,1,FR10 control
CLT50,1,CLT50
CHANGEOFHR,1,Change of HR
SOLUBILITYRATIO,1,Solubility ratio
LOG(10'3IC50),1,log(10'3/IC50)
MPCMIC,1,MPC/MIC
PLAQUEINHIBITIONRESULT,1,Plaque inhibition result
LYSIS,1,Lysis
NODEATHSTREATED,1,No. deaths/treated
GSHLEVEL(MG),1,GSH level (mg)
ICL5,1,ICL5
PGI,1,PGI
PCACO-2,1,PCaco-2
CLINEDSCREENTEST,1,Clined screen test
PKAPP,1,pKapp
NOPROTECTEDTESTED,1,No. protected/tested
MAODEAMINATION,1,MAO deamination
DNAUC,1,DNAUC
AUCTOTAL,1,AUC total
EMESIS,1,Emesis
SENSORYEVALUATION,1,Sensory evaluation
NBTPOSITIVECELLS,1,NBT positive cells
NED,1,NED
AGGREGATIONRESPONSE,1,Aggregation response
MID,1,MID
TISSUEWEIGHT,1,Tissue weight
MEANTIMETOSEIZURE,1,Mean time to seizure
ICMAX,1,ICmax
TOTALGLOMERULI,1,Total glomeruli
AVERAGEWEIGHTGAIN,1,Average weight gain
ARRHYTHMIASTIMES,1,Arrhythmias times
APE,1,apE
VDSS,1,Vdss
UNBOUND,1,Unbound
OBSERVEDLOGAPA,1,Observed log APA
%OFENGAGEMENT,1,% of engagement
AUMCT,1,AUMCt
CMAXSS,1,Cmax/SS
CMAXTUMOR,1,Cmax_tumor
CC50,1,CC50
NOOFMICESURVIVED,1,No. of mice survived
REMAINED,1,Remained
THERAPEUTICDOSE,1,Therapeutic dose
LOG(1I50),1,log(1/I50)
MG-MID,1,MG-MID
PARASITECLEARANCETIME,1,Parasite_Clearance_time
ENTRYLATENCY,1,Entry latency
IUP,1,IUP
INCREASEINLD50,1,Increase in LD50
EXCESSMST,1,Excess MST
POSTANITBIOTICEFFECT,1,Post anitbiotic effect
TD50,1,TD50
MUSCARINICAGONISTINDEX,1,Muscarinic agonist index
ANTAGONISM,1,Antagonism
50%NAPROXENFORMED,1,50% naproxen formed
LIFESPAN,1,Life span
DELTATG,1,Delta TG
CS50,1,CS50
INJECTED,1,Injected
KBETA,1,K beta
PK3',1,pK3'
FPGCORRECTION,1,FPG correction
CLZF,1,CLz/F
C50G,1,C50g
INITIALHEARTRATE,1,Initial heart rate
CONTROLTUMORVOLUME,1,Control tumor volume
CHANGEOFPREDOSE,1,Change of predose
NOOFCIRCLINGS,1,No. of circlings
P(1MIC),1,p(1/MIC)
BASALINHIBITION,1,Basal inhibition
A2SELECTIVITY,1,A2 selectivity
L,1,L
HF,1,HF
TOTALINFARCTVOLUME,1,Total infarct volume
CHANGEINCONFLICT,1,Change in conflict
YA,1,Ya
WBC,1,WBC
LC10,1,LC10
DISSOCIATIONCONSTANT,1,Dissociation constant
AG80,1,AG80
LOGP(100-P),1,Log P/(100-P)
BODYWEIGHTLOSS,1,Body weight loss
PEFF,1,Peff
CHANGEINIC50,1,Change in IC50
VOLUMEOFASCRITFLUID,1,Volume of ascrit fluid
RELATIVEEFFICIENCY,1,Relative efficiency
DELTAPKA,1,delta pKa
GM-MIC,1,GM-MIC
PRL,1,PRL
PARTIALREMISSION,1,Partial remission
CF,1,CF
ABSAC30,1,AbsAC30
SHRDELTABLOODPRESSURE,1,SHR delta blood pressure
EXTRACTIONRATIO,1,Extraction ratio
EC50IGC,1,EC50 iGC
PRA2,1,pRA2
RESISTANCEFACTOR,1,Resistance factor
EDMES(25),1,EDMES(2.5)
ED150,1,ED150
ORGANDISTRIBUTION,1,Organ distribution
CHANGEINVOLUME,1,Change in volume
TG,1,TG
CLONAZEPAM,1,Clonazepam
7-DAYWEIGHTCHANGE,1,7-day weight change
C10APD90,1,C10APD90
SURVIVORSAT24H,1,Survivors at 24 h
DAY9-RTV,1,Day 9-RTV
PK1A,1,pK1a
TA,1,T/A
SALURETICSCORE,1,Saluretic score
VRT(T),1,VRT(t)
ABSORPTION,1,Absorption
Q,1,Q
RELATIVEID50,1,Relative ID50
NOOFMICEINFECTEDTOTAL,1,No. of mice infected /total
NH,1,nH
GLUTATHIONE,1,Glutathione
HMGRACTIVITY,1,HMGR activity
RECOVERYRATE,1,Recovery rate
ANTI-HIVACTIVITY,1,Anti-HIV activity
H2O2PROT,1,H2O2 prot
DELTAMABP,1,Delta MABP
PLASMATG,1,Plasma TG
NOOFMETASTASES,1,No. of metastases
ED90,1,ED90
LC50RATIO,1,LC50 ratio
MPA,1,MPA
RATIOAUCMIC,1,RatioAUC/MIC
LOG10CCID50G,1,Log10CCID50/g
PLASMALEPTIN,1,Plasma_leptin
BIOREDUCTION,1,Bioreduction
ITP,1,ITP
CHANGEINRESPONSERATE,1,Change in response rate
SAFTEYMARGIN,1,Saftey margin
EC50RATIO,1,EC50 ratio
%CONTROLSPECIFICBINDING(MEANN=2),1,% control specific binding (Mean n=2)
DECREASEINFIGHTING,1,Decrease in fighting
KPCB,1,KPCB
PSYCHOTROPICEFFECT,1,Psychotropic Effect
WEIGHTRATIO,1,Weight ratio
FMUT,1,Fmut
OFRATSTURNING,1,Of rats turning
MORTALITYTHRESHOLD,1,Mortality threshold
EQUILIBRIUMOD340,1,Equilibrium OD340
1KI,1,1/Ki
INHIBITORYEFFECT,1,Inhibitory effect
MBC995,1,MBC99.5
MEANNOOFDAYSPOST-INFECTIONTODEATH,1,Mean no. of days post-infection to death
C20,1,C20
VZF,1,Vz/F
MEANNUMBEROFPARASITES,1,Mean number of parasites
PA10,1,pA10
QT,1,QT
IUPAD50,1,IUP AD50
CALCULATEDRATIO,1,Calculated Ratio
NOOFINFECTEDCELLS,1,No. of infected cells
SEVERITY,1,Severity
ANTICONVULSANTDOSE,1,Anticonvulsant dose
MAXI-KCURRENT,1,Maxi-K current
DIOXYGENUPTAKERATE,1,Dioxygen uptake rate
CENTRALSELECTIVITY,1,Central selectivity
FRACTIONCLEAREDRENALLY,1,Fraction cleared renally
RATEOFFORMATION,1,Rate of formation
ENZYMEINHIBITION,1,Enzyme inhibition
GGTINCREASE-ACTIVITYSCORE,1,GGT Increase - Activity Score
TRANSFECTIONEFFICIENCY,1,Transfection efficiency
SUCCEEDEDTESTED,1,Succeeded/tested
WEIGHT(MGG),1,Weight (mg/g)
ALPHA50,1,Alpha 50
IC5,1,IC5
CHANGEINMST,1,Change in MST
RELATION,1,Relation
HYDROXYPROLINERELEASE,1,Hydroxyproline release
T3,1,T3
NOOFRATS,1,No. of rats
MYDRIASIS,1,Mydriasis
ED3,1,ED3
INVITROACTIVITY,1,In vitro activity
MDHREACTIVATION,1,MDH Reactivation
ODMAX,1,OD max
PERMEABILITYCOEFFICIENT,1,Permeability coefficient
CUREDANIMALS,1,Cured animals
ATHEROGENICINDEX,1,Atherogenic index
BQL,1,BQL
MAPD90,1,MAPD90
CELLDENSITY,1,Cell density
THROMBOXANEB2(TXB2),1,Thromboxane B2 (TxB2)
PLASMA[14C]CHOLESTEROL,1,Plasma [14C] cholesterol
UPTAKERATE,1,Uptake rate
PAD,1,pAD
MOTILITYREDUCTIONCYTOTOXICITY,1,MOTILITY REDUCTION/CYTOTOXICITY
DRUGMETABOLISM,1,Drug metabolism
CA2+TRANSPORTSM,1,Ca2+ transport S/M
TOTALIRONOUTPUT,1,Total iron output
RHR,1,RHR
TRITIUMRELEASE,1,Tritium release
NOOFESCAPEFAILURE,1,No. of escape failure
ACIDTITER,1,Acid titer
DRUGCONCENTRATION,1,Drug concentration
EDAREC,1,ED Arec
URINARYEXCRETION,1,Urinary excretion
EC60,1,EC60
PRESUMEDDRUG-RELATEDDEATHS,1,Presumed drug-related deaths
TDSRATIO,1,TDS ratio
VASOPRESSORRESPONSES,1,Vasopressor responses
CONTROLRETCHES,1,Control retches
PIGMENTATIONCAPACITY,1,Pigmentation capacity
CLR,1,CLr
SCMET,1,scMet
MAXDECREASEINBLOODPRESSURE,1,Max decrease in blood pressure
MTT,1,MTT
ED13,1,ED1/3
CT10RATIO,1,CT10 ratio
LOGK(LUNG),1,logK(lung)
UTERUSEFFECT,1,Uterus effect
TM,1,Tm
STENOSIS,1,Stenosis
SELECTIVITYINBINDING,1,Selectivity in binding
ACTUALDURACTION,1,Actual duraction
IMMUNOSUPRESSIVEACTIVITY,1,Immunosupressive activity
MECHANISTICREFERENCE,1,Mechanistic reference
GROSSMORPHOLOGY,1,Gross morphology
RUMAX,1,RUmax
AMYLASESTIMULATION,1,Amylase stimulation
APA,1,APA
DISEASECONTROL,1,Disease control
ID,1,ID
BMAX1,1,Bmax1
NEPHROTOXICITY,1,Nephrotoxicity
DISTRIBUTION,1,Distribution
INVIVODURATION,1,In vivo duration
CAROTIDFLOWREDUCTION,1,Carotid flow reduction
GAIN,1,Gain
NB,1,NB
CELLPROLIFERATIONAC50,1,Cell Proliferation AC50
1IC50,1,1/IC50
PRCF,1,PRCF
INFECTIONSCOREMEAN,1,Infection score mean
EDMAX,1,EDmax
UOSM,1,U osm
FLT,1,FLT
MEDIANTUMORALVOLUME,1,Median tumoral volume
CHANGEINBLOODFLOW,1,Change in blood flow
SEC50,1,SEC50
TISSUEAREA,1,Tissue area
DEGREEOFRESISTANCE,1,Degree of resistance
CMIN,1,Cmin
FPEC50,1,fpEC50
-LOGKD,1,-Log KD
THERAPEUTICRATIO,1,Therapeutic ratio
CHANGEINSTROKEVOLUME,1,Change in stroke volume
THYMIDINEREVERSAL,1,Thymidine reversal
RK,1,rK
BILEFLOW,1,Bile flow
DILISEVERITYCLASS,1,DILI_severity_class
ANTILIPIDPEROXIDATION,1,Antilipid peroxidation
DELTAS,1,deltaS
RESIDUALRRACTIVITY,1,Residual RR activity
TENSILESTRENGTH,1,Tensile strength
ERYTHROIDINDUCTION,1,Erythroid induction
HALFDURATION,1,Half duration
OPTIMUMTC,1,Optimum T/C
KHD,1,Khd
HEMELOSS,1,Heme loss
NOOFDOGSUSED,1,No. of dogs used
PICSEIZURE,1,PIC seizure
DECREASEINQAINTERVAL,1,Decrease in QA interval
AGONISTPOTENCY,1,Agonist potency
NOOFPITS,1,No. of pits
RELATIVEF%,1,Relative F%
TUBULINBINDING,1,Tubulin binding
MORBIDITY,1,Morbidity
LIVERCONCENTRATION,1,Liver concentration
RNAFRACTION,1,RNA fraction
MCD,1,MCD
HEPATOTOXICITY(CHRONICLIVERDISEASE),1,Hepatotoxicity (chronic liver disease)
FBFRATIO,1,FBF Ratio
AGGREGATE,1,Aggregate
VIRUSYIELDREDUCTION,1,Virus yield reduction
G30,1,G30
SKINGRAFTSURVIVAL,1,Skin Graft Survival
ILEALACTIVITY,1,Ileal activity
AVERAGECHANGEINBODYWEIGHT,1,Average change in body weight
LEVELINSERUM,1,Level in serum
INTRINSICACTIVITY,1,Intrinsic activity
CHANGEINDASYNTHESIS,1,Change in DA synthesis
PA2APP,1,pA2 app
RENALCLEARANCE,1,Renal clearance
RN,1,Rn
HPB,1,HPB
LEISHMANICIDALACTIVITY,1,Leishmanicidal activity
SURVIVORSATDAY15,1,Survivors at day 15
ANTIGENP24CONTENT,1,Antigen p24 content
TRANSACTIVATION,1,Transactivation
TOTALDPM,1,Total DPM
INFECTEDERYTHROCYTES,1,Infected erythrocytes
ED250,1,ED250
MEANAXONALAREA,1,Mean axonal area
DELTARBF,1,Delta RBF
AERP,1,AERP
KM(APP),1,Km(app)
INIHIBITION,1,Inihibition
PIC90,1,pIC90
K2',1,k2'
SERUMCA2+,1,Serum Ca2+
IC33,1,IC33
DELTACPMX10E-3,1,Delta cpm x10e-3
PLASMA[5-FU],1,Plasma_[5-FU]
GASTRICSCORE,1,Gastric score
PENETRATION,1,Penetration
GPTLEVEL,1,GPT Level
BC,1,BC
K3',1,k3'
HIND-PAWLICKLATENCYTIME,1,Hind-paw lick latency time
LOGD75,1,logD7.5
EFFECTIVECONCENTRATION,1,Effective concentration
RELATIVEEC30,1,Relative EC30
CA2+REDUCTION,1,Ca2+ reduction
FECALRECOVERY,1,Fecal recovery
LOGK(BLOOD),1,logK(blood)
ALPCHANGETO,1,ALP_CHANGE_TO
PALPHAKA,1,p alphaKa
SKINREACTION,1,Skin reaction
LOGIC50(UM),1,Log IC50(uM)
DSB,1,DSB
LOGBF,1,Log B/F
IC40,1,IC40
DISSOCIATIONRATIO,1,Dissociation ratio
CHANGE,1,Change
QTCDELTA,1,QTc delta
SIMULATION,1,Simulation
CHANGESINDYNAMICCOMPLIANCE,1,Changes in dynamic compliance
FOCIDISH,1,Foci/dish
TUMORHALFGROWTH,1,Tumor half growth
CACO-2PAPP,1,Caco-2 Papp
MEDIAN,1,Median
EMIN,1,Emin
INACTIVATIONTIME,1,Inactivation time
DELTACT,1,deltaCT
VDU,1,Vdu
AVERAGECONSUMED,1,Average consumed
AAD,1,A/Ad
SC200,1,SC200
TOXICITYDAYSURVIVORS,1,Toxicity day survivors
UTEROTROPICEFFECT,1,Uterotropic effect
TURNSFIRSTHOUR,1,Turns/first hour
WLCPRA,1,WLC PRA
GI20,1,GI20
RELATIVEINITIALRATE,1,Relative initial rate
STABILTY,1,Stabilty
NGRATIO,1,NG ratio
TRIGCHANGE,1,TRIG_CHANGE
MAXPOSSIBLEEFFECT,1,Max possible effect
MBIC=>90,1,MBIC=>90
STERILIZED,1,Sterilized
INFLUX,1,Influx
AST,1,AST
EDEMAVARIATION,1,Edema variation
KAPPX10E-7,1,K app x10e-7
RESORBINGIMPLANTS,1,Resorbing implants
IABC,1,I ABC
LOG1D125(MMKG-1),1,Log 1/D125 (mM kg-1)
HISTOPATHOLOGY,1,Histopathology
LOG1S0,1,log1/S0
FKI,1,fKi
RELATIVEBINDINGAFFINITY,1,Relative binding affinity
SERUMMG2+LEVEL,1,Serum Mg2+ level
NOOFRELAPSES,1,No. of relapses
DOSEEXCRETED,1,Dose excreted
AM,1,Am
LOG(1KM),1,log(1/Km)
MD,1,MD
ID75,1,ID75
VIRUSTITER,1,Virus titer
TGIR,1,TGIR
DELTANONHDL-C,1,Delta non HDL-C
ABERRANTCELLS,1,Aberrant cells
CPI,1,CPI
CT2,1,CT2
PROLONGATION,1,Prolongation
EXCRETIONCL-,1,Excretion Cl-
WBCCHANGE,1,WBC_CHANGE
SPERMATOGENICINDEX,1,Spermatogenic index
MACROPHAGEACTIVATION,1,Macrophage activation
EXCRETIONK+,1,Excretion K+
RATEOFMETABOLISM,1,Rate of metabolism
MINPLAGUEINHIBITORY,1,Min plague Inhibitory
PFCSPLEEN,1,PFC/spleen
NA+RESTORATION,1,Na+ restoration
TURNOVER,1,Turnover
-LOGIC50,1,-Log IC50
PTEXTENSION,1,PT extension
MED25,1,MED25
LOGKON,1,Log kon
PLAQUEACCUM,1,Plaque accum
LD30,1,LD30
OCCLUSIONTIME,1,Occlusion time
ACCEPTORACTIVITY,1,Acceptor activity
HEPATOTOXICITY(ANIMALTOXICITYKNOWN),1,Hepatotoxicity (animal toxicity known)
MEANVALUE,1,Mean value
HISTONEMODIFICATION,1,Histone_modification
-DELTAG,1,-Delta G
HC90,1,HC90
UNCUTDNA,1,Uncut DNA
NOPROTECTEDNODOSED,1,No. protected/ No.dosed
ORALACTIVITY,1,Oral activity
MIC>90,1,MIC>90
LD0,1,LD0
RELATIVEACTIVATION,1,Relative activation
NOOFSURVIVALS,1,No. of survivals
ACTIVITYRATIO,1,Activity ratio
IC90MUTANTIC90WT,1,IC90 mutant/IC90 WT
BMD,1,BMD
VAR,1,VAR
MNCC,1,MNCC
CONTROLRELAXATION,1,Control relaxation
TC@50MGKG,1,T/C @ 50mg/kg
SURVIVORSTOTAL,1,Survivors / total
LSD,1,LSD
RELATIVERESISTANCE,1,Relative resistance
MCH,1,MCH
LOGPO,1,Log Po
DIFFERENTIALAFFINITY,1,Differential affinity
COOPERATIVEEFFECT,1,Cooperative effect
BOTTOM,1,BOTTOM
KMAXKS,1,kmax/KS
T12(APP),1,t1/2(app)
EC91,1,EC91
INTRINSIC,1,Intrinsic
MAXTOLERATEDDOSE,1,Max tolerated dose
HELICITY,1,Helicity
TMSW,1,TMSW
MIC60,1,MIC60
PBI,1,PBI
NOOFMICEDEADDAYDIED,1,No. of mice dead/day died
ACTIVITYREMANING,1,Activity remaning
TTO,1,TTO
HC10,1,HC10
CLDF,1,CLd/F
RVRED15,1,RVR ED15
IC85,1,IC85
LWI,1,LWI
MINIMALBACTERIOSTATICCONCENTRATION,1,Minimal bacteriostatic concentration
CURES@10MGKG,1,Cures@ 10mg/kg
MPE50,1,MPE50
SPMAX,1,Sp Max
ROTARODTOXICITY,1,Rotarod toxicity
LYMLE,1,LYMLE
RELATIVECONCENTRATION,1,Relative concentration
CYTOTOXICACTIVITY,1,Cytotoxic activity
HEMISPHERESREDUCTION,1,Hemispheres reduction
URINEOSMOLALITY,1,Urine osmolality
MPD,1,MPD
OVULATINGRATS,1,Ovulating rats
INHIBITORYRATIO,1,Inhibitory ratio
HEARTWEIGHT,1,Heart weight
ANTIMALARIALACTIVITY,1,Antimalarial activity
AVERAGETUMORWEIGHT,1,Average tumor weight
APD,1,APD
SPF,1,SPF
LDHRELEASE,1,LDH release
RELATIVEKI,1,Relative Ki
FRACTIONCHANGE,1,Fraction change
CONTROLVOMITS,1,Control vomits
BK,1,BK
VDSSF,1,Vdss/F
LOGCELLKILL,1,Log cell kill
-LOGKD50,1,-Log KD50
NOOFWDS60MIN,1,No. of WDS/60 min
MEC20,1,MEC2.0
SKINUPTAKE,1,Skin uptake
NA,1,Na
AUCDOSE,1,AUC/dose
GLUCOSERISE,1,Glucose rise
RATEOFRECOVERY,1,Rate of recovery
LOGP',1,Log P'
ABSAC26UM,1,AbsAC26_uM
JUDGMENTS,1,Judgments
BGL,1,BGL
FRPAT10MICROM,1,FRP at 10microM
POPULATIONHOECHSTHIGHINTENSITYOBJECTS(%),1,Population Hoechst High Intensity Objects (%)
TOTALACIDOUTPUT,1,Total acid output
INHIBITORYDOSE,1,Inhibitory dose
CYTOCIDALACTIVITY,1,Cytocidal activity
BONEDAMAGESCORE,1,Bone damage score
FBPMEANSCORE,1,FBP mean score
MITOGENICEFFECT,1,Mitogenic effect
NOOFUPTAKESITES,1,No. of uptake sites
%INHIBITIONOFCONTROLSPECIFICBINDING,1,% Inhibition of Control Specific Binding
CMAXNORMALISED,1,Cmax normalised
ALATLEVELS,1,ALAT levels
P[BH+50],1,p[BH+50]
CHANGEOFAREA,1,Change of area
DECREASEINNOOFAVOIDENCERESPONSES,1,Decrease in No. of avoidence responses
PIGMENTBINDING,1,Pigment binding
RU,1,RU
KERATIO,1,Ke ratio
SERUMLHLEVEL,1,Serum LH level
C5MIN,1,C5 min
DELTAA,1,deltaA
DELTAGM,1,Delta Gm
NNOSACTIVITY,1,nNOS activity
IS,1,IS
PIC25,1,pIC25
KIA,1,KiA
VOCALIZATIONTIME,1,Vocalization time
DAYSTOTUMORDOUBLING,1,Days to tumor doubling
LLRSCORE,1,LLR score
MI50,1,MI50
DELTATMSTAUROSPORINEPOSITIVECONTROL,1,delta Tm Staurosporine positive control
TCLOWERING,1,TC lowering
AA,1,AA
DEAD,1,Dead
CHANGEOFCO,1,Change of CO
IE50,1,IE50
TDS,1,TDS
BETA2DURATION,1,Beta2 duration
PROGESTERONEPRODUCTION,1,Progesterone production
CP(F),1,Cp(f)
TAILFLICKLATENCY,1,Tail flick latency
F34,1,F3/4
IC99,1,IC99
MEDIANSURVIVALDAY,1,Median survival day
INCREASEINCONCENTRATION,1,Increase in concentration
S-GOTLEVEL,1,s-GOT level
MIC,1,MIC
SERUMLDL-CHOLESTEROL,1,Serum LDL-cholesterol
CMAXRATIO,1,Cmax_ratio
EPMR,1,EPMR
ED(1MV),1,ED (1mV)
VOMITINGFREQUENCY,1,Vomiting frequency
RATIOLD50EC50,1,Ratio LD50/EC50
MINEFFECTIVEDOSE,1,Min effective dose
LAD,1,LAD
LOGGTI,1,Log GTI
BRAINCONTENT,1,Brain content
RELATIVETHRESHOLDDOSE,1,Relative threshold dose
IFI,1,IFI
TLAG,1,Tlag
NN,1,n/N
AUDPC,1,AUDPC
ED195,1,ED19.5
CMINPBMC,1,Cmin_PBMC
LNKT,1,ln Kt
GHI,1,GHI
PLASMACLEARANCE,1,Plasma clearance
%BOUND,1,% bound
GLUC,1,GLUC
[CA2+],1,[Ca2+]
LD16,1,LD16
MEAN%GROWTH(N=2)FOR01ΜMPROBECONCENTRATION,1,Mean % growth (n = 2) for 0.1 µM probe concentration
SPERMIDINECONCENTRATION,1,Spermidine concentration
HYPOGLYCEMIC,1,Hypoglycemic
MAXAVERAGE,1,Max/average
ESCLOSS,1,Esc loss
AVERAGEWEIGHTCHANGE,1,Average weight change
NADHOXIDIZED,1,NADH oxidized
CAGELEAVING,1,Cage leaving
CA2+CURRENT,1,Ca2+ current
HFRATIO,1,HF ratio
MEANFREEPLASMACONCENTRATION,1,Mean free plasma concentration
TOTALLIVERWEIGHT,1,Total liver weight
MIC=>50,1,MIC=>50
CATSCORE,1,Cat score
RELATIVEPERMIABILITY,1,Relative permiability
DAYOFFIRSTPOSITVEREACTION,1,Day of first positve reaction
PLASMATOTALCHOLESTEROL,1,Plasma total cholesterol
INCREASEINEARTHICKNESS,1,Increase in ear thickness
RESIDUALAMINE(EE),1,Residual amine (ee)
NHILL,1,nHill
SPONTANEOUSREPERFUSION,1,Spontaneous reperfusion
FIC30,1,fIC30
INCREASEINLIFE-SPAN,1,Increase in life-span
PRESSORACTIVITY,1,Pressor activity
IG50,1,IG50
SURFACEINVOLVEMENT,1,Surface involvement
ONSETFORSLEEP,1,Onset for sleep
IC02,1,IC0.2
MIC999,1,MIC99.9
INFLAMMATIONUNITS,1,Inflammation units
MAXIMUMTMAX,1,Maximum Tmax
CMIN(1),1,Cmin(1)
FOLD-INDUCTION,1,Fold-induction
LOG(1MIC),1,log(1/MIC)
-LOGKDISS,1,-Log Kdiss
I42,1,I42
%OFGROWTHRATE,1,% of growth rate
CHOLESTEROLREDUCTION,1,Cholesterol reduction
RETCHES,1,Retches
VT50,1,VT50
RATIOOFSTIMULATION,1,Ratio of stimulation
FT12,1,ft1/2
MDD50,1,MDD50
ULCERSCORE,1,Ulcer score
ID50,1,ID50
AMOUNTOFMETABOLITE,1,Amount of metabolite
ICDATP-50,1,ICdATP-50
K'A,1,K'a
CIC95,1,CIC95
CAR,1,CAR
RLUNG,1,Rlung
ENHANCEMENTRATIO,1,Enhancement ratio
DELTAHDL-C,1,Delta HDL-C
ANTIINFLAMMATORYACTIVITY,1,Antiinflammatory Activity
CSATCO,1,Csat/Co
S50,1,S50
AQUEOUSSOLUBILITY,1,Aqueous solubility
NOOFANIMALSSURVIVED,1,No. of animals survived
ID90,1,ID90
SAFETYINDEX,1,Safety index
HVINTERVAL,1,HV interval
VREL,1,Vrel
"KD,APP",1,"Kd,app"
LOG10CELLKILL,1,Log 10 cell kill
INHIBITION(MEAN),1,Inhibition (mean)
EFFICACYRATIO,1,Efficacy ratio
ED145,1,ED14.5
RELATIVESALIDIURETICACTIVITY,1,Relative salidiuretic activity
RACAPP,1,RAC app
DHP-ISTABILITY,1,DHP-I stability
DU,1,Du
K5,1,K5
TG2XLAG,1,TG 2X lag
RBCX10E3,1,RBC x 10e 3
MOLARRATIO,1,Molar ratio
SERUMSTABILITY,1,Serum stability
HGB,1,HGB
TDECREASE,1,T decrease
COOPERATIVITY,1,Cooperativity
SURVIVIALTOTAL,1,Survivial / total
SENSITISATION,1,Sensitisation
KCATKINACT,1,K cat/Kinact
ADMINISTEREDDOSE,1,Administered dose
VIRALTITER,1,Viral titer
BODYWEIGHTINFI,1,Body weight In. / Fi.
CELLTOXICITY,1,Cell toxicity
MAXPROTECTIVEEFFECT,1,Max protective effect
LIPID-SOLUBLERADIOACTIVITY,1,Lipid-soluble radioactivity
CULTURENEGATIVE,1,Culture negative
CORONARYFLOW,1,Coronary flow
UTERINEWEIGHT,1,Uterine weight
MAXPI,1,Max PI
DEVELOPEDTENSION,1,Developed tension
VIABLECELLS,1,Viable cells
UV,1,UV
SURVIVORSATDAY28,1,Survivors at day 28
BINDINGINHIBITION,1,Binding inhibition
CYTOTOXITY,1,Cytotoxity
CC100,1,CC100
PROLIFERATION,1,Proliferation
D2SELECTIVITY,1,D2 selectivity
INDUCTION,1,Induction
EDEMA,1,Edema
IBUPROFEN,1,Ibuprofen
RATEMAX,1,Rate max
EU,1,EU
HYPERACTIVITY,1,Hyperactivity
INHIBITIONTYPE,1,Inhibition type
LOG(1BC),1,log(1/BC)
LV,1,LV
HCMVYIELDREDUCTION,1,HCMV yield reduction
CARDIOSELECTIVITY,1,Cardio selectivity
RESTORATION,1,Restoration
ENANTIOMERICCOMPOSITION,1,Enantiomeric composition
NORESPANIMALSTOTAL,1,No. resp animals / Total
MEANACTIVITYCOUNTS,1,Mean activity counts
MAXBLOODPRESSUREFALL,1,Max blood pressure fall
RELATIVEUTEROTROPHICACTIVITY,1,Relative uterotrophic activity
"PKA,2",1,"pKa,2"
AVERAGEIOP,1,Average IOP
URINARYNA+,1,Urinary Na+
CT5,1,CT5
MONO,1,MONO
RETIRBC,1,RETIRBC
PKAVALUE,1,pKa value
VFT,1,VFT
CHANGEINENTRYLATENCY,1,Change in entry latency
MEAN%GROWTH(N=2)FOR100ΜMPROBECONCENTRATION,1,Mean % growth (n = 2) for 10.0 µM probe concentration
LDAPP,1,LD app
PINCREASE,1,P Increase
RELT,1,rel T
HBSSOLUBILIZED,1,HbS solubilized
%CONTROL,1,% Control
CHANGEHDL-C,1,Change HDL -C
MEC2,1,MEC2
CLINICALREFERENCE,1,Clinical reference
APOPTOSIS,1,Apoptosis
LOGSI,1,logSI
FPGSACTIVITY,1,FPGS activity
CHANGEINTM,1,Change in Tm
FEEDEFFICIENCY,1,Feed efficiency
WORMMOVEMENTINHIBITION,1,Worm movement inhibition
DELTAMEANBLOODPRESSURE,1,Delta mean blood pressure
COMPOUNDREMAINING,1,Compound remaining
AUC100,1,AUC 100
LOG(ILSMAX),1,log(ILSmax)
INOTROPICEFFECT,1,Inotropic effect
APPTT,1,APPTT
NOOFDEATHSMICEINJECTED,1,No. of deaths/mice injected
NECROSIS,1,Necrosis
GSHLEVEL,1,GSH level
DELTAFFA,1,Delta FFA
GABARATIO,1,GABA ratio
HG,1,Hg
RELATIVETOCONTROL,1,Relative to control
PLASMAALTAT24H,1,Plasma ALT at 24 h
C0,1,C0
LOWERING,1,Lowering
HDLCHOLESTEROL,1,HDL cholesterol
SURVIVALRANGE,1,Survival range
TOTALURINEACTIVITY,1,Total urine activity
BPR,1,BPR
MONOMER,1,Monomer
REACTIVATION,1,Reactivation
DILIPOSITIVENEGATIVE,1,DILI positive/negative
MAXCONCENTRATION,1,Max_Concentration
ZINCFINGERREACTIVITY,1,Zinc finger reactivity
LA,1,LA
RD1000,1,RD1000
LOG(1ED80),1,log(1/ED80)
ACTIVITYMABP,1,Activity MABP
C1,1,C1
BACTERIALGROWTH,1,Bacterial growth
MFC,1,MFC
SURVIVORSALIVETOTAL,1,Survivors alive/total
DPM,1,DPM
BINDINGACTIVITY,1,Binding activity
OCC80,1,Occ80
AGONISM,1,Agonism
TAD,1,TAD
RELATIVEINHIBITORYPOTENCY,1,Relative inhibitory potency
DIAMETEROFINHIBITIONZONE,1,Diameter of inhibition zone
BRAINPENETRATIONINDEX,1,Brain penetration index
PHOSPHOLIPIDOSIS,1,Phospholipidosis
LOGK'IAM,1,Log K' IAM
2DGUPTAKE,1,2DG uptake
VOLUMEDISTRIBUTION,1,Volume distribution
KDSS,1,KDss
LOG[-5],1,Log [-5]
MAXEFFECT,1,Max effect
LDH50,1,LDH50
FDOSE,1,F/dose
DELTAWEIGHT,1,Delta weight
GLUCOSEUTILIZATION,1,Glucose utilization
NOOFUNTREATEDCELLS,1,No. of untreated cells
TCUNTREATED,1,T/C untreated
IC50H,1,IC50H
DECREASEINSYSTOLICBLOODPRESSURE,1,Decrease in Systolic blood pressure
MEANSURVIVALINDAYS,1,Mean survival in days
KOBSS,1,K obs / s
CA2+ELEVATION,1,Ca2+ elevation
GROWTHZONE,1,Growth zone
MAXFALLINBLOODPRESSURE,1,Max fall in blood pressure
FT50,1,FT50
SER,1,SER
DT50,1,DT50
PF50,1,PF50
MAXDECREASE,1,Max decrease
GS,1,GS
RELATIVEINITIALSLOPE,1,Relative initial slope
VCT,1,VCT
WEIGHTCHANGEDIFFERENCE,1,Weight change difference
INHIBITIONOFDAMAGE,1,Inhibition of damage
TBPSSHIFT,1,TBPS shift
NOOFLUNGLESIONS,1,No. of lung lesions
DMAX,1,Dmax
CUREDINFECTED,1,Cured/Infected
TUMORINHIBITIONRATIO,1,Tumor inhibition ratio
AUC,1,AUC
PKI1-PKI2,1,pKi1-pKi2
RELATIVEPHOSPHORYLATIONRATE,1,Relative phosphorylation rate
MBBC,1,MBBC
BPRATIO,1,B/P ratio
TC-CQ,1,T/C-CQ
QMAX,1,Qmax
TC@20MGKG,1,T/C @ 20mg/kg
STABILITY,1,Stability
MEDIANTOXICITY,1,Median toxicity
BEHAVIORALEFFECT,1,Behavioral effect
CHANGEINCL-CURRENT,1,Change in Cl- current
MINIMUMSINGLEDOSE,1,Minimum single dose
DEC,1,Dec
PEAKCONCENTRATION,1,Peak concentration
%T>MIC,1,%T>MIC
SOCIALINTERACTION,1,Social interaction
"PKA,1",1,"pKa,1"
CLFREE,1,CL free
INFLUXCL,1,influx_CL
ITIACTIVITY,1,ITI activity
OLIGOSHIFTED,1,Oligo shifted
REVERSIONACTIVITY,1,Reversion activity
TEMPERATUREDECREASE,1,Temperature decrease
RELATIVITY,1,Relativity
INCREASEINMEANSURVIVALTIME,1,increase in mean survival time
FAUCDOSE,1,fAUC/dose
KBP,1,KBp
RELATIVEKM,1,Relative Km
CHANGEOFBODYWEIGHT,1,Change of body weight
AVERAGESURVIVALDAYS,1,Average survival days
NOOFSUNCUSVOMITED,1,No. of suncus vomited
FR,1,FR
VASCULARACCUMULATIONRATIO,1,Vascular accumulation ratio
LOG[-7],1,Log [-7]
AUCC,1,AUC c
NOOFANIMALS,1,No. of animals
DELTALOGDOCT-DOD74,1,delta Log Doct-dod 7.4
FPIC50,1,fpIC50
CONCENTRATION@MAXI,1,Concentration @ Maxi
ACCUMULATEDCOUNTS,1,Accumulated counts
LENGTH,1,Length
CLOGD,1,CLogD
CELL,1,Cell
RELATIVEFLUORESCENTUNIT,1,Relative Fluorescent Unit
EFFICACYINDEX,1,Efficacy index
ANTIPSYCHOTIC,1,Antipsychotic
ACTVITY,1,Actvity
ABSAC35UM,1,AbsAC35_uM
ULCERATION,1,Ulceration
ANABOLICACTIVITY,1,Anabolic activity
ANALGESICEFFECT,1,Analgesic effect
KIH,1,KiH
GATEDCURRENT,1,Gated current
TUMORVOLUME,1,Tumor volume
%INJECTEDDOSECM3,1,% injected dose/cm3
WBCX10E-3,1,WBC x10e-3
INDUCTIONOFCATALEPSY,1,Induction of catalepsy
MAXINHIBITORYEFFECT,1,Max inhibitory effect
LIVERWEIGHT,1,Liver weight
CIRATIO,1,C/I ratio
VAREA,1,Varea
FORMATION,1,Formation
UPTAKEVALUE,1,Uptake value
WORMREDUCTION,1,Worm reduction
MAXRESPOSE,1,Max respose
DNAUNWINDINGCONCENTRATION,1,DNA unwinding concentration
LOG(ACTIVITY),1,log(activity)
UTEROTROPICACTIVITY,1,Uterotropic activity
ILS(TC),1,ILS (T/C)
TOXICITY,1,Toxicity
KALKYL,1,K alkyl
URINARYGLUCOSEEXCRETION,1,Urinary glucose excretion
SUSCEPTIBILITY,1,Susceptibility
PROBABILITY,1,Probability
RELATIVELIVERWEIGHT,1,Relative liver weight
RECOVERYATOBPLUSINHIBITOR(MEAN),1,Recovery A to B plus inhibitor (mean)
ACTIVITYREMAINING,1,Activity remaining
GLUCOSELOWERINGOBOBDOSE,1,Glucose lowering ob/ob dose
AMOUNTOFTNF-ALPHA,1,Amount of TNF-alpha
1KOBSD-KA,1,1/kobsd-ka
REMOVAL,1,Removal
SERUMTOTALTRIGLYCERIDES,1,Serum total triglycerides
PROTEINCONTENT,1,Protein content
DIFFERENTIATIONACTIVITYRATIO,1,Differentiation activity ratio
T50,1,T50
-LOG(1HC50),1,-log(1/HC50)
KINACTI,1,K inact/I
AD50,1,AD50
CHANGENONHDL-C,1,Change non HDL-C
CMC,1,CMC
FIC80,1,fIC80
CARDIACCONTRACTILEFORCE,1,Cardiac contractile force
MAT,1,MAT
KISS,1,Ki ss
NOOFWRITHINGS,1,No. of writhings
CELLULARREVERSION,1,Cellular reversion
CHEMOTHERAPEUTICINDEX,1,Chemotherapeutic index
CHANGEOFSBP,1,Change of SBP
ANTIUTEROTROPICEFFECT,1,Antiuterotropic effect
T2,1,T2
RELATIVEAGONISTACTIVITY,1,Relative agonist activity
FICI90,1,FICI90
VDRAFFINITY,1,VDR affinity
LOGTUMORCELLKILL,1,Log tumor cell kill
GABAENHANCEMENT,1,GABA enhancement
SUBSTRATEEFFICIENCY,1,Substrate efficiency
GMOUSE,1,g/mouse
FR10TREATED,1,FR10 treated
EFFLLUX,1,Effllux
K6,1,K6
PKAB1,1,pKa_B1
PITURNOVER,1,PI turnover
TUMORBURDEN,1,Tumor burden
SURVIVALAFTER10DAYS,1,Survival after 10 days
ET-1LEVEL,1,ET-1 level
LOGM50,1,Log M50
DIAMETER,1,Diameter
MEANINHIBITION,1,Mean inhibition
-LOGLC50,1,-Log LC50
DELTAMV,1,Delta mV
LOGEMAX,1,logEmax
DRUGDISCRIMINATIONEFFECT,1,Drug discrimination effect
UI,1,UI
TIMETOMAXBSR,1,Time to max. BSR
RATIOATPASEACTIVITY,1,Ratio_ATPase activity
MI,1,MI
LC25,1,LC25
EMESISCMAX,1,Emesis_Cmax
DRUGPERIOD,1,Drug period
TC50IC50,1,TC50/IC50
REPELLENCY,1,Repellency
OSAV,1,OSAV
MED10,1,MED10
KAKI,1,ka/Ki
CATALEPTICEFFECT,1,Cataleptic effect
LIGHTTRANSMISSION,1,Light transmission
MIC99,1,MIC99
EC986,1,EC98.6
MAXBINDING,1,Max binding
SELECTIVITYFACTOR,1,Selectivity factor
CORRELATIONCOEFFICIENT,1,Correlation coefficient
PGI50,1,pGI50
CPD50,1,CPD50
EFFECTONPOLYAMINEPOOLS,1,Effect on polyamine pools
RELATIVEAGONISTICACTIVITY,1,Relative agonistic activity
MEANRELATIVESURVIVINGFRACTION,1,Mean relative surviving fraction
IMPAIRED,1,Impaired
RATEOFINHIBITION,1,Rate of inhibition
DOPAC,1,DOPAC
EXTRACTION,1,Extraction
LOG10FFU,1,log10FFU
INFARCTVOLUME,1,Infarct volume
TEMPERATURECHANGE,1,Temperature change
REPRESSION,1,Repression
WEIGHTDIFFERENCE,1,Weight difference
INTAKE,1,Intake
PTZSEIZURE,1,PTZ seizure
MAXCONTRACTILEFORCE,1,Max contractile force
FLUINTENSITY,1,Flu intensity
ABSAC50,1,AbsAC50
MDACONTENT,1,MDA content
PARALYSIS,1,Paralysis
-LOGI50,1,-Log I50
RC50,1,RC50
MAXDELTAAPD95,1,Max delta APD95
BINDINGSITEPREFERENCE,1,Binding site preference
NEGATION,1,Negation
A0,1,A0
V,1,V
INTIMAAREA,1,Intima area
PKAAPP,1,pKa app
LOG1E50,1,Log 1/E50
MEDTUMORWEIGHT,1,Med tumor weight
AUCGLUREDUCTION(MMXMIN),1,AUC glu reduction(mM x min)
DNAFRAGMENTATION,1,DNA fragmentation
GLUCOSEUPTAKE,1,Glucose uptake
DRUGRESPONSE,1,Drug response
IC10,1,IC10
AMOUNTEXCRETED,1,Amount excreted
%RECOVERY,1,% recovery
SELECTIVITYRATING,1,Selectivity rating
UNCHANGEDNDEA,1,Unchanged NDEA
RELATIVETOXICITY,1,Relative toxicity
TRANSCRIPTIONALACTIVITY,1,Transcriptional activity
KINETICSOLUBILITY,1,Kinetic_solubility
CIP,1,CIp
POLYAMINECONTENT,1,Polyamine content
MTA,1,MTA
CONCBRAIN,1,Conc_brain
PKAB3,1,pKa_B3
RELMAX,1,Rel max
REDUCEDFOODINTAKE,1,Reduced food intake
OTINTERVAL,1,OT interval
AMINEFORMED,1,Amine formed
TESTESWEIGHT,1,Testes weight
-LOGIC50IC50,1,-Log IC50/IC50
LOGKAT,1,Log KAT
ID50MGKG,1,ID50 mg/kg
PLASMALIPIDLEVEL,1,Plasma lipid level
EC25,1,EC25
INJECTEDDOSEGTISSUE,1,Injected dose/g tissue
VOLSYN,1,VOLSYN
CI90,1,CI90
PEC99,1,pEC99
LOGPMW,1,Log Pmw
SLEEPTIME,1,Sleep time
PLATELET,1,Platelet
THROMBINTIME,1,Thrombin time
30DAYSURVIVORS,1,30 day survivors
DECREASEINLIFESPAN,1,Decrease in life span
RAP,1,RAP
LESION,1,Lesion
SA,1,SA
30DAYSSURVIVORS,1,30 days survivors
EXTENTOFDNABINDING,1,Extent of DNA binding
LOGD55,1,LogD5.5
PLASMAHALF-LIFE,1,Plasma half-life
INTERFERONRESPONSE,1,Interferon response
FD,1,FD
MAXSUPPRESSION,1,Max suppression
NOOFANIMALSEXHIBITINGTOXICITYNUMBEROFANIMALSTESTED,1,No. of animals exhibiting toxicity / Number of animals tested
MIC=<50,1,MIC=<50
EC24,1,EC24
SPECIFICRADIOACTIVITY,1,Specific radioactivity
LYM,1,LYM
METABOLITELEVELS,1,Metabolite levels
PED50,1,pED50
ED50MGKG,1,ED50 mg/kg
AUCN,1,AUC N
MAXAPD95,1,Max APD95
CRITICALCONCENTRATION,1,Critical concentration
KAKRKR,1,kaKr/kr
ALD50,1,ALD50
MAXIMUMINHIBITION,1,Maximum inhibition
GD200[D],1,GD200 [d]
ANTIPAPILLOMAACTIVITY,1,Antipapilloma activity
EOSINHIBITION,1,EOS inhibition
RELAXEDDNA,1,Relaxed DNA
ADDUCTFORMATION,1,Adduct formation
ANTIBACTERIALACTIVITY,1,Antibacterial activity
FPTMSAD,1,FPT msad
ATAXIA,1,Ataxia
PALMITOYL-COAOXID,1,Palmitoyl-CoA oxid
TEST,1,Test
SUSCEPTIBILTYRATIO(LIVERINTESTINE),1,Susceptibilty Ratio (Liver/Intestine)
RELATIVEAMPLITUDE,1,Relative amplitude
IC50IC50,1,IC50/IC50
URINARYRECOVERY,1,Urinary recovery
RATECONSTANT(K),1,Rate constant (k)
%AUCEXTRA,1,%AUCextra
MFC995,1,MFC99.5
RATIOTUMOURPLASMA,1,Ratio_tumour/plasma
ATRIALMAPD90,1,Atrial MAPD90
AMOUNTBOUND,1,Amount bound
CHANGEINBLOODGLUCOSE,1,Change in blood glucose
CT10,1,CT10
DELTATCID50,1,deltaTCID50
"K(P,UU,BRAIN)",1,"K(p,uu,brain)"
AVERAGEWEEKLYWEIGHTCHANGE,1,Average weekly weight change
ACCUMULATIONCOEFFICIENT,1,Accumulation coefficient
S-GPTLEVEL,1,s-GPT level
LOG1ACTIVITY,1,log1/activity
MEMREC,1,Mem Rec
HIGH,1,High
PKACT,1,pKact
LOG(1LD50),1,log(1/LD50)
IRONBINDING,1,Iron binding
XC50,1,XC50
MYRISTOYLPEPTIDE,1,Myristoylpeptide
LTKBBDDILISEVERITYSCORE,1,LTKB_BD DILI severity score
SUPRESSIVEEFFECT,1,Supressive effect
CHANGEINMABP,1,Change in MABP
FP,1,fp
SURVIVAL,1,Survival
HYPOGLYCEMICACTIVITY,1,Hypoglycemic activity
-LOG1KB,1,-Log 1/Kb
CHEMOTACTICINDEX,1,Chemotactic index
LOGRATECONSTANT,1,Log rate constant
ECSRATIO,1,ECS ratio
PLASMA,1,Plasma
ADHESION,1,Adhesion
PHOTO-CROSS-LINKINGOFDNA,1,Photo-cross-linking of DNA
LOG1D50,1,Log 1/D50
FICI,1,FICI
DELTAMMHG,1,Delta mmHg
PA2,1,pA2
TOTALCOUNTS,1,Total counts
ALPLEVEL,1,ALP Level
APPARENTBINDINGCONSTANT,1,Apparent binding constant
LOG(RATIOIC50),1,log(RatioIC50)
SPECIFICITY,1,Specificity
HYPOTENSIVEACTIVITY,1,Hypotensive activity
NORELEASE,1,NO release
CACO-2PERMEABILITY,1,Caco-2 permeability
MFC<=999,1,MFC<=99.9
MEANGRAPHMIDPOINT,1,Mean graph mid point
GC200[D],1,GC200 [d]
INDUCEDCONVULSION,1,Induced convulsion
MFC99,1,MFC99
MAXAGONISTACTIVITY,1,Max agonist activity
LOGA,1,Log A
"KI,APP",1,"Ki,app"
RATIOTD50ED50,1,Ratio TD50/ED50
ACTIVITY(UMOLMGOFPROTEINMIN),1,Activity (umol/mg.of protein. min)
GFR,1,GFR
FCMIN,1,fCmin
FREEC,1,Free C
TMIN,1,Tmin
DELTAMAP,1,Delta MAP
CORRECTRESPONSES,1,Correct responses
MTD16,1,MTD/16
CCID50,1,CCID50
SERUMTOTALCHOLESTEROL,1,Serum total cholesterol
K2KS,1,k2/Ks
DELTAAPD90,1,Delta APD90
ALPHA-ADRENOLYTICACTIVITY,1,Alpha-adrenolytic activity
SURVIVORSTREATED,1,Survivors / treated
ACTIVEDOSE,1,Active dose
FRP,1,FRP
REDUCEDPARASITEMIA,1,Reduced_parasitemia
-LOGACTIVITY,1,-Log activity
CROSSREACTION,1,Cross reaction
KSOLV,1,Ksolv
REVERSAL,1,Reversal
TIMEABOVEIC50,1,Time above IC50
SUMMATIONMABP,1,Summation MABP
GASTRICULCERINDEX,1,Gastriculcer index
PD100,1,PD100
AVERAGEONSET,1,Average onset
RINGIMMOBILITY,1,Ring immobility
C12H,1,C12h
SR,1,SR
CHANGEINSENSITIVITY,1,Change in sensitivity
FORMATIONOFCOMPOUND,1,Formation of compound
UTEROTROPHICEFFECT,1,Uterotrophic effect
CONTRAGESTATIONALACTIVITY,1,Contragestational activity
MIC50MIC90,1,MIC50/MIC90
BIODISTRIBUTION,1,Biodistribution
PA2PKB,1,pA2/pKB
CROSSLINKING,1,Cross linking
ED2,1,ED2
BASALACTIVITY,1,Basal activity
CONTROLCOMPOUNDIC50,1,Control compound IC50
ORGANWEIGHTRATIO,1,Organ weight ratio
T34,1,T3/4
FOLDSTIMULATION,1,Fold stimulation
SPLEENWEIGHT,1,Spleen weight
ABRASIONSCORE,1,Abrasion score
OCC,1,Occ
QTINTERVAL,1,QT interval
NOOFTUMORSMOUSE,1,No. of tumors/mouse
LOGKS,1,log Ks
FVDSS,1,fVdss
PCF,1,pCF
MED20,1,MED20
CA2+FLUX,1,Ca2+ flux
MEAN%OFCONTROL,1,mean % of control
VD(APP),1,Vd(app)
CT1,1,CT1
RATEOFDEATH,1,Rate of death
P-450LOSS,1,P-450 loss
DELTACURATEDELTACINSULIN,1,Delta C urate / delta C insulin
CHANGEINWBC,1,Change in WBC
DECREASEINRFU,1,Decrease in RFU
SYMPTOMINITIATION,1,Symptom initiation
EFFICACY,1,Efficacy
SERUMTSH,1,Serum TSH
MIC97,1,MIC97
TOXICITYZONE,1,Toxicity zone
VACUOLERESPONSE,1,Vacuole response
CMAX,1,Cmax
KAAPP,1,Ka app
TUMORCURE,1,Tumor cure
BICARBONATELEVEL,1,Bicarbonate level
BINDINGENERGY,1,Binding energy
TUBULINCONTENT,1,Tubulin content
MTTREDUCTION,1,MTT reduction
NATURE,1,Nature
FEMORALBLOODFLOW,1,Femoral blood flow
NTD50,1,NTD50
METABOLISM,1,Metabolism
QUENCH,1,Quench
CARDIACFORCE,1,Cardiac force
LOG(1K),1,log(1/K)
THRESHOLDCURRENT,1,Threshold current
NOOFCHICKS,1,No. of chicks
DELTALOGD,1,delta logD
HSFRELEASE,1,HSF release
MACREDUCTION,1,MAC reduction
DELTALATENCYTIME,1,Delta latency time
%BOUNDALBUMIN,1,%Bound_Albumin
LOG1KM,1,Log 1/Km
DELTAS-H,1,Delta S-H
LD84,1,LD84
PRECURSORINHIBITION,1,Precursor inhibition
PSA,1,PSA
FOLDREVERSION,1,Fold reversion
INHIBITORYCONCENTRATION,1,Inhibitory concentration
PAP,1,PAP
TIMECONSTANT,1,Time constant
PIC30,1,pIC30
T-CELLBINDING,1,T-cell binding
"EMAX,DISS",1,"Emax,diss"
EXCRETION,1,Excretion
TEMPERATURE,1,Temperature
KW,1,Kw
DR20,1,DR20
DELTASBP,1,Delta SBP
BASALBINDING,1,Basal binding
RATIO(CICE),1,Ratio (Ci/Ce)
LD33,1,LD33
EARTHICKNESS,1,Ear thickness
MIC=<90,1,MIC=<90
P24SYNTHESIS,1,p24 synthesis
RELATIVEPHOSPHORYLATION,1,Relative phosphorylation
RIA,1,RIA
INCREASEINIC50,1,Increase in IC50
LOG1EC50,1,Log 1/EC50
T-CELLINHIBITION,1,T-cell inhibition
P[A]50,1,p[A]50
TIMEOVER100NGML,1,Time over 100ng/ml
APOPTOTICINDEX,1,Apoptotic index
G1,1,G1
NORMALIZEDABUNDANCESFORDMSO,1,Normalized abundances for DMSO
UNTREATEDCONTROL,1,Untreated control
NOOFFOCIPERDISH,1,No. of foci per dish
AVERAGEINHIBITION,1,Average inhibition
FLUORESCENCEACTIVITYRATIO,1,Fluorescence activity ratio
CHLORIDE,1,CHLORIDE
MAXACTIVITY,1,Max_Activity
AVGIC90,1,Avg IC90
CUMULATIVEDOSE,1,Cumulative dose
IE100,1,I / E100
TRACTIONTEST,1,Traction test
MEDIANTUMOR,1,Median tumor
TBOUND,1,T bound
CBFRATIO,1,CBF Ratio
LOGPC18,1,Log Pc18
FLOWRATE,1,Flow rate
EC999,1,EC99.9
PIGMENTINDUCTION,1,Pigment induction
PKAA2,1,pKa_A2
TCT,1,TCT
RESTINGPOTENTIAL,1,Resting potential
FTMEANSCORE,1,FT mean score
ED50ED50(TAXOL),1,ED50 / ED50 (taxol)
PKI(UM),1,pKi(uM)
REVERSEPOTENTIAL,1,Reverse potential
CTT2,1,Ctt2
CONTENT,1,Content
K+EXCRETION,1,K+ excretion
KB1,1,KB1
CONTROLATTHEDOSEOF500MICROGMOUSE,1,Control at the dose of 50.0microg/mouse
CONTROLDEATHDAY,1,Control death day
-TDELTAS,1,-TdeltaS
NAD,1,NAD
ANTIUTEROTROPHICACTIVITY,1,Antiuterotrophic activity
RESPONDING,1,Responding
FORMATIONOFERYTHEMA,1,Formation of erythema
CLONICSEIZURES,1,Clonic seizures
SURVIVALAFTER30DAYS,1,Survival after 30 days
AVERAGETURNSFIRST15MIN,1,Average turns/first 15 min
CLEAVAGE,1,Cleavage
NM,1,NM
SUBG0,1,SubG0
LOGCFU,1,Log CFU
CARBOXYLASEACTIVITY,1,Carboxylase activity
DEGRANULATINGACTIVITY,1,Degranulating activity
FBA,1,FBA
COMPLETESURVIVALDOSE,1,Complete survival dose
SBP,1,SBP
DELTAAMIN,1,Delta A/min
MAXDISPLACEMENT,1,Max displacement
AVOIDANCERESPONSE,1,Avoidance response
BINDINGSTOICHIOMETRY,1,Binding stoichiometry
DECREASEOFSPONTANEOUSFIRINGRATE,1,Decrease of spontaneous firing rate
TISSUESWELLING,1,Tissue swelling
REDUCTIONINBLOODPRESSURE,1,Reduction in blood pressure
PC3,1,pC3
RATIOCIC95IC50,1,Ratio CIC95/IC50
"MEDIANSURVIVALTIME,DAYS",1,"median survival time, days"
LOGPOCTN,1,Log Poct N
IPSCORE,1,Ip score
ZONESIZE,1,Zone size
SLOWBINDING,1,Slow binding
B-AA-B,1,B-A/A-B
VIRUSINACTIVATION,1,Virus inactivation
ELEVATION,1,Elevation
RELATIVEANTITUMORACTIVITY,1,Relative antitumor activity
I40,1,I40
CONCENTRATIONRATIO,1,Concentration ratio
LAMBDA-EX,1,Lambda-ex
NSB,1,NSB
INCREASED,1,Increased
AVERAGEBODYWEIGHTCHANGE,1,Average body weight change
SURVIVINGFACTOR,1,Surviving factor
RATIOKI(APP),1,Ratio Ki(app)
RATIOOFDOSE,1,Ratio of dose
ORALDOSE,1,Oral dose
IDBRAIN,1,ID/brain
SNI,1,Sni
PKR+,1,pKR+
SGOTINCREASE-INDEXVALUE,1,SGOT Increase - Index Value
FMAX,1,Fmax
SD50,1,SD50
FERRETEMESIS,1,Ferret emesis
TONICSEIZURES,1,Tonic seizures
CP(F)MAX,1,Cp(f)max
HABC,1,H ABC
CAACTIVITY,1,CA activity
SIGMAP,1,Sigmap
RBC,1,RBC
PKHB,1,pKHB
V2,1,V2
OXYTOCICACTIVITY,1,Oxytocic activity
MEANWEIGHT,1,Mean weight
NOEFFECTIVE,1,No. effective
EXTENTOFSKINLESIONS,1,Extent of skin lesions
INOTROPICPOTENCY,1,Inotropic potency
RELATIVEHYDROLYSIS,1,Relative hydrolysis
B50,1,B50
T-CELL,1,T-cell
ANALGESIADURATION,1,Analgesia duration
LDHINCREASE-NUMBEROFREPORTS,1,LDH Increase - Number of Reports
TWITCHTENSION,1,Twitch tension
DISTRIBUTIONCOEFFICIENT,1,Distribution coefficient
CL(%Q),1,CL(%Q)
"[A]T,L",1,"[A]T,L"
EUDISMICRATIO,1,Eudismic ratio
GE,1,GE
NOOFOPENARMENTRIES,1,No. of openarm entries
HR,1,HR
TZ,1,tz
PROTECTIONRATIO,1,Protection ratio
EDDELTA5,1,ED delta5
KOBS11MS,1,K obs / 1 1/Ms
EC100,1,EC100
CONVERSIONDOSE,1,Conversion dose
SECONDORDER,1,Second order
COMMUNICATINGCELLS,1,Communicating cells
PHOTOTOXICEFFECT,1,Phototoxic effect
LVDPDTMAX,1,LV dP/dtmax
GICLEARENCE,1,GI clearence
DIET,1,Diet
RATIOLC50,1,RatioLC50
LOGCHANGE,1,Log change
LOG2FC,1,log2FC
SERUMCHOLESTEROL,1,Serum cholesterol
PROTEIN,1,Protein
E2:E1,1,E2:E1
TOTALRATE,1,Total rate
PHORBOLDISPLACEMENT,1,Phorbol displacement
GIC50,1,GIC50
SEPARATION,1,Separation
INJECTED(DOSEG),1,Injected (dose/g)
NOOFANIMALSPROTECTEDNOANIMALSTESTED,1,No. of animals protected / no animals tested
NOOFFALLS,1,No. of falls
SINUSBEATS,1,Sinus beats
PMA,1,PMA
STATICREMISSION,1,Static remission
ALP,1,ALP
MFC100,1,MFC100
DECREASEOFSBP,1,Decrease of SBP
OCCLUSIONS,1,Occlusions
PWT,1,PWT
AUCGLUREDUCTION,1,AUC glu reduction
RELATIVECYTOTOXICITY,1,Relative cytotoxicity
AVERAGEGROSSPATHOLOGYSCORES+-SE,1,Average gross pathology scores+/- SE
INDUCTIONNUMBER,1,Induction number
PRA,1,pRA
RRT,1,RRT
DAYOFDEATH,1,Day of death
NAPROXENPRODUCED,1,Naproxen produced
INCREASE(EMAX),1,Increase (Emax)
PASSIVITY,1,Passivity
AVERAGESURVIVED,1,Average survived
REDUCTIONOFLIVEWORMS,1,Reduction of live worms
DRUGRELEASE,1,Drug release
DEIODINATION,1,Deiodination
VC,1,Vc
CARDIOTOXICITY,1,Cardiotoxicity
KIMUTKIWT,1,Kimut/Kiwt
CONTROLDMSOFRAGMENTEDNUCLEI%,1,Control DMSO Fragmented Nuclei %
RATECHANGE,1,Rate change
DEPOLARISATION,1,Depolarisation
AVERAGEDOSE,1,Average dose
TGIRATIO,1,TGI ratio
MEANTUMORVOLUME,1,Mean tumor volume
CACO-2A-B,1,Caco-2 A-B
RE,1,RE
TCS50,1,TCS50
LAGTIME,1,Lag time
DTTINHIBITION,1,DTT inhibition
ROTATIONALBEHAVIOR,1,Rotational behavior
RADIATIONEQUIVALENT,1,Radiation equivalent
PMIC,1,pMIC
RELATIVETS,1,Relative TS
PRODUCTION,1,Production
ANTIFERTILITYPOTENCY,1,Antifertility potency
TIMEOFHALFINACTIVATION,1,Time of half inactivation
TESTCONTROLSURVIVAL,1,Test/control survival
CHANGEINFOOT-LICKINGLATENCY,1,Change in foot-licking latency
TE50,1,TE50
DELTAP50,1,Delta P50
CONTRACTILEFORCE,1,Contractile force
MIC>98,1,MIC>98
PAPPBTOA(MEAN),1,Papp B to A (mean)
TFP,1,TF/P
ANTI-FIGHTINGBEHAVIOUR,1,Anti-fighting behaviour
MED99,1,MED99
LATENCYTOEXIT,1,Latency to exit
LOSSOFCELLS,1,Loss of cells
LOG1S,1,log1/S
PEAKINHIBITION,1,Peak inhibition
TUMORMASS,1,Tumor mass
NOOFMALESMATED,1,No. of males mated
NOOFMONKEYS,1,No of monkeys
AVERAGETURNS,1,Average turns
HYPOTENSION,1,Hypotension
%OFACTIVITY,1,% of activity
BRONCHOSELECTIVITY,1,Broncho selectivity
RATEOFROTATION,1,Rate of rotation
EPSMED,1,EPS MED
CONCPLASMA,1,Conc_plasma
FI50,1,FI50
H2ACTIVITY,1,H2 activity
ACIDHYDROLYSIS,1,Acid hydrolysis
FOLDCHANGE,1,Fold change
EOSLE,1,EOSLE
LASTTHERAPYDAY,1,Last therapy day
RELATIVESTIMULATORYACTIVITY,1,Relative stimulatory activity
URINARYLEVEL,1,Urinary level
SPECIFICDISPLACEMENT,1,Specific Displacement
LIPOPHILICITY,1,Lipophilicity
LD,1,LD
WATERCONSUMPTION,1,Water consumption
RELATIVEPOTENCYRATIO,1,Relative Potency Ratio
ANALGESICEFFICACYCOMPAREDTOEPIBATIDINE,1,Analgesic efficacy compared to epibatidine
DECREACEINBP,1,Decreace in BP
BUN,1,BUN
CURE,1,Cure
CHOLINEUPTAKE,1,Choline uptake
TC@40MGKG,1,T/C @ 40mg/kg
EC68,1,EC68
MNEC,1,MNEC
HILLCOEFFICIENT,1,Hill coefficient
FICI50,1,FICI50
SPECIFICINDEX,1,Specific index
ED70,1,ED70
VOLUMEOFURINE,1,Volume of urine
EC90,1,EC90
IRREVERSIBLEBINDING,1,Irreversible binding
THERMALMELTINGCHANGE,1,Thermal melting change
PK2,1,pK2
NADHOXIDN,1,NADH oxidn
DELTAI,1,Delta I
C50,1,C50
KIUC,1,Kiuc
DECREASEINHYPOTHALAMUSNOREPINEPHRINE,1,Decrease in hypothalamus norepinephrine
BEHAVIORRESPONSE,1,Behavior response
DEGREEOFCROSSRESISTANCE,1,Degree of cross resistance
WEIGHTLOSS,1,Weight loss
MINIMALDOSE,1,Minimal dose
ABSAC1000UM,1,AbsAC1000_uM
MAXDELTAMAP,1,Max delta MAP
THERAPEUTICEFFICACY,1,Therapeutic efficacy
MBC90,1,MBC90
MODIFICATION,1,Modification
INHIBITORYPOTENTIAL,1,Inhibitory potential
RESPONSERATE,1,Response rate
RADIOLABELRECOVERY,1,Radiolabel recovery
[CA2+]VARIATION,1,[Ca2+] variation
DELTAFC,1,Delta FC
MOUSEBEHAVIORACTIVITY,1,Mouse behavior activity
ANALGESICEFFICACY,1,Analgesic efficacy
TC(RATIOOFTREATEDTOCONTROL),1,T/C (ratio of treated to control)
CPMMILLIONCELLS,1,cpm/million cells
LOGPOTENCY,1,Log potency
PARAPARETICMICE,1,Paraparetic mice
EPS,1,EPS
WEIGHTCHANGE,1,Weight change
VOLUMEREDUCTION,1,Volume reduction
BINDINGCONSTANT,1,Binding constant
AGONISTICEFFECT,1,Agonistic effect
REDUCTIONOFIOP,1,Reduction of IOP
INCREASEDLIFESPAN,1,Increased life span
PLASMAMAGNESIUMCHANGEBY,1,Plasma magnesium_CHANGE_BY
SERUMCONCENTRATION,1,Serum concentration
AURC,1,AURC
PIMETABOLISM,1,PI metabolism
MAXVASOCONSTRICTION,1,Max vasoconstriction
BLOODLOSS,1,Blood loss
CYD50,1,CyD50
FECES,1,Feces
DISPLACEMENTOFDP,1,Displacement of DP
OTHER,1,Other
I7,1,I7
AUCSECONDTREATMENT,1,AUC second treatment
CUMULATIVEAMOUNT,1,Cumulative amount
CHANGEINCAMP,1,Change in cAMP
LOG(43000KI),1,log(43000/Ki)
CYTOKINEINDUCTION,1,Cytokine induction
PEC05,1,pEC0.5
THERAPEUTICINDEX,1,Therapeutic index
COMPOUNDINURINE,1,Compound in urine
PROTECTIVEACTIVITY,1,Protective activity
APDC,1,APDc
WEIGHTCHANGES,1,Weight changes
PROTEININTERACTIONENERGY,1,Protein interaction energy
T12HMIN,1,T1/2 h/min
MEANDAYSURVIVAL,1,Mean day survival
LOG1T,1,Log 1/T
UNREACTEDDRUG,1,Unreacted drug
TERMBW,1,TERMBW
RATIOPLASMACONCENTRATIONIC50,1,Ratio plasma concentration/IC50
FFRACTION,1,F_fraction
LOG(1ED30),1,log(1/ED30)
G30MIN,1,g/30min
CTP,1,CTP
PL-017SHIFT,1,PL-017 shift
GDPED50,1,GDP ED50
SUBMIC,1,SubMIC
RECEPTOROCCUPIED,1,Receptor occupied
LOG(1SD90),1,log(1/SD90)
VASCULARRELAXATION,1,Vascular relaxation
MAXDELTAMABP,1,Max delta MABP
LOG(PERMEABILITY),1,log(permeability)
LOG(RBA),1,log(RBA)
OFHDL-C,1,Of HDL-C
ID60,1,ID60
EC98,1,EC98
ACTIVITYSCALE,1,Activity scale
K+OUTPUT,1,K+ output
EXTREMESTREATED,1,Extremes treated
PROTECTIVEDOSE,1,Protective dose
CREAT,1,CREAT
GAMMACMC,1,gammaCMC
DECREASEINPRESSURE,1,Decrease in pressure
ID84,1,ID84
ALKALINEPHOSPHATASEINCREASE-INDEXVALUE,1,Alkaline Phosphatase Increase - Index Value
DNAALKYLATION,1,DNA alkylation
HEPSECHOLECYSTITIS,1,HepSE_cholecystitis
DT,1,DT
SURVIVORINCREASE,1,Survivor increase
EP,1,Ep
T12RATIO,1,t1/2_ratio
LOG1ED30,1,Log 1/ED30
GI90,1,GI90
PERIPHERALRESTRICTIONINDEX,1,Peripheral restriction index
RELATIVEINOTROPICPOTENCY,1,Relative inotropic potency
%PFU,1,%PFU
VDF,1,Vd/F
LOGCC50,1,logCC50
PE,1,Pe
POPULATIONHEALTHYNUCLEI(%),1,Population Healthy Nuclei (%)
VENTRICULARMAPD90,1,Ventricular MAPD90
PHDEPENDENCE,1,pH dependence
PC25,1,pC25
SURVIVORSATDAY9,1,Survivors at day 9
D-2,1,D-2
BRAINCONCENTRATION,1,Brain concentration
MAXENHANCEMENT,1,Max enhancement
ACETYLCHOLINERELEASE,1,Acetylcholine release
FPTASEACTIVITY,1,FPTase activity
STYSEIZURE,1,STY seizure
MAXIMUMTESTCONCENTRATIONTHATDIDNOTEXHIBITCYTOTOXICITY,1,Maximum test concentration that did not exhibit cytotoxicity
SF50,1,SF50
CHOLCHANGE,1,CHOL_CHANGE
INFLUXKI,1,Influx Ki
LT50,1,LT50
CPA,1,CPA
BWD,1,BWD
PD200,1,PD200
RATSBLOCKED,1,Rats blocked
REDUCEDSREBF1GENEEXP,1,Reduced_Srebf1_gene_exp
FABS,1,Fabs
SD200,1,SD200
PLASMATC,1,Plasma TC
REMOVALOFMICROFILARIAE,1,Removal of microfilariae
GR50,1,GR50
P-VALUE,1,P-value
DELTA,1,Delta
LUCIFERASEACTIVITY,1,Luciferase activity
CCONTROL,1,Ccontrol
QUANTITY,1,Quantity
INHIBITORLEVEL,1,Inhibitor level
COLLAPSETIME,1,Collapse time
CAPACITY,1,Capacity
CHANGEFROMCONTROL,1,Change from control
MAXREDUCTION,1,Max reduction
FACOACTIVITY,1,FACO Activity
GSH-PXACTIVITY,1,GSH-Px activity
PROTECTIVERATIO,1,Protective ratio
CORTEXCLEARANCE,1,Cortex_Clearance
ALBCHANGE,1,ALB_CHANGE
DELTAF75,1,Delta F75
RELATIVELOSSOFPOTENCY,1,Relative loss of potency
GHMAX,1,GHmax
G-PROTEINACTIVATION,1,G-protein activation
LOGC,1,Log C
INHIBITIONEFFECT,1,Inhibition effect
PREJUNCTIONALANTAGONISTPOTENCY,1,Prejunctional antagonist potency
TIMEOFDOSINGBEFOREANTIGENCHALLENGE,1,Time of dosing before antigen challenge.
RVCF,1,RVCF
POTASSIUM,1,POTASSIUM
TASTECHARACTER,1,Taste character
K(ON)K(OFF),1,k(on)/k(off)
OFCONTROL,1,Of control
IN,1,IN
MUKAPPARATIO,1,Mu/kappa ratio
SB,1,SB
MPE,1,MPE
ANTI-PENTEFFECT,1,Anti-pent effect
HI,1,HI
NORMAL,1,Normal
RHA,1,RHA
PKAB2,1,pKa_B2
THYMIDYLATESHIFT,1,Thymidylate shift
OD(540NM),1,OD(540nm)
AGONISTICPOTENCY,1,Agonistic potency
MAXWEIGHTLOSS,1,Max weight loss
NETSWELLING,1,Net Swelling
CURESNOOFANIMALS,1,Cures/no. of animals
T12LAMBDA,1,t1/2lambda
PARENTREMAININGATTIME,1,Parent remaining at time
PROPORTIONOFSURVIVORS,1,Proportion of survivors
BLOODSUGARLOWERING,1,Blood sugar lowering
KRKMAX,1,Kr/kmax
TONIC,1,Tonic
BIODISTRIBUTIONRATIO,1,Biodistribution ratio
PAR,1,PAR
DIFFERENTIATION,1,Differentiation
TIMEINFLIGHT,1,Time in flight
LOGPOTENCYRATIO,1,Log potency ratio
FUNGICIDALCONCENTRATION,1,Fungicidal concentration
GMSACTIVITY,1,GMS activity
CURERATE,1,Cure rate
SURVIVALEXTENSION,1,Survival extension
RPF,1,RPF
CITH,1,CITH
LOG(M50),1,log(M50)
PROMINENZ,1,Pro/Min/Enz
CAMPACCUMULATION,1,cAMP accumulation
LOG1RATIO,1,Log 1/ratio
LESIONCOVERAGE,1,Lesion coverage
ID95,1,ID95
RESPONSE,1,Response
TRANS,1,Trans
MAXSBP,1,Max SBP
PERCENTREMAINING,1,Percent remaining
INHIBITION(ALPHA=001),1,Inhibition (alpha = 0.01)
PLASMACORTICOSTERONE,1,Plasma corticosterone
MAXCAMP,1,Max cAMP
P,1,P
K+NA+RATIO,1,K+/Na+ ratio
NAD+LEVEL,1,NAD+ level
GTRATE,1,GT rate
LOGKOA,1,log KOA
LOSSOFAFFINITY,1,Loss of affinity
CMAXTMAX,1,Cmax/Tmax
SUVMAX,1,SUVmax
BBBIMPERMEABLE,1,BBB Impermeable
RA,1,RA
COUNTS30,1,Counts/30
CVDOSE,1,CV dose
WEIGHTCHANGEOFAP-S,1,Weight change of AP-S
ANTI-FACTORXAACTIVITY,1,Anti-Factor Xa activity
SUPPRESSIVEDOSE,1,Suppressive dose
TUMORWEIGHTREDUCTION,1,Tumor weight reduction
ANXIOLYTICACTIVITY,1,Anxiolytic activity
PKI,1,pKi
HEPSEELEVATEDLIVERFUNCTIONTESTS,1,HepSE_elevated liver function tests
DOSE(URINARYRECOVERY),1,Dose (urinary recovery)
DL50,1,DL50
DURATIONTIME,1,Duration time
HYDROLYSIS,1,Hydrolysis
TG100,1,TG100
RELATIVEET-AIC50,1,Relative ET-A IC50
REA,1,REA
TIMECONSTANTT1,1,Time constant T1
FLOAEL,1,fLOAEL
MIC82,1,MIC82
GI99,1,GI99
DIURESIS,1,Diuresis
RELATIVEINHIBITORYACTIVITY,1,Relative inhibitory activity
K10E4,1,K/10e4
CSFLEVELS,1,CSF levels
NA+EXCRETION,1,Na+ excretion
LT999,1,LT99.9
PHOTOXICREACTION,1,Photoxic reaction
A-SELECTIVITY,1,A-selectivity
CELLNO,1,Cell no
CIC,1,CIC
TISSUELEVEL,1,Tissue level
CURATIVEINDEX,1,Curative Index
PMIC50,1,pMIC50
REVERSETRANSCRIPTASEACTIVITY,1,Reverse transcriptase activity
PERMEABILITYRATE,1,Permeability rate
MAXDOSE,1,Max dose
LC999,1,LC99.9
RESISTANCEREVERSAL,1,Resistance reversal
DELTALOG10CFU,1,deltalog10CFU
MLS,1,MLS
LOGTCID50,1,Log TCID50
BLOCK,1,Block
ERYTHEMA,1,Erythema
VMREL,1,Vm rel
TIDALVOLUME,1,Tidal volume
CPDOSE,1,Cp/dose
DRUGUPTAKE(FREE),1,Drug uptake(free)
MDL,1,MDL
CALCIUMRELEASE,1,Calcium release
-LOGSW,1,-Log Sw
NEUROTOXICITY,1,Neurotoxicity
MLC,1,MLC
PLASMAHISTAMINE,1,Plasma histamine
EH,1,EH
CURES,1,Cures
FR50,1,FR50
LOGKCAT,1,logKcat
RATIOED50MIC50,1,Ratio ED50/MIC50
IC70,1,IC70
ED10,1,ED10
LOGAPA,1,Log APA
CORTICALINFARCTVOLUME,1,Cortical infarct volume
DELTAPIC50WT-MUTANT,1,delta pIC50 wt-mutant
HSLOCURRENT,1,hSlo current
LOG1CLD50,1,log1/CLD50
MOLAREQUIVALENCEBOUND,1,Molar equivalence bound
NOOFCELLS,1,No. of cells
GC50,1,GC50
CONTENTOFCELLCYCLE,1,Content of cell cycle
KSH,1,K SH
CELLSKILLED,1,Cells killed
MBP(DELTA),1,mBP(delta)
IMPROVED,1,Improved
IC50[E],1,IC50/[E]
VV,1,VV
RT3PRODUCTION,1,rT3 Production
ALKALINEPHOSPHATASEINCREASE-ACTIVITYSCORE,1,Alkaline Phosphatase Increase - Activity Score
HEPATOTOXICITY(CIRRHOSIS),1,Hepatotoxicity (cirrhosis)
HVALEVEL,1,HVA level
KASS,1,K ass
STEREOTYPYSCORE,1,Stereotypy score
GI80,1,GI80
MEANRESPONSE,1,Mean response
MAXCOLLATERALINDEX,1,Max collateral index
CLH,1,CLH
CURES@80MGKG,1,Cures@ 80 mg/kg
THYROIDSTATUS,1,Thyroid status
DRUGTRANSPORT,1,Drug transport
CONTROLDMSOAPOPTOTICCELLS(%),1,Control DMSO Apoptotic Cells (%)
DISCRIMINATIONRATIO,1,Discrimination ratio
CMINRATIO,1,Cmin_ratio
IC27,1,IC27
NOOFTUMOURS,1,No. of tumours
REVERSALACTIVITY,1,Reversal activity
MAXTC,1,Max T/C
-LN(MIC),1,-ln (MIC)
XFOLD,1,x fold
NOOFMICEEFFECTEDNOOFTREATED,1,No. of mice effected/No. of treated
CELLS,1,Cells
MCC50,1,MCC50
AGONISTEFFECT,1,Agonist effect
KIF,1,Kif
TC12,1,T/C 1.2
T12BETA,1,T1/2 beta
DOSAGE,1,Dosage
LOGSWEETBITTER,1,Log sweet/bitter
HACUIMPROVEMENT,1,HACU improvement
STATICTUMORS,1,Static tumors
FUNGICIDAL,1,Fungicidal
"K(P,UU,CSF)",1,"K(p,uu,CSF)"
NOOFTOXICDEATHS,1,No. of toxic deaths
LUCIFERASEINFECTIONASSAY-IC90,1,LUCIFERASE INFECTION ASSAY - IC90
APOPTOSISINDEX,1,Apoptosis index
MINANTIVIRALCONCENTRATION,1,Min antiviral concentration
DELTAK,1,Delta K
AZTFORMATION,1,AZT formation
GRI,1,GRI
-LOGKI,1,-Log Ki
BLEEDINGTIME,1,Bleeding time
BMF,1,BMF
BASOLE,1,BASOLE
HEPSEJAUNDICE,1,HepSE_jaundice
DECREASEINBMAX,1,Decrease in Bmax
FNOAEL,1,fNOAEL
AVERAGEWEIGHT,1,Average weight
DARELEASE,1,DA release
MGM,1,MGM
AUBC,1,AUBC
CMAX(RATIO),1,Cmax (Ratio)
%OFCONTROL,1,% of control
MED50,1,MED50
TOP,1,TOP
LOGC50,1,logC50
INCREASEOVERCONTROL,1,Increase over control
MED90,1,MED90
CARBAMOYLATINGACTIVITY,1,Carbamoylating activity
DURATIONOFREVERSAL,1,Duration of reversal
CONTRACTILITY,1,Contractility
SURVIVALDAYS,1,Survival days
REDUCTIONOFPROSTATEWEIGHT,1,Reduction of prostate weight
UTC,1,UTC
LOWESTEFFECTIVEDOSE,1,Lowest effective dose
RELATIVEBINDINGPOTENCY,1,Relative binding potency
MEANULCERINDEX,1,Mean ulcer index
NOOFANIMALSPROTECTEDNUMBEROFANIMALSTESTED,1,No. of animals protected/number of animals tested
ALPHAMAX,1,Alpha max
PLASMALEVELS,1,Plasma levels
KINETIC,1,Kinetic
LIPIDLEVEL,1,Lipid level
CP(T),1,Cp(T)
AVERAGELUNGWEIGHT,1,Average lung weight
CLEAVAGERATE,1,Cleavage rate
MEANUTERINEWEIGHT,1,Mean uterine weight
AUCMETABOLITEAUCRADIOLABEL,1,AUC metabolite/AUC radiolabel
BILDIR,1,BILDIR
PREGNANT,1,Pregnant
OCCED50,1,Occ ED50
NOOFREVERTANTSPERPLATE,1,No. of revertants per plate
POSITIVEPAWS,1,Positive paws
PKAE2,1,pKa E2
TUMORINCIDENCE,1,Tumor incidence
ZONEDIAMETER,1,Zone diameter
CHELATOR,1,Chelator
VARIATIONOFEDEMAVOLUME,1,Variation of edema volume
AMOUNTOFCROSS-LINKEDPROTEIN,1,Amount of cross-linked protein
MI05,1,MI0.5
ANIMALSDEAD,1,Animals dead
EFFLUXKI,1,Efflux Ki
PFC,1,PFC
EC16,1,EC16
ACT,1,ACT
%OFKINASEACTIVITY,1,% of kinase activity
CELLULARGROWTH,1,Cellular growth
DI50,1,DI50
AD90,1,AD90
I16,1,I16
HEPATOTOXICITY(CYTOLYTIC),1,Hepatotoxicity (cytolytic)
CONTROLOFP-450MARKER,1,Control of P-450 marker
SURVIVORSATDAY8,1,Survivors at day 8
CHOLESTEROL,1,Cholesterol
NORMALIZATION,1,Normalization
CONTROLUPTAKE,1,Control Uptake
MEC,1,MEC
NOCUREDTOTAL,1,No. cured/total
ANIMALSAFFECTED,1,Animals affected
TOXICTOTAL,1,Toxic/total
CFU-GEMM,1,CFU-GEMM
KDERROR,1,Kd Error
PRESSURE,1,Pressure
CSSMIN,1,Css min
AVERAGE14-DAYMGR,1,Average 14-day MGR
TD10,1,TD10
PLATELETCOUNT,1,Platelet count
POTENCYDYRK1BUM,1,Potency_Dyrk1b_uM
JUMPLATENCYTIME,1,Jump latency time
GI75,1,GI75
RESIDUALINSULINSECRETION,1,Residual insulin secretion
CZ,1,Cz
BIOAVAILABILITYINCREASE,1,Bioavailability Increase
PEMR,1,pEMR
PMED,1,pMED
EXUDATEVOLUME,1,Exudate volume
TOXICDEATHS,1,Toxic deaths
CELLGROWTH,1,Cell growth
CREATCHANGEBY,1,CREAT_CHANGE_BY
REVERSIBLE,1,Reversible
AUMCLAST,1,AUMClast
ANIMALS,1,Animals
HALUCINOGENICACTIVITY,1,Halucinogenic activity
KMAPP,1,Km app
CHANGEMAP,1,Change MAP
CONCENTRATIONOFCL-,1,Concentration of Cl-
CHALLENGETIME,1,Challenge time
WRITHINGNUMBER,1,Writhing number
EC1000,1,EC1000
CYTOTOXICCONCENTRATION,1,Cytotoxic concentration
MEANSURVIVAL,1,Mean survival
ANTIDIURETICACTIVITY,1,Antidiuretic activity
HEPSEHEPATITIS,1,HepSE_hepatitis
ID40,1,ID40
TIMEOFLICKING,1,Time of licking
CLTF,1,CLt/F
AUCED50,1,AUC ED50
SURVIVALTIME,1,Survival time
NOOFNEWTUMORS,1,No. of new tumors
LC90,1,LC90
UPTAKE,1,Uptake
ABSAC40UM,1,AbsAC40_uM
CSINDEX,1,CS index
VMAX(UM),1,Vmax (uM)
ERMAX,1,ER max
DOSERANGE,1,Dose range
AGONISMINFLECTIONPOINT,1,Agonism inflection point
MDRRATIO,1,MDR ratio
TOPICALIRRITATIONSCORE(0-21),1,Topical irritation score(0-21)
CONVULSIONTHRESHOLD,1,Convulsion threshold
PROTECTED,1,Protected
DELTATAO,1,Delta TAO
PLASMANEFA,1,Plasma_NEFA
MEANHR,1,Mean HR
ANTIHYPERTENSIVESCORE,1,Antihypertensive score
URINEBILE,1,Urine/bile
TOTALTURNINGS,1,Total turnings
NON-SPECIFICBINDING,1,Non-specific binding
ABILITY,1,Ability
AAL,1,AAL
COMPETITIONFACTOR,1,Competition factor
CMT,1,CMT
DEGREEOFACTIVATION,1,Degree of activation
PIC100,1,pIC100
NETLOGKILL,1,Net log kill
VD,1,Vd
TGICORRELATIONCOEFFICIENT,1,TGI correlation coefficient
E,1,E
NON-HDL-C,1,Non-HDL-C
MEAN%GROWTH(N=2)FOR1000ΜMPROBECONCENTRATION,1,Mean % growth (n = 2) for 100.0 µM probe concentration
IMMOBILITYTIME,1,Immobility time
DIFFUSION,1,Diffusion
PREGNANCYINDEX,1,Pregnancy index
EFF,1,Eff
RETENTION,1,Retention
RATIOLD50IC50,1,Ratio LD50/IC50
E2RESPONSE,1,E2 response
CHANGEINTUMORAREA,1,Change in tumor area
HEPATOTOXICITY(MALIGNANTTUMOUR),1,Hepatotoxicity (malignant tumour)
SHUTDOWNTIME,1,Shutdown time
SERUMTRIGLYCERIDE,1,Serum triglyceride
GII50,1,GII50
ANTIVIRALSELECTIVITY,1,Antiviral selectivity
PLASMAMIC,1,Plasma MIC
BENZIDINEPOSITIVECELLS,1,Benzidine positive cells
ANTIHYPERTENSIVEACTIVITY,1,Antihypertensive activity
REVERSIBILITYRATIO,1,Reversibility ratio
APD90,1,APD90
DTAGG,1,dTagg
VIABILITY,1,Viability
PTI,1,pTI
CELLULARCONCENTRATION,1,Cellular concentration
POPULATIONMEMBRANEPERMEABLE-PHENOTYPE(%),1,Population Membrane Permeable-Phenotype (%)
GASTRICTOXICITY,1,Gastric toxicity
BDW,1,BDW
PRODRUGREMAINS,1,Prodrug remains
ED20,1,ED20
I14,1,I14
THERAPEUTICEFFECT,1,Therapeutic effect
INCREASEIN[CA+2],1,Increase in [Ca+2]
LOG(1MED),1,log(1/MED)
LOG1MIC,1,Log 1/MIC
SGPTINCREASE-ACTIVITYSCORE,1,SGPT Increase - Activity Score
CAMP,1,cAMP
SUBCUTANEOUSSCORE,1,Subcutaneous score
PPB,1,PPB
LEARNINGTIME,1,Learning time
METABOLICSTABILITY,1,Metabolic stability
HEPATOTOXICITY(MECHANISM),1,Hepatotoxicity (mechanism)
%NUCLEOTIDEPRESENT,1,% nucleotide present
ADRENOCHROMEFORMATION,1,Adrenochrome formation
REVERSINGACTIVITY,1,Reversing activity
EC30,1,EC30
PK1,1,pK1
IC80,1,IC80
-LOG(1MIC),1,-log(1/MIC)
TICKACTION,1,Tick action
TPI,1,TPI
SCXRATIO,1,S/CX Ratio
GROWTHDELAY(T-CC),1,Growth delay (T-C/C)
NA+RATIO,1,Na+ ratio
PC2A,1,pC2A
AVERAGEIC90,1,Average IC90
FREL,1,Frel
NOOFLUNGMETASTASIS,1,No. of lung metastasis
MSC,1,MSC
CYTOTOXICENDPOINT,1,Cytotoxic endpoint
FULLINHIBITION,1,Full inhibition
MBEC999,1,MBEC99.9
KICOMP,1,Ki comp
MEAN%GROWTH(N=2)FOR10ΜMPROBECONCENTRATION,1,Mean % growth (n = 2) for 1.0 µM probe concentration
T12H,1,T1/2 h
KCATKI,1,k cat/Ki
TUMOURINHIBITION,1,Tumour inhibition
PROTECTION,1,Protection
GLUCOSE,1,Glucose
MIC65,1,MIC65
BWLOSS,1,BW loss
NI,1,NI
HSF,1,HSF
KUP,1,Kup
PHOTOTOXICITY,1,Phototoxicity
PDELTAIOP,1,pDelta IOP
FOLDACTIVATION,1,Fold activation
PK,1,pK
MFC50,1,MFC50
ER-PHAGYSUPPRESSION,1,ER-phagy suppression
KAPPX10E6,1,K app x10e6
REGRESSIONRESPONSE,1,Regression response
GPI,1,GPI
SERUMLIPOPROTEINCHOLESTEROL,1,Serum lipoprotein cholesterol
PROTEINBOUND,1,Protein bound
AMOUNTRECOVEREDINURINE,1,Amount Recovered in urine
LCC99,1,LCC99
PHOSLPD,1,PHOSLPD
SELECTIVITYRATIO,1,Selectivity ratio
INHIBITION(500ΜM),1,Inhibition (500 µM)
AVERAGETUMORVOLUME,1,Average tumor volume
WATERINTAKE,1,Water intake
MAX,1,Max
ATPCONTENT,1,ATP content
CHANGEINTPR,1,Change in TPR
ED99,1,ED99
OCCULATIONS,1,Occulations
SPECIFICBINDINGPERMGOFPROTEIN,1,Specific binding per mg of protein
NOOFPITSSLICE,1,No. of pits/slice
ED0,1,ED0
OPTIMALDOSE,1,Optimal dose
MAXREVERSAL,1,Max reversal
HEPATOCYTESTABILITY,1,Hepatocyte stability
LM,1,LM
BEI,1,BEI
MEANED50,1,Mean ED50
DELTA(V12),1,delta(V1/2)
DECREASEINBLOODGLUCOSE,1,Decrease in blood glucose
TFS,1,TFS
DOSE-MODIFYINGFACTOR,1,Dose-modifying factor
UTEROTROPHICACTIVITY,1,Uterotrophic activity
NORMALBEATS,1,Normal beats
CHANGEOFHEMOCONCENTRATION,1,Change of hemoconcentration
DELTAHDL,1,Delta HDL
STROKEVOLUME,1,Stroke volume
IC12,1,IC12
DELTAP,1,Delta p
LD40,1,LD40
BMAXH,1,BmaxH
HEPSECIRRHOSIS,1,HepSE_cirrhosis
ANIMALDEATH,1,Animal death
PCPACTIVITY,1,PCP activity
BINDINGSELECTIVITY,1,Binding selectivity
KBS,1,KbS
LL,1,LL
TREATEDCELLS,1,Treated cells
NOOFDOGSREVERTED,1,No. of dogs reverted
COLONYFORMATION,1,Colony formation
MAXMEANWEIGHTLOSS,1,Max mean weight loss
MUD,1,MUD
IC35,1,IC35
CLH(APP),1,CLH(app)
LOG1MIC(MML-1),1,Log 1/MIC (mM L-1)
NETGRAINCOUNTS,1,Net grain counts
NOOFLIVINGCELLS,1,No. of living cells
CL-RENAL,1,CL-renal
NEWTUMORS,1,New tumors
AVERAGE,1,Average
CATALASE,1,Catalase
ANXIOLYTICAFFECT,1,Anxiolytic affect
ULCERATIVEINDEX,1,Ulcerative index
ERPR,1,ER/PR
SEDATIVEDOSE,1,Sedative dose
SURVIVALMEDIAN,1,Survival median
GRIPSTRENGTH,1,Grip strength
ILS30,1,ILS30
GASTRICLESIONS,1,Gastric lesions
T1,1,T1
HEARTWEIGHTABSOLUTE,1,Heart weight absolute
PEC50,1,pEC50
ER,1,ER
VMAXL,1,VmaxL
GSHREACTIVITY,1,GSH reactivity
F,1,F
RATIOPIC50,1,Ratio pIC50
MEDIANSURVIVAL,1,Median survival
LOG2,1,Log2
CHANGEINSYSTOLICBP,1,Change in systolic BP
IE1,1,IE1
DELTALOGPOCT-DOD,1,delta logPoct-dod
VENOM,1,Venom
C24,1,C24
EDDELTA,1,ED delta
DENATURATIONRATECONSTANT,1,Denaturation rate constant
SN,1,S/N
ANTI-UTEROTROPHICEFFECT,1,Anti-uterotrophic effect
CC10,1,CC10
AGE,1,Age
TI50,1,TI50
ANALGESIC,1,Analgesic
HEPSEHEPATICNECROSIS,1,HepSE_hepatic necrosis
LOG1C,1,Log 1/C
AFC50,1,AFC50
RS,1,Rs
LOGK1,1,Log K1
FRACTIONEXCRETEDUNCHANGED,1,Fraction excreted unchanged
DELTACA,1,Delta Ca
NOOFSHOCKS,1,No. of shocks
CUREDTREATED,1,Cured/treated
FIC20,1,fIC20
TIMEINLIGHT,1,Time in light
LOGPLOGD,1,Log P/Log D
GI25,1,GI25
POSITIVECONTROL,1,Positive control
INCREASEINHR,1,Increase in HR
CHANGEINDPDT,1,Change in dP/dt
TOX,1,TOX
BASAL,1,Basal
DBP15,1,DBP15
TIMETOMAXINHIBITION,1,Time to max. inhibition
LOG(1LC50),1,log(1/LC50)
REMAINING(WITHOUTCOFACTOR),1,Remaining (without cofactor)
NOOFANIMALSALIVE,1,No. of animals alive
K2C,1,k2c
ED97,1,ED97
PTZ,1,PTZ
RMAX,1,Rmax
[35S]TBPSSHIFT,1,[35S] TBPS shift
NOOFRATSWITH5-HTSYNDROME,1,No. of rats with 5-HT syndrome
IDXKGOFBODYWEIGHTGOFTISSUE,1,ID x kg of body weight/g of tissue
EDUCTION,1,eduction
HC5,1,HC5
DELTAIOP,1,Delta IOP
CBF-ID75,1,CBF-ID75
CONVERSION,1,Conversion
RTG,1,RTG
KQ,1,Kq
ILB,1,ILB
LUCIFERASEEXPRESSIONCONTROL-IC50,1,LUCIFERASE EXPRESSION CONTROL - IC50
RANGEOFSURVIVAL,1,Range of survival
GHAUC0-180,1,GH AUC 0-180
BINCORPORATION,1,B incorporation
MIC>85,1,MIC>85
MAXFALL,1,Max fall
OSMOLALITY,1,Osmolality
PED40,1,pED40
TMAXDOSE,1,Tmax/dose
FOS,1,Fos
CTLACTIVITY,1,CTL activity
TOXICLEVEL,1,Toxic level
INCC50,1,INCC50
EEMAX,1,E/Emax
METHEMOGLOBIN,1,Methemoglobin
LOSSOFRIGHTINGREFLEX,1,Loss of righting reflex
ONSETOFACTION,1,Onset of action
TOTALCL,1,Total CL
PARTITIONCOEFFICIENT,1,Partition coefficient
PAWVOLUME,1,Paw volume
CONCENTRATIONURINE,1,Concentration_urine
PEAKDELTAHR,1,Peak deltaHR
HVA,1,HVA
DECREASEINTHEQAINTERVAL,1,Decrease in the QA interval
INTRINSICVASORELAXATION,1,Intrinsic vasorelaxation
C5AAFFINITY,1,C5a affinity
SOLUBILITY(MEAN),1,Solubility (mean)
NOOFMICEPROTECTEDTESTED,1,No. of mice protected/tested
EC50,1,EC50
CHANGEOFDBP,1,Change of DBP
MHPGSO4,1,MHPG_SO4
SEIZURESCORE,1,Seizure score
ORALDURATION,1,Oral duration
ANTI-ANALGESIC,1,Anti-analgesic
"KPOTA,B",1,"Kpot A,B"
TOTALUPTAKE,1,Total uptake
PKIRATIO,1,pKi ratio
UC50,1,UC50
NOOFENTRIES,1,No. of entries
BIC,1,BIC
OVRATTOTAL,1,ov. rat/total
TUMORGROWTHDELAY,1,Tumor growth delay
CA2+,1,Ca2+
THERAPEUTICINDEX99,1,Therapeutic index 99
TUMORNUMBER,1,Tumor number
LD60,1,LD60
DRUGRESPONDING,1,Drug responding
DC,1,DC
ZIMAXKZI,1,ZImax/KZI
SBPCHANGE,1,SBP change
RLUWELL,1,RLU/well
TOTALLYSIS,1,Total lysis
CHANGEOFBODYTEMPERATURE,1,Change of body temperature
MAXUTERINEWEIGHT,1,Max uterine weight
PARENTCOMPOUND,1,Parent compound
SPECIFICINCORPORATION,1,Specific incorporation
DNARELAXATION,1,DNA relaxation
LOGTA100,1,Log TA100
KE(APP),1,Ke(app)
LC95,1,LC95
PHOSPHOR,1,Phosphor
TASTE,1,Taste
INFECTEDMOSQUITOES,1,Infectedmosquitoes
ULCEROGENICINDEX,1,Ulcerogenic index
POPULATIONAPOPTOTIC(%),1,Population Apoptotic (%)
DOPALEVEL,1,DOPA level
SPST,1,Sp St
S,1,S
ACTIVATION,1,Activation
IMPLANTS,1,Implants
ED80,1,ED80
TUMORWEIGHT,1,Tumor weight
RBA2,1,RBA2
DEPENDENCY,1,Dependency
MND,1,MND
MBEC50,1,MBEC50
FRPC20,1,FRP C20
INTRINSICSOLUBILITY,1,Intrinsic_solubility
DEATHS,1,Deaths
5-HTSYNDROME,1,5-HT syndrome
CFUG,1,CFU/g
CONC@MAXFOLDINCR,1,Conc @ Max Fold Incr
MAXPLATELETRESPONSE,1,Max platelet response
MEANNOCOLONIES,1,Mean no. colonies
MAXIMALNON-TOXICDOSE50,1,Maximal non-toxic dose 50
CELLKILLACTIVITY,1,cell kill activity
RESIDUALBINDING,1,Residual binding
LOGY,1,Log Y
AUC(APP),1,AUC(app)
TUMORRESPONSE,1,Tumor response
CONTROLDMSOGROWTHRATE,1,Control DMSO Growth Rate
HEPATICCHOLESTEROL,1,Hepatic cholesterol
MYCELIALGROWTH,1,Mycelial growth
3LOGKILL,1,3 log kill
LD10,1,LD10
TCCORR,1,T/C corr
D,1,D
EXCESSZONERADIUS,1,Excess zone radius
KESELECTIVITYRATIO,1,Ke selectivity ratio
ULTRAFILTRATION,1,Ultrafiltration
INCORPORATIONRATE,1,Incorporation rate
INDEX,1,Index
TISSUELEVELS,1,Tissue levels
STIMULATION,1,Stimulation
ERP(DELTA),1,ERP (delta)
AT1AFFINITY,1,AT1 affinity
REDUCTIONINAUC,1,Reduction in AUC
KMKCAT,1,Km/Kcat
MEQUIVOFNA+KG,1,mequiv of Na+/kg
VDAREA,1,Vd area
COLONYCOUNT,1,Colony_count
PKAA1,1,pKa_A1
MBC99,1,MBC99
FB,1,FB
MA,1,MA
HEARTBEAT,1,Heart beat
X,1,X
COMPOSITEACTIVITY-MARGINAL,1,Composite Activity - Marginal
LD100,1,LD100
RELATIVEVELOCITY,1,Relative velocity
INSULIN-SENSITIZINGACTIVITY,1,Insulin-sensitizing activity
REMAININGRATE,1,Remaining rate
MEANACTIVITY,1,Mean activity
MAXLOWERINGMABP,1,Max lowering MABP
CMAXDOSE,1,Cmax/dose
CD100,1,CD100
DELTAII,1,Delta I/I
PKL,1,pKL
SLOPEOFSCHILDPLOT,1,Slope of Schild plot
LD50X140,1,LD50 x 1/40
1MIC,1,1/MIC
T12REGEN,1,T1/2 regen
SUPPRESSION,1,Suppression
URINARYVOLUME,1,Urinary volume
DEATHSTOTAL,1,Deaths/total
HYPERGLYCEMICACTIVITY,1,Hyperglycemic activity
SSC,1,SSC
REPLACEMENT,1,Replacement
CHANGEINBLOODPRESSURE,1,Change in blood pressure
AUGMENTATION,1,Augmentation
MOLARPOTENCY,1,Molar potency
LOGDSF,1,Log DSF
PTGI,1,pTGI
KDSPR,1,KdSPR
TUMOR,1,Tumor
BODYWEIGHTGAIN,1,Body weight gain
BLOODVOLUME,1,Blood volume
BBC50,1,BBC50
CLAST,1,Clast
EC125,1,EC125
MFC90,1,MFC90
CC20,1,CC20
PEC90,1,pEC90
IA,1,IA
ANTIVIRALEFFECT,1,Antiviral effect
BEHAVIORALSYNDROME,1,Behavioral syndrome
KI2,1,Ki2
BORONINMEDIAAT0H,1,Boron in media at 0h
D150,1,D150
CELLCYCLEEFFECT,1,Cell cycle effect
BINDINGCOMPETITION,1,Binding competition
MEANFOLDSTIMULATION,1,Mean fold stimulation
1-LOGKI,1,1-logKi
SD80,1,SD80
CI50,1,CI50
EXTRACTED,1,Extracted
EC37,1,EC37
MAXIMALCHANGE,1,Maximal change
%,1,%
GRIPSCORE,1,Grip score
RELATIVEED50,1,Relative ED50
RELATIVEMETABOLICSTABILITY,1,Relative metabolic stability
HK,1,Hk
NOACTIVE,1,No. active
AUCNORMALISED,1,AUC normalised
CASPASEINDUCTION,1,Caspase induction
DOSEELEVATION,1,Dose elevation
EC150,1,EC150
MEQUIVOFHCL,1,mequiv of HCl
LOG1ISA,1,Log 1/ISA
ACCUMULATIONCOUNTS,1,Accumulation counts
%OFEFFECT,1,% of effect
MHC10,1,MHC10
FRACTION,1,Fraction
S-PHASE,1,S-phase
PC20,1,pC20
KI(18X10E-11),1,Ki(1.8x10e-11)
PLAT,1,PLAT
MBEC,1,MBEC
SWEETNESSPOTENCY,1,Sweetness potency
MAXIMALEFFICACY,1,Maximal efficacy
BINDING,1,Binding
DC50,1,DC50
ARTHRITISSCORES,1,Arthritis scores
IRONCLEARENCE,1,Iron clearence
AOC,1,AOC
DRUGLEVEL,1,Drug level
ASORBANCE,1,Asorbance
IDORGAN,1,ID/organ
MAXHEMORRHAGE,1,Max hemorrhage
MAXSCORE,1,Max score
PFU,1,PFU
NSR,1,NSR
MEANRBF,1,Mean RBF
V1,1,V1
CAMPPRODUCTION,1,cAMP production
ECLT,1,ECLT
DURATIONOFSEIZURE,1,Duration of seizure
CMAXPTH,1,Cmax_PTH
MCHC,1,MCHC
HD50,1,HD50
HOMOVANILLICACIDCONCENTRATION,1,Homovanillic acid concentration
MYOBLASTSWITHPARASITES,1,Myoblasts with parasites
RELATIVEUPTAKE,1,Relative uptake
CELLNODISHX10E3,1,Cell no./dish x10E3
CHANGEINAMPLITUDERESPONSE,1,Change in amplitude response
SAQ,1,Saq
ANOGENITALDISTANCE,1,Anogenital distance
IC20,1,IC20
TBPSIC50,1,TBPS IC50
LOGCFUGOFTISSUE,1,Log cfu/g of tissue
AMOUNT,1,Amount
VDSS(APP),1,Vdss(app)
MAXACHIEVABLEBIOAVAILABILITY,1,Max Achievable Bioavailability
UR,1,UR
LOSS,1,Loss
SURVIVALINCREASE,1,Survival increase
EC170,1,EC170
NADCONTENT,1,NAD content
EXPINHIBCONSTANT,1,Exp Inhib Constant
EC50H,1,EC50H
RPE,1,RPE
PLASMACONC,1,Plasma conc
THERMOGENESIS,1,Thermogenesis
POPULATIONTUBULIN-DIFFERENT-PHENOTYPE(%),1,Population Tubulin-Different-Phenotype (%)
LDLCHOLESTEROL,1,LDL cholesterol
OFF-RATE,1,Off-rate
BINDINGINTENSITY,1,Binding intensity
CLINT,1,CLint
36CL-UPTAKE,1,36Cl- uptake
AVERAGEACTIVITY,1,Average activity
DNADAMAGE,1,DNA damage
SUPPRESSIONRATIO,1,Suppression ratio
PKH,1,pKH
EXPLORATIONMOTILITY,1,Exploration motility
LD90,1,LD90
PARASITESNOPER100MYOBLASTS,1,Parasites no. per 100 Myoblasts
ED300,1,ED300
CATALEPSY,1,Catalepsy
FIBRINO,1,FIBRINO
POSITIVE,1,Positive
FG,1,Fg
OXYGENUPTAKE,1,Oxygen uptake
RELATIVERESPONSE,1,Relative response
AFFINITYCONSTANT,1,Affinity constant
KGMAX,1,Kgmax
IC16,1,IC16
REDUCTIONINCLRENAL,1,reduction in CL_renal
AVERAGEBODYWEIGHT,1,Average body weight
UD50,1,UD50
COMPLETEREMISSION,1,Complete remission
PP2ASELECTIVITY,1,PP2A Selectivity
MINERALIZINGAPPOSITIONRATE,1,Mineralizing apposition rate
LTC,1,LTC
REVERTANTCOLONIESPERPLATE,1,Revertant colonies per plate
DNAONFILTER,1,DNA on filter
PCB50,1,pCB50
SPREAD,1,Spread
SC,1,SC
WEIGHTCHANGEONDAY5,1,Weight change on day 5
R,1,R
VENTRICULARRELATIVEREFRACTORYPERIOD,1,Ventricular relative refractory period
MAXMBP,1,Max MBP
MEANEXCRETIONOFNA+,1,Mean excretion of Na+
FIBRILFORMATION,1,Fibril formation
TIMEOFPEAKACTION,1,Time of peak action
TUMOR-FREE,1,Tumor-free
SENSITIVITY,1,Sensitivity
SUV,1,SUV
MBIC100,1,MBIC100
DEADTREATED,1,Dead/treated
LCE,1,L/CE
COUNT,1,Count
TCSURVIVALDAYS,1,T/C survival days
CYTOTOXICITY,1,Cytotoxicity
MOLARPRIMAQUINEINDEX,1,Molar primaquine Index
NOOFAVOIDANCE,1,No. of avoidance
ALLODYNIASCORE,1,Allodynia score
ACTIVATIONFACTOR,1,Activation Factor
INCREASEINDPM,1,Increase in DPM
NEGATIVECHRONOTROPICACTIVITY,1,Negative chronotropic activity
NAD+CONTENT,1,NAD+ content
MF,1,MF
CHANGEINMAP,1,Change in MAP
RATIOLC50IC50,1,Ratio LC50/IC50
CT3,1,CT3
LETHALITY,1,Lethality
RECEPTORBINDING,1,Receptor binding
PCB,1,pCB
GTFOLDSTIMULATION,1,GT fold stimulation
AFI,1,AFI
MCPHAILINDEX,1,McPhail index
AUCNPO,1,AUC Npo
ENDOSTEALERODEDSURFACE,1,Endosteal eroded surface
IPA,1,IPA
LOGK2,1,Log K2
TPO,1,TPO
PC95,1,PC95
LAMBDAZ,1,LambdaZ
CCELLULAR,1,Ccellular
AI,1,AI
INJECTEDDOSE(G),1,Injected dose (g)
TOXICITYRELATEDDEATH,1,Toxicity related death
POLYAMINE,1,Polyamine
CP(F)DOSE,1,Cp(f)/dose
NOCURED,1,No. cured
ED33,1,ED33
CONTROLDMSOPYKNOSEDNUCLEI(%),1,Control DMSO Pyknosed Nuclei (%)
LD80,1,LD80
HEPATICEXTRACTIONRATIO,1,Hepatic Extraction ratio
MED=>50,1,MED=>50
ABSAC047UM,1,AbsAC0.47_uM
CA2+TRANSPORT,1,Ca2+ transport
TDELTAS,1,TdeltaS
CLIP,1,CLIP
AVERAGESURVIVAL(DAYS),1,Average survival (days)
TISSUEDISTRIBUTION,1,Tissue distribution
EXTENT,1,Extent
TC(D),1,T/C (d)
RATEOFOXIDATION,1,Rate of oxidation
NOOFPLATELETS,1,No. of platelets
PI50,1,pI50
IC50EC50,1,IC50/EC50
PTZPROTECTION,1,PTZ protection
ABD50,1,ABD50
MAC,1,MAC
PFCSPLLEEN,1,PFC/splleen
SURVIVORSATDAY30,1,Survivors at day 30
CONTRACTION,1,Contraction
ED50MGANIMALDAY,1,ED50 mg/animal/day
PEC170,1,pEC170
LNKP,1,ln Kp
PKRED,1,pKred
TCX100,1,T/C x100
LOGKDELTA,1,Log K delta
RF50,1,rf50
RVMAX,1,RVmax
HAMMETTCONSTANT,1,Hammett constant
PARASITESUPPRESSION,1,Parasite suppression
LOGP(LUNG),1,logP(lung)
NOOFRATSDIED,1,No. of rats died
PPKB,1,ppKb
LVEDP,1,LVEDP
PH,1,pH
PARASITECLEARANCE,1,Parasite_Clearance
I23,1,I23
TESTOSTERONE,1,Testosterone
CYOTOXICITY,1,Cyotoxicity
NSRSURVIVALRATE,1,NSR survival rate
LCC999,1,LCC99.9
ED85,1,ED85
MRT(T),1,MRT(t)
APD70,1,APD70
SKINTESTSINTENSITY,1,Skin tests intensity
ABSAC054UM,1,AbsAC0.54_uM
ANTIVIRALINDEX,1,Antiviral index
BRAINBLOODCONCENTRATION,1,Brain/Blood concentration
MAXBSR,1,Max BSR
O2CONSUMPTION,1,O2 consumption
LOGSOSIP,1,Log SOSIP
NOTOTAL,1,No. total
TRANSCRIPTIONALACTIVATION,1,Transcriptional activation
LOGCL,1,logCL
SURVIVALDOSE,1,Survival dose
HYPNOSISPOTENTIATION,1,Hypnosis potentiation
BATHOCHROMICSHIFT,1,Bathochromic shift
BEHAVIORALRESPONSE,1,Behavioral response
MTXRATIO,1,MTX ratio
HORIZONTALACTIVITY,1,Horizontal activity
AIDHACTIVITY,1,AIDH activity
SPONTANEOUSACTIVITY,1,Spontaneous activity
PGPABAANALOGUERATIO,1,Pgp AbA/analogue ratio
UPTAKERATIO,1,Uptake ratio
MEC50,1,MEC50
DRUGDISSOLUTION,1,Drug dissolution
LOG1B+1,1,Log 1/B+1
ANTAGONISMEFFECTS,1,Antagonism effects
ROTATIONNUMBER,1,Rotation number
CHALLENGEDOSE,1,Challenge dose
VOLUMECHANGE,1,Volume change
TOTALBINDINGINHIBITED,1,Total binding inhibited
CFUML,1,CFU/ml
LD5,1,LD5
SERUMMETABOLITE,1,Serum metabolite
RATEOFREDUCTION,1,Rate of reduction
K'I,1,K'i
STAININDEX,1,Stain index
ROI,1,ROI
KEFF(REL),1,k eff (rel)
RELATIVEDIFFERENTIATINGACTIVITY,1,Relative differentiating activity
GITOLERANCE,1,GI tolerance
SODIUM,1,SODIUM
RELAPSES,1,Relapses
KUN,1,Kun
CHOL,1,CHOL
MINID,1,Min ID
RADIOLIGANDBOUND,1,Radioligand bound
PW,1,Pw
RECOVEREDINURINE,1,Recovered in urine
KIL,1,KiL
RELATIVESTIMULATIONINDEX,1,Relative stimulation index
DOBS,1,Dobs
CHANGESYSTOLICBP,1,Change systolic BP
LESIONSCORE,1,Lesion score
LOG(1MLD),1,log(1/MLD)
IMBALANCE,1,Imbalance
GLUCURONIDATIONRATE,1,Glucuronidation rate
IC15,1,IC15
DURATION,1,Duration
CQ,1,CQ
DIFFERENCEINRETENTIONTIME,1,Difference in retention time
GELLARCOOKACTIVITY,1,Gellar cook activity
PCD,1,pCD
ANALGESICEFFICACYCOMPAREDTOMORPHINE,1,Analgesic efficacy compared to morphine
BLOODCLEARANCE,1,Blood clearance
CHANGEFROMCONTROL(LVDPDT),1,Change from Control (LV dp/dt)
CMAXMETABOLITE,1,Cmax_metabolite
LOG[MRI],1,Log [MrI]
PAPPBTOAPLUSINHIBITOR(MEAN),1,Papp B to A plus inhibitor (mean)
CRCCRC0,1,CRC/CRC0
AVERAGEFORSKINREACTION,1,Average for skin reaction
PLEURALFLUID,1,Pleural fluid
%CLEARED,1,%Cleared
HEPATOTOXICITY,1,Hepatotoxicity
RELATIVEINFLUX,1,Relative influx
BINDINGPOTENCY,1,Binding potency
DELTAMA,1,Delta MA
LOGK-1,1,Log K-1
I20,1,I20
TUMORS,1,Tumors
RADIATIONPROT,1,Radiation prot
MEANDURATION,1,Mean duration
UPTAKESELECTIVITY,1,Uptake selectivity
TO,1,TO
P50DP50C,1,P50d/P50c
INCREASEINMAP,1,Increase in MAP
DBPCHANGE,1,DBP change
EROSIONS,1,Erosions
LIVERCHOLESTEROL,1,Liver cholesterol
LIPOPROTEINLEVEL,1,Lipoprotein level
A,1,A
POTENTIAL,1,Potential
CHANGEINWEIGHT,1,Change in weight
FECALWEIGHT,1,Fecal weight
LOG10CFUML,1,log10CFU/ml
GABACURRENT,1,GABA current
ENHANCEMENT,1,Enhancement
ENDOSTEALMINERALIZINGSURFACE,1,Endosteal mineralizing surface
MTC,1,MTC
CGI,1,CGI
ANTI-ARHYTHMIC,1,Anti-arhythmic
SECRETION,1,Secretion
LOG1TH+200,1,Log 1/Th+200
I80,1,I80
RELATIVEWEIGHTLOSS,1,Relative weight loss
CELLCYCLEFRACTION,1,Cell cycle fraction
FREERADICALSCAVENGING,1,Free radical scavenging
LTS,1,LTS
DOSEINTERVAL,1,Dose interval
NOTOXICITYTESTED,1,No. toxicity/tested
CT50,1,CT50
AAC,1,AAC
FEC50,1,fEC50
5-HTLEVEL,1,5-HT Level
KSAPP,1,Ks app
C20FRP,1,C20 FRP
TOTALCHOLESTEROL,1,Total cholesterol
PRESYNAPTICANTAGONISM,1,Presynaptic antagonism
CONTROLDMSOMEMBRANEPERMEABLE-PHENOTYPECELLS(%),1,Control DMSO Membrane Permeable-Phenotype Cells (%)
DIFFUSIONANALYSIS,1,Diffusion analysis
TOLERANCE,1,Tolerance
P74,1,P7.4
MAXTEMPERATUREDECREASE,1,Max temperature decrease
HAPTOGLOBIN,1,Haptoglobin
LOGBR,1,Log BR
UNALTEREDCOMPOUND,1,Unaltered compound
-LOGALPHA,1,-Log alpha
REMAININGAT40MIN,1,Remaining at 40 min
TIMECONSTANTT2,1,Time constant T2
GLYCINEANTAGONISM,1,Glycine antagonism
CHANGEINBODYTEMPERATURE,1,Change in body temperature
KILOW,1,Ki low
TMED50,1,TMED50
REMAINING,1,Remaining
INCREASEINPLASMAAMYLASE,1,Increase in plasma amylase
MEANDAYOFDEATHFORTOTALDEAD,1,Mean day of death for total dead
PK4,1,pK4
FPT,1,FPT
LESIONCLEARANCE,1,Lesion_Clearance
ACCELERATION,1,Acceleration
PPM,1,PPM
VRT,1,VRT
AMOUNTINURINE,1,amount in urine
KAFF,1,K aff
PC50,1,PC50
DOSEGOFTISSUE,1,Dose/g of tissue
VOLUME,1,Volume
PHA,1,PHA
INHIBITIONUPTAKE,1,Inhibition uptake
DURATIONOFPLATEAU,1,Duration of plateau
PA2(APP),1,pA2(app)
VBETA,1,Vbeta
METABOLICTURNOVER,1,Metabolic turnover
LOG(10'6IC50),1,log(10'6/IC50)
P50,1,P50
MAXINCREASE,1,Max increase
HYPERMOTILITY,1,Hypermotility
ED95,1,ED95
PERFORMANCE,1,Performance
POTENCYCLK2UM,1,Potency_Clk2_uM
ARP,1,ARP
SUBSTRATE,1,Substrate
PAWSWELLING,1,Paw swelling
TUMORBLOODRATIO,1,Tumor/blood ratio
MNTD90,1,MNTD90
RHODAMINE-123ACCUMULATION,1,Rhodamine-123 accumulation
NMDAEFFECT,1,NMDA effect
MDR,1,MDR
PROLIFERATIVERESPONSE,1,Proliferative response
LOGD65,1,LogD6.5
MBC<=999,1,MBC<=99.9
BWLMAX,1,BWLmax
PEAKRHGH,1,Peak rhGH
RATIOLIVERBLOOD,1,Ratio_liver/blood
BONEMINERALDENSITY,1,Bone mineral density
TAILVEINTOXICITY,1,Tail vein toxicity
IC05,1,IC05
GSTACTIVITY,1,GST activity
CI25,1,CI25
RANGEOFDEATHS,1,Range of deaths
PREVENTIVEINDEX,1,Preventive_index
LVP,1,LVP
PROLACTINRELEASERATE,1,Prolactin release rate
G2M,1,G2/M
LOGCDQR,1,Log CDQR
MOTILITY,1,Motility
MAXJUMPINGRATE,1,Max jumping rate
CHEMOSENSITIZINGACTIVITY,1,Chemosensitizing activity
ABSAC200UM,1,AbsAC200_uM
EPOXIDEFORMATION,1,Epoxide formation
ED60,1,ED60
CYTOSTATICACTIVITY,1,Cytostatic activity
HEPATOTOXICITY(TIMETOONSET),1,Hepatotoxicity (time to onset)
OLIGOMODIFIED,1,Oligo modified
MIC=>95,1,MIC=>95
VI,1,Vi
K-1DECREASE,1,K-1 decrease
ANTINOCICEPTION,1,Antinociception
SD,1,SD
NOOFRETCHES,1,No. of retches
KISO,1,Kiso
MTL,1,MTL
LOGKE,1,Log Ke
LESIONFREQUENCY,1,Lesion frequency
AD100,1,AD100
PCMAANTAGONISM,1,PCMA antagonism
UNWINDING,1,Unwinding
DILATION,1,Dilation
IZAARAARLV,1,IZ/AAR / AAR/LV
RADIOACTIVECONSTITUENTS,1,Radioactive constituents
SUPRESSION,1,Supression
HEPG2TOXASSAY-CC90,1,HEPG2TOX ASSAY - CC90
TMSHIFT,1,Tm shift
BILIARYEXCRETION,1,Biliary excretion
SERUMCREATININECONC,1,Serum creatinine conc
CONTROLRESPONSE,1,Control response
ODC,1,ODC
TIMETOPEAKTENSION,1,Time to peak tension
TTC,1,TTC
NOOFPOSITIVEANIMALS,1,No. of positive animals
ACIDSECRETION,1,Acid secretion
ACTUALCLEARANCE,1,Actual clearance
-LOGIC25,1,-Log IC25
PAWWEIGHTINCREASE,1,Paw weight increase
ANTIHYPERTENSIVE,1,Antihypertensive
TUMORLATENCY,1,Tumor latency
HGBLEVELS,1,Hgb levels
EXUDATE,1,Exudate
RELATIVEEFFECT,1,Relative effect
1N,1,1/n
KINACTKM,1,K inact/Km
EC025,1,EC0.25
LOGKOFF,1,Log koff
EXPRESSION,1,Expression
RELATIVEACTIVITY,1,Relative activity
BASELINE,1,Baseline
GI50RATIO,1,GI50 ratio
NR,1,NR
AVERAGERATIO,1,Average ratio
ANTAGONISTICACTIVITY,1,Antagonistic activity
SURVIVALS,1,Survivals
ARTERIALOCCLUSION,1,Arterial occlusion
K50,1,K50
MASSINDEX,1,Mass index
RATING,1,Rating
PKABN,1,pKa BN
RATEOFPHOSPHORYLATION,1,Rate of phosphorylation
CONTROLCELLNUMBER,1,Control cell number
COMPLETESPONTANEOUSREVERSAL,1,Complete spontaneous reversal
SYNERGISTICEFFECT,1,Synergistic effect
EC200,1,EC200
MEANLATENCY,1,Mean latency
IMPROVEMENT,1,Improvement
TOX50,1,Tox50
INVERSERELATIVEPOTENCY,1,Inverse relative potency
SUBCUTSCORE,1,Subcut score
SMT,1,SMT
CHANGEINSYSTOLICPRESSURE,1,Change in systolic pressure
LOGPNALK,1,Log PNalk
MBC100,1,MBC100
-LNK,1,-ln K
INFECTED,1,Infected
MOLARITY,1,Molarity
LOGK3,1,Log K3
SYNAPTICSITE,1,Synaptic site
DBP,1,DBP
EC2X,1,EC2x
FALLENTREATED,1,Fallen/treated
SURVIVORSATDAY4,1,Survivors at day 4
DNACLEAVAGE,1,DNA cleavage
MEANRELATIVEPOTENCY,1,Mean relative potency
RH,1,RH
SMAX,1,Smax
POPULATIONMITOTICCELLS(%),1,Population Mitotic Cells (%)
LOGILSMAX,1,Log ILS max
SC50,1,SC50
SGOTINCREASE-NUMBEROFREPORTS,1,SGOT Increase - Number of Reports
RATEOFDECREASE,1,Rate of decrease
DEATH,1,Death
ANTAGONISTEFFECT,1,Antagonist effect
IRRITATION,1,Irritation
LOGEFFECT,1,Log effect
THROMBOXANEB2LEVEL,1,Thromboxane B2 level
BPI,1,BPI
CHANGEOFCF,1,Change of CF
GOF,1,GOF
CHANGEINREACTIONTIME,1,Change in reaction time
LOGITP(CONC),1,Logit_p(conc)
HDL-C,1,HDL-C
RELATIVESIGNAL,1,relative signal
INFECTIOUSVIRUS,1,Infectious virus
MIDLOGLC50,1,MID log LC50
MTS50,1,MTS50
ANTIVIRALACTIVITY,1,Antiviral activity
[A],1,[A]
ACETYLATION,1,Acetylation
%AUC,1,%AUC
EC80,1,EC80
EDEMADENSITY,1,Edema density
SYNERGYEC50,1,Synergy EC50
HITSCORE,1,Hit score
B,1,B
EC40,1,EC40
CAC,1,CAC
ORALDIURETICACTIVITY,1,Oral diuretic activity
PREDRUG,1,Predrug
VZ,1,Vz
WEIGHTGAIN,1,Weight gain
LIVERCATALASE,1,Liver catalase
REDUCTIONINTG,1,Reduction in TG
AUCINF,1,AUC inf
PLASMATRIGLYCERIDE,1,Plasma_triglyceride
LOGDMAX,1,Log Dmax
BAT,1,BAT
EC12,1,EC12
PIC50(APP),1,pIC50(app)
AGGREGATES,1,Aggregates
PROLACTINTREATMENT,1,Prolactin treatment
PKA3,1,pKa3
ENZYMELEVEL,1,Enzyme level
RELATIVE,1,Relative
INCREASEINTEMPERATURE,1,increase in temperature
AGONISTACTIVITY,1,Agonist activity
POTENCYDYRK1AUM,1,Potency_Dyrk1a_uM
PROPERTY,1,Property
MIC95,1,MIC95
RATIOCC50IC50,1,Ratio CC50/IC50
PDR,1,PDR
CONTROLATTHEDOSEOF50MICROGMOUSE,1,Control at the dose of 5.0microg/mouse
RICESTEMLENGTH,1,Rice stem length
THY-1EXPRESSION,1,Thy-1 expression
CD90,1,CD90
RTW,1,RTW
SIGNFREEDOSE,1,Sign free dose
FUNCTIONALSELECTIVITY,1,Functional selectivity
SERUMCONC,1,Serum conc
DEOXYRIBOSEDEGRADATION,1,Deoxyribose degradation
DISPLACEMENT,1,Displacement
HEPATICBLOODFLOW,1,Hepatic blood flow
ISA,1,ISA
IT100,1,IT100
LOGPDODN,1,Log Pdod N
C13,1,C1.3
PCY,1,PCY
LC1,1,LC1
LOG1ID50,1,Log 1/ID50
TVI,1,TVI
PEC50DISS,1,pEC50 diss
HEPATOTOXICITY(BENIGNTUMOUR),1,Hepatotoxicity (benign tumour)
"ONSETFORSLEEP,MIN",1,"Onset for sleep, min"
MGMID,1,MG MID
CMI,1,CMI
12KCATKM,1,1/2Kcat/Km
REMAINS,1,Remains
LICKINGLATENCY,1,Licking latency
FREQUENCY,1,Frequency
ID16,1,ID16
RELATIVEFLORESCENCE,1,Relative florescence
GSH,1,GSH
TCVALUE,1,T/C value
PLD50,1,pLD50
FI5,1,FI5
MEANPAWDIAMETER,1,Mean paw diameter
AHA,1,AHA
PABC,1,P ABC
CONCENTRATIONINBRAIN,1,Concentration in Brain
-LOG(SOLUBILITY),1,-log(solubility)
PVCS,1,PVCs
-LOG(1EC50),1,-log(1/EC50)
SERUMHDL-CHOLESTEROL,1,Serum HDL-cholesterol
RESISTANCEINDEX,1,Resistance index
PRODRUGRECONVERSION,1,Prodrug reconversion
CHANGEINHEARTRATE,1,Change in heart rate
KDKI,1,KD/Ki
ABSAC1,1,AbsAC1
RD50,1,RD50
DELTABLOODPRESSURE,1,Delta blood pressure
UD,1,UD
SURVIVALSTOTAL,1,Survivals / total
E50,1,E50
LOG10(%HIA+10),1,log10(%HIA +10)
DIFFERENTIAL,1,Differential
%MAX(MEAN),1,%Max (Mean)
%TURNOVER,1,% turnover
SELECTIVEINDEX,1,Selective index
INTERNALISATION,1,Internalisation
PD2APP,1,pD2 app
BG,1,BG
RHRL,1,RH/RL
COUNTH,1,Count/h
NORMALIZEDABUNDANCESFORCOMPOUND,1,Normalized abundances for compound
ASATLEVELS,1,ASAT levels
C2,1,C2
TRACER,1,Tracer
MP,1,MP
TAC,1,TAC
GHPEAK,1,GH peak
POSTJUNCTIONALANTAGONISTPOTENCY,1,Postjunctional antagonist potency
LOG1KIAPP,1,Log 1/Ki app
NOOFPROTECTEDANIMALSTOTAL,1,No. of protected animals/total
CMAX(APP),1,Cmax(app)
MNTC,1,MNTC
INHIBITIONPOTENCY,1,Inhibition potency
INCREASE,1,Increase
TUMORFREESURVIVORS,1,Tumor free survivors
TCMIN,1,T/C min
DRUGDEGRADATION,1,Drug degradation
LHCONCENTRATION,1,LH concentration
HTD,1,HTD
BAPP,1,Bapp
MED,1,MED
NECROSISRESPONSE,1,Necrosis response
PGE2LEVEL,1,PGE2 Level
C30,1,c30
[3H]TDRUPTAKE,1,[3H] TdR uptake
T129,1,T1/29
DPDT(MAX),1,dp/dt(max)
TIMETORIGHTING,1,Time to righting
VPF,1,Vp/F
NOOFSTRAINS,1,No. of strains
VAGINALACTIVITY,1,Vaginal activity
PEC100,1,pEC100
ACTIVITYFACTOR,1,Activity Factor
ALPHAX10E,1,Alphax10E
AVERAGELESIONSCORE,1,Average lesion score
MARGINBEFOREONSETOFTACHYCARDIA,1,Margin before onset of tachycardia
RELATIVEVIABILITY,1,Relative viability
ABSAC40,1,AbsAC40
LOG10CFUDAY,1,log10cfu/day
OMNIMED,1,OMNI med
CD50,1,CD50
AVERAGEPROPORTION,1,Average proportion
KDL,1,KdL
COVALENTBINDING,1,Covalent binding
AVERAGEUTERINEWEIGHT,1,Average uterine weight
PIHYDROLYSIS,1,PI hydrolysis
SCWREDUCTION,1,SCW reduction
KRED,1,kred
PCACO2,1,Pcaco2
MAXDELTAFRP,1,Max delta FRP
TOTALPROTEIN,1,Total protein
AVERAGEGI50,1,Average GI50
AC10,1,AC10
VERTEBRALBLOODFLOW,1,Vertebral blood flow
STIMULATORYACTIVITY,1,Stimulatory activity
ACUTEELECTROSHOCKACTIVITY,1,Acute electroshock activity
LOGTCI,1,Log TCI
WEIGHTINCREASE,1,Weight increase
TD,1,TD
MEANPEAKAPTT,1,Mean peak APTT
INITIALRATES,1,Initial rates
FE,1,FE
SLEEPRATIO,1,Sleep ratio
MRP,1,MRP
NOOFPOSITIVECASES,1,No. of positive cases
CAV(SS),1,Cav(ss)
AUC(0-24)NORMALISED,1,AUC(0-24) normalised
MSIC,1,MSIC
COUNTS30MIN,1,Counts/30 min
PKAPY,1,pKapy
MITOTICFIGURES,1,Mitotic figures
HD100,1,HD100
CA2+SERUM,1,Ca2+ serum
NOPARTIAL,1,No. partial
QH,1,QH
ACTIVECULTURE,1,Active culture
QUENCHING,1,Quenching
LOG1CMC,1,log1/CMC
ALKALINEPHOSPHATASEACTIVITY,1,alkaline phosphatase activity
DELTALOGS,1,Delta logS
SLEEPLATENCY,1,Sleep latency
PAPPATOBPLUSINHIBITOR(MEAN),1,Papp A to B plus inhibitor (mean)
NOOFCOUNTS,1,No. of counts
-LOG(INH100-INH),1,-log(inh/100-inh)
C10AIRC10N2,1,C10 air/C10 N2
PAH,1,pAh
MBIC80,1,MBIC80
INTINSICACTIVITY,1,Intinsic activity
KT4,1,KT4
MEANBLOODPRESSURE,1,Mean blood pressure
SGPTINCREASE-NUMBEROFREPORTS,1,SGPT Increase - Number of Reports
RADIOACTIVEABSORPTION,1,Radioactive absorption
RANGE,1,Range
IC50(APP),1,IC50(app)
HMAX,1,Hmax
VMAXREL,1,Vmax rel
CKI,1,cKi
AUCP,1,AUC p
INCIDENCEOFRBCDECREASE,1,Incidence of RBC decrease
NOOFPOSRXNS,1,No. of pos rxns
ABSAC039UM,1,AbsAC0.39_uM
LETHALDOSE,1,Lethal dose
CSS-4W,1,Css-4w
FOLDACTIVITY,1,Fold_activity
REFIONCOSTATICINDEX,1,Ref I oncostatic index
NOOFIMPLANTSPREGNANCY,1,No. of implants/pregnancy
CELLULARUPTAKE,1,Cellular uptake
RSATR,1,RSA tR
URATE,1,URATE
ANESTHESIADURATION,1,Anesthesia duration
RATEOFHYDROLYSIS,1,Rate of hydrolysis
NOOFRATSDISPLAYINGDASYNDROME,1,No. of rats displaying DA syndrome
PL,1,PL
3H-TDRINCORPOLATION,1,3H-TdR incorpolation
CHANGEINTEMPARATURE,1,Change in temparature
MAXAGGREGATIONRESPONSE,1,Max aggregation response
EMETICEPISODES,1,Emetic episodes
UNCHANGED,1,Unchanged
RATIOKE,1,Ratio Ke
CT-LUCITAR,1,CT-luci TAR
CHANGEINTC,1,Change in TC
NOOFWRITHES,1,No. of writhes
NA+IONCONTENT,1,Na+ ion content
DELTAED50,1,Delta ED50
%INHIBITIONOFCONTROLVALUES(MEANN=2),1,% Inhibition of Control Values (Mean n=2)
MRC,1,MRC
PROTEIN-DNACOMPLEXFORMATION,1,Protein-DNA complex formation
REDUCTION,1,Reduction
TC25,1,TC25
NUCLEICACIDS,1,Nucleic acids
HEPSELIVERFUNCTIONTESTSABNORMAL,1,HepSE_liver function tests abnormal
CELLULARCONTENT,1,Cellular content
FU,1,Fu
FOLDSHIFT,1,Fold shift
DOSEG,1,Dose/g
GRACTIVITY,1,GR activity
CHI,1,CHI
D10,1,D10
CTAU,1,Ctau
GROWTHINHIBITON,1,Growth inhibiton
CATALEPSYSCORE,1,Catalepsy score
MIDPOINTDOSE,1,Midpoint dose
LOGKO,1,Log Ko
URINEK+,1,Urine K+
REDUCEDBP,1,Reduced BP
AGONISTINDEX,1,Agonist index
MINERALAPPOSITIONRATE,1,Mineral apposition rate
LALTEST,1,LAL test
SCORE,1,Score
AVERAGELATENCY,1,Average latency
PLASMAINTEGRAL,1,Plasma integral
MPC4,1,MPC4
RESISTANCE,1,Resistance
DESENSITISATION,1,Desensitisation
TOTALDOSE,1,Total dose
PAPP,1,Papp
INVERSEAGONISM,1,Inverse agonism
MINLYTICCONCENTRATION,1,Min lytic concentration
HED,1,HED
MYOBLASTWITHPARASITES,1,Myoblast with parasites
KD50,1,KD50
GLUCOSELOWERINGRELATIVETOPOSITIVECONTROL,1,Glucose lowering relative to positive control
NACLCONCENTRATION,1,NaCl concentration
LOG(IA),1,log(IA)
ENZYMEACTIVITY,1,Enzyme activity
RBADATA,1,RBA data
RT50,1,RT50
PNF,1,pNF
DECAY-TIMECONSTANT,1,Decay-time constant
LOG1CED90,1,log1/CED90
INHIBITION(AT100UM),1,inhibition (at 100uM)
DURATIONOFANESTHESIA,1,Duration of anesthesia
TESTEDCONTROL,1,Tested/Control
EC10X,1,EC10x
EXPLORATORYACTIVITY,1,Exploratory activity
BFU,1,BFU
URINENA+,1,Urine Na+
RELATIVEBINDING,1,Relative binding
OFNON-HDL-C,1,Of non-HDL-C
VISCOSITY,1,Viscosity
CSS-12W,1,Css-12w
THRESHOLDVALUE,1,Threshold value
Q50,1,Q50
NOOFMICEPROTECTED,1,No. of mice protected
EC,1,EC
KAKR,1,ka/kr
PLASMA-E2CONCENTRATION,1,Plasma-E2 concentration
POSTDRUG,1,Postdrug
AUCT,1,AUCt
MIC100,1,MIC100
FAFG,1,FaFg
HTSDATA,1,HTS data
LOG1D125(L1210)(MMKG-1),1,Log 1/D125 (L1210) (mM kg-1)
PDEINHIBITION,1,PDE inhibition
UNMETABOLIZED,1,Unmetabolized
IF,1,IF
PLC50,1,pLC50
LOG1ED40,1,Log 1/ED40
MEANEFFECTIVEDOSE,1,Mean effective dose
ACTIVTY,1,Activty
MEDIANLIFESPAN,1,Median life span
AVERAGESEIZURESCORE,1,Average seizure score
K13+K23,1,K13+K23
HYPOKINESIA,1,Hypokinesia
HEPSEBILIRUBINEMIA,1,HepSE_bilirubinemia
IFNGAMMACONCENTRATION,1,IFN gamma concentration
MAP,1,MAP
K+2KI,1,K+2/Ki
NOOFANIMALSPROTECTED,1,No. of animals protected
MTD2,1,MTD/2
CHANGEINOVARIANFOLLICULARATRESIA,1,Change in ovarian follicular atresia
ZONEOFINHIBITION,1,Zone of inhibition
LOGM,1,Log M
EMESISED,1,Emesis_ED
ILC,1,ILC
TERMINALELIMINATIONT12,1,Terminal elimination t1/2
NETCELLKILL,1,Net cell kill
INTRINSICACTVITY,1,Intrinsic actvity
LOGPTA,1,Log PTA
HEMOLYSIS,1,Hemolysis
ABSOLUTERATIO,1,Absolute ratio
FREE,1,Free
GID75,1,GID75
MAXCONTRACTION,1,Max contraction
HEPATOTOXICITY(ACUTE),1,Hepatotoxicity (acute)
FDI,1,FDI
PNMED,1,p nMED
NOOFDEATHS,1,No. of deaths
MEANNOOFREVERTANTS,1,Mean no. of revertants
ERP,1,ERP
CONSUMPTION,1,Consumption
MOLARCONTENT,1,Molar content
NOOFAXONALPOINTS,1,No. of axonal points
AD99,1,AD99
CURESTOTAL,1,Cures/total
VASOCONSTRICTIONEFFECT,1,Vasoconstriction effect
2XTG,1,2x TG
VELOCITY,1,Velocity
EBD20,1,EBD20
INFLECTIONPOINT,1,Inflection point
INITIALRATE,1,Initial_rate
CMR,1,CMR
INCIDENCECOUNT,1,Incidence_count
REDUCTIONINMOVEMENT,1,Reduction in movement
IC100,1,IC100
T12INCREASE,1,T1/2 increase
DELTALOGIC50,1,deltalogIC50
ALDHACTIVITY,1,AlDH activity
T-CC,1,T-C/C
GLUCOSENORMALISATION,1,Glucose normalisation
MEANINCREASEINSURVIVAL,1,Mean increase in survival
MEANVOLUMEOFHINDPAWS,1,Mean volume of hind paws
DURATIONOFINCREASEINSLA,1,Duration of increase in SLA
HIA,1,HIA
IC50REDUCTION,1,IC50 reduction
PROSTAGLANDINE2LEVEL,1,Prostaglandin E2 level
AFFINITYSTATE1,1,Affinity state 1
RATIO[3H]:TUBULIN,1,Ratio_[3H]:tubulin
VASORELAXANTEFFECT,1,Vasorelaxant effect
K-1APP,1,k-1 app
DECREASERVR,1,Decrease RVR
MTD,1,MTD
CELLSATURATION,1,Cell saturation
AP50,1,AP50
CONTROLCURRENT,1,Control current
ABSAC50UM,1,AbsAC50_uM
PKX,1,pKx
LETHALTOXICITY,1,Lethal toxicity
TRANSPORTERDEGRATECONST(K),1,Transporter deg rate const (k)
SALURETICPOTENCY,1,Saluretic potency
THERMODYNAMICSOLUBILITY,1,Thermodynamic solubility
TIMETOOFFSET,1,Time to offset
THRESHOLDCONCENTRATION,1,Threshold concentration
N20FORMED,1,N20 formed
RC10,1,RC10
EF90,1,EF90
MTXEQUIVALENT,1,MTX equivalent
THYLPOSITIVECELLSSPLEEN,1,Thylpositive cells/spleen
VSS,1,Vss
CPE50,1,CPE50
MODIFICATIONOFADSORBEDDRUG,1,Modification of adsorbed drug
I13,1,I13
HYPOTHERMICEFFECT,1,Hypothermic effect
TEWL,1,TEWL
BW,1,BW
KOBSX10E2,1,K obs x10e2
EXTERNALNUCLEOSIDE,1,External nucleoside
ANTIEMETICACTIVITY,1,Antiemetic activity
ANTAGONISTEFFICACY,1,Antagonist efficacy
ASF,1,ASF
SYNERGY,1,Synergy
LEASTDOSE,1,Least dose
PHAGOCYTOSIS,1,Phagocytosis
INHIBITIONPOTENCYTII,1,Inhibition potency T/II
DISTRIBUTIONRATIO,1,Distribution ratio
PROT,1,PROT
POESCORE,1,POE score
MICROSOMALSTABILITY,1,Microsomal stability
RELATIVEMETABOLICRATE,1,Relative metabolic rate
DOM,1,DOM
MTS,1,MTS
PIC50,1,pIC50
URINEOUTPUT,1,Urine output
THROMBUSWEIGHT,1,Thrombus weight
NA+INACTIVATION,1,Na+ inactivation
MAXEFFICACY,1,Max efficacy
T09,1,t0.9
T12IV,1,T1/2 iv
LOGFU,1,logFu
RMP,1,RMP
MBC50,1,MBC50
MEANINDEX,1,Mean index
-LOGCONCENTRATION,1,-Log concentration
ALKALINEPHOSPHATASEINCREASE-NUMBEROFREPORTS,1,Alkaline Phosphatase Increase - Number of Reports
NLCK,1,NLCK
BODYWEIGHT,1,Body weight
MTDRATIO,1,MTD ratio
DANERATIO,1,DA/NE ratio
INDUCEDFREQUENCY,1,Induced frequency
ISAAR,1,IS/AAR
EMPTY,1,Empty
BLOODLACTATE,1,Blood lactate
LIPASE,1,LIPASE
GLYCAEMIAEVOLUTION,1,Glycaemia evolution
TOTALSCORE,1,Total score
BLOODACH,1,Blood AcH
ACTIVITYA,1,Activity A
LDL,1,LDL
ABC,1,ABC
MRD,1,MRD
MAXIOPREDUCTION,1,Max IOP reduction
FANA,1,Fana
NOOFTRANSFERS,1,No. of transfers
ABSAC35,1,AbsAC35
PKA4,1,pKa4
PDHACTIVEPDHTOTAL,1,PDH active/PDH total
LIPIDPEROXIDATION,1,Lipid peroxidation
MTDTGI50,1,MTD/ TGI50
CRRELEASE,1,Cr release
CLUF,1,CLu/F
NOOFROSETTES100JURKATTCELLS,1,No. of rosettes/100 Jurkat T cells
ED25,1,ED25
TRANSPORTINHIBITION,1,Transport inhibition
NUCLEARCATARACT,1,Nuclear cataract
FUNCTION,1,Function
ERPOBSERVATIONS,1,ERP observations
F(CAVE),1,f(Cave)
URINEVOLUME,1,Urine volume
CYTOPROTECTIVEEFFECT,1,Cytoprotective effect
RAPP,1,rapp
REDUCTIONINRBS,1,Reduction in RBS
NA+OUTPUT,1,Na+ output
TRANSACYLATIONRATE,1,Transacylation rate
POSTSYNAPTICANTAGONIST,1,Postsynaptic antagonist
OFFSETTIME,1,Offset time
ANTI-INFECTIOUSEFFECT,1,Anti-infectious effect
IRREVERSIBILITY,1,Irreversibility
CELLNUMBER,1,Cell number
LOG10CCID50,1,log10CCID50
I75,1,I75
CSAT,1,Csat
IC200,1,IC200
KHO,1,kHO
HORIZONTALSCREEN,1,Horizontal screen
HD40,1,HD40
URINARYOUTPUT,1,Urinary output
BMAXL,1,BmaxL
%HEPATICBLOODFLOW,1,%hepatic blood flow
LOWERINGACTIVITY,1,Lowering activity
FALLING,1,Falling
PEAKSTRIATALUPTAKE,1,Peak striatal uptake
DOPAMINELEVEL,1,Dopamine level
NC,1,NC
NADHOXIDATION,1,NADH oxidation
IONENHANCEMENT,1,Ion enhancement
CHANGEINRATBLOODSUGAR,1,Change in rat blood sugar
PEC15,1,pEC15
CYTOTOXICITYIC50,1,Cytotoxicity IC50
RATIOIC50,1,Ratio IC50
ELEVATIONOFTHRESHOLD,1,Elevation of threshold
LOGK'O,1,Log k'o
MONOLE,1,MONOLE
LESIONS,1,lesions
REDUCTIONFACTOR,1,Reduction factor
CHANGEINLVDPDT,1,Change in LV dp/dt
BODYTEMPDROP,1,Body temp drop
ALBGLOB,1,ALBGLOB
MGC,1,MGC
T12EFF,1,t1/2eff
MEDIANSURVIVALTIME,1,Median survival time
RECTALTEMPERATURE,1,Rectal temperature
MED98,1,MED98
RATECONSTANTAPP,1,rate constant app
PREJUNCTIONALAGONISTPOTENCY,1,Prejunctional agonist potency
VMAXH,1,VmaxH
RSA,1,RSA
ALBUMIN,1,Albumin
LOGPC,1,logPc
DELTABG,1,Delta BG
PKIC,1,pKic
PEI,1,PEI
LESIONLENGTH,1,Lesion length
FRESHWEIGHT,1,Fresh weight
ACTIVITYSCORE,1,Activity Score
ANTI-EMETIC,1,Anti-emetic
CC50%,1,CC50%
EPINEPHRINELEVEL,1,Epinephrine level
DELTAHEARTRATE,1,Delta heart rate
NOOFSENSITIVEANIMALS,1,No. of sensitive animals
INH,1,INH
LOSSOFINACTIVATION,1,Loss of inactivation
RADIOACTIVITY,1,Radioactivity
KMH,1,KmH
INHIBITIONACTIVITY,1,Inhibition activity
KK,1,k/K
PO2,1,PO2
PIC50(MM),1,pIC50(mM)
ALB,1,ALB
MAXREV,1,Max rev
LOGS0,1,logS0
ORGANWEIGHT,1,Organ weight
FEMURWEIGHT,1,Femur weight
LOG(1D40),1,log(1/D40)
TED,1,TED
"KC,U",1,"kC,U"
EIR,1,EIR
DECREASEINCVR,1,Decrease in CVR
ANTITUMOURACTIVITY,1,Antitumour activity
IP3-SENSITIVECA2+STORES,1,IP3-sensitive Ca2+ stores
CTS,1,CTS
TURNS,1,Turns
CHOLESTEROLCONTENT,1,Cholesterol content
CYTOKINETICRESPONSE,1,Cytokinetic response
AVERAGESURVIVALTIME,1,Average survival time
ROOTGALLINGINDEX,1,Root_galling_index
HSASHIFT,1,HSA shift
CLEARANCE,1,Clearance
GPGBTENSION,1,GPGB tension
MFC999,1,MFC99.9
GLUCOSELEVEL,1,Glucose level
ACTIVITYB,1,Activity B
ILSMAXOD,1,ILSmaxOD
TLM,1,TLm
IC37,1,IC37
IFN,1,IFN
NBTPOSITIVITY,1,NBT positivity
GABAAGONISM,1,GABA agonism
RELATIVEVALUE,1,Relative value
1KREL,1,1/krel
DURATIONOFPEAKACTION,1,Duration of peak action
VSSF,1,Vss/F
CONTROLSURVIVALSTOTAL,1,Control survivals/total
ARTHRITICSCORE,1,Arthritic score
POSTANTIBIOTICEFFE,1,Post Antibiotic Effe
PC1,1,pC1
CDOG,1,CDOG
NOOFMICECURED,1,No. of mice cured
HEPG2TOXASSAY-CC50,1,HEPG2TOX ASSAY - CC50
Q12,1,Q1/2
SUPPRESSIONOFPARASITEMIA,1,Suppression of parasitemia
LC80,1,LC80
SGPTACTIVITY,1,SGPT activity
PKINC,1,pKinc
TOTALCOENZYME,1,Total coenzyme
IC95,1,IC95
TUMORLIVERRATIO,1,Tumor/liver ratio
DURATIONOFIMMOBILITY,1,Duration of immobility
LOGMBC,1,Log MBC
ACTIVATIONTIME,1,Activation time
ATTACKS,1,Attacks
EC2,1,EC2
CFRRATING,1,CFR rating
SHR,1,SHR
CMVYIELD,1,CMV yield
MEANGRAFTSURVIVAL,1,Mean graft survival
RP,1,RP
CA2+EXCRETION,1,Ca2+ excretion
NOOFOCCLUSIONS,1,No. of occlusions
ADOMETDC,1,AdoMetDC
RELATIVESTABILITY,1,Relative stability
PLASMACA2+,1,Plasma Ca2+
NOOFMICEALIVE,1,No. of mice alive
PXI50,1,pXI50
MAXINHIBITIONCONCENTRATION,1,Max inhibition concentration
IVP,1,IVP
RELATIVEPEROXIDATION,1,Relative peroxidation
O2PRODUCTION,1,O2 production
MEANAORTICFLOW,1,Mean aortic flow
ABRATIO,1,A/B ratio
%INHIBITIONOFCONTROLAGONISTRESPONSE,1,% Inhibition of Control Agonist Response
LOGPOCTA,1,Log Poct A
KIHIGH,1,Ki high
NCOR1RECRUITMENT,1,NcoR1_recruitment
SNA,1,SNA
ALPHA-LIPOPROTEINCHOLESTEROL,1,Alpha-lipoprotein cholesterol
1KMAX,1,1/kmax
TUBULIN,1,Tubulin
CTSINCREASE,1,CTS increase
DELTAF,1,Delta F
RESULT,1,Result
GROWTHDELAY,1,Growth delay
COLLATERALINDEX,1,Collateral index
CIT,1,CIT
EC25(UNBOUND),1,EC25(unbound)
MEANRESPONSEMIN,1,Mean response/min
MMC,1,MMC
BRAINLEVELS,1,Brain levels
TOXICITYSURVIVORS,1,Toxicity Survivors
GROSSLOGKILL,1,Gross log kill
FMEC,1,fMEC
E100,1,E100
AUEC,1,AUEC
HEPATOTOXICITY(ASSOCIATIONWITHVASCULARDISEASE),1,Hepatotoxicity (association with vascular disease)
TVR,1,TVR
POTENCYCLK3UM,1,Potency_Clk3_uM
ORIGINALAMPLITUDE,1,Original amplitude
KI,1,Ki
THYMIDINEUPTAKE,1,Thymidine uptake
CLONES,1,Clones
VARIATIONCONTROL,1,Variation/Control
HDL-CCHANGE,1,HDL-C change
MODULATIONFACTOR,1,Modulation factor
MBIC90,1,MBIC90
KELIM,1,k_elim
PLASMAHALFLIFE,1,Plasma half life
HVACONTROL,1,HVA control
C10N2,1,C10 N2
LYSISDIAMETER,1,Lysis diameter
TUBULINPOLYMERIZATION,1,Tubulin polymerization
TOTALCELLCOUNT,1,Total Cell Count
HYPERSENSITIVITYFACTOR,1,Hypersensitivity factor
RFU,1,RFU
UN,1,UN
NOOFEMETICEPISODES,1,No. of emetic episodes
COMBINATIONINDEX,1,Combination_index
-LOGK05,1,-Log K0.5
INITIALBLOODPRESSURE,1,Initial blood pressure
TRIGLYCERIDES,1,Triglycerides
-LOG(1MED),1,-log(1/MED)
FAUC,1,fAUC
CHLORINEUPTAKE,1,Chlorine uptake
MIC=>80,1,MIC=>80
RATSTURNING,1,Rats turning
MEANLOGCONCENTRATIONRATIO,1,Mean log concentration ratio
EMAXH,1,EmaxH
LDED80,1,LD/ED80
CELLPROLIFERATIONIC50,1,Cell Proliferation IC50
C0DOSE,1,C0/dose
PARASITAEMIA,1,Parasitaemia
NE,1,NE
IDTHYROID,1,ID/thyroid
CARDIACFREQUENCY,1,Cardiac frequency
INHIBITION(%OFCONTROL),1,Inhibition (% of control)
MBC,1,MBC
RETRACTIONTIME,1,Retraction time
FLEA,1,Flea
HAR,1,HAR
HCMVYIELD,1,HCMV yield
EIC50,1,EIC50
IRONMOBILIZED,1,Iron mobilized
RELATIVESEAPACTIVITY,1,Relative SEAP activity
REDUCEDCYP7A1GENEEXP,1,Reduced_Cyp7a1_gene_exp
KAMINE,1,K amine
DNACLEAVAGEACTIVITY,1,DNA cleavage activity
DALEVEL,1,DA level
KMX10E3,1,Km x10e3
FT>MIC,1,fT>MIC
MEANDAYAPPEARANCEOFLESIONS,1,Mean day appearance of lesions
RELATIVEVMAX,1,Relative Vmax
DECREASEINHEARTRATE,1,Decrease in heart rate
RECEPTOROCCUPANCY,1,Receptor occupancy
LDLO,1,LDLO
INHIBITIONPERIOD,1,Inhibition period
ACTIVATION(%OFCONTROL),1,Activation (% of control)
PLASMAIL-6,1,Plasma_IL-6
PROCONVULSANTACTION,1,Proconvulsant action
BODYTEMPERATUREDROP,1,Body temperature drop
MEANLOGD,1,mean log D
CSS-48H,1,Css-48h
ALPHAT12(APP),1,alphat1/2(app)
ILS,1,ILS
SELECTIVITYCOEFFICIENT,1,Selectivity coefficient
ONSETTIME,1,Onset time
T>EC50,1,T>EC50
TRAPSTAINING,1,TRAP staining
CALCIUM,1,CALCIUM
MOLECULARELLIPTICITY,1,molecular ellipticity
NOOFSENSITIVE,1,No. of sensitive
LOGRAI,1,Log RAI
RAC,1,RAC
REACTIVITY,1,Reactivity
ED30DBP,1,ED30 DBP
BODYWEIGHTREDUCTION,1,Body weight reduction
AP,1,AP
ACTIVITY(NMOLMGOFPROTEINMIN),1,Activity (nmol/mg.of protein. min)
HEPSECOMBINEDSCORES,1,HepSE_Combined Scores
PLAQUEREDUCTION,1,Plaque reduction
TGI50,1,TGI50
FBP,1,FBP
POPULATIONPYKNOSEDNUCLEI(%),1,Population Pyknosed Nuclei (%)
MED999,1,MED99.9
INTACT,1,Intact
MC100,1,MC100
BLOODLEVEL,1,Blood level
MEANCHANGE,1,Mean change
DNABINDING,1,DNA binding
KBB,1,Kbb
MIC=<80,1,MIC=<80
STRETCHES,1,Stretches
NITRICOXIDE,1,Nitric oxide
DRUGCONC(LDL),1,Drug Conc (LDL)
EXCRETIONNA+,1,Excretion Na+
LOGKP,1,log Kp
ANTIFUNGALACTIVITY,1,Antifungal activity
TAILFLICK,1,Tail flick
LOG2MIC,1,Log2 MIC
LOGESA,1,Log ESA
TREATMENTPERIOD,1,Treatment period
OFDOSEEXCRETED,1,Of dose excreted
ID(PERGOFTISSUE),1,ID (per g of tissue)
CELLPROLIFERATIONEC50,1,Cell Proliferation EC50
APPARENTENZYMEACTIVITY,1,Apparent enzyme activity
UREANITROGENCONCENTRATION,1,Urea Nitrogen Concentration
DAYS,1,Days
PROGRESSEDTUMORS,1,Progressed tumors
GM,1,GM
EC20,1,EC20
ANIMALSCURED,1,Animals cured
OPSINSHIFTACTIVITY,1,Opsin shift activity
COLONICWEIGHT,1,Colonic weight
SURVIVALRATE,1,Survival rate
COCAINE,1,Cocaine
RATIOAUC(INF),1,Ratio AUC(inf)
ACTIVE,1,Active
POPULATIONMITOCHONDRIADIFFERENT-PHENOTYPE(%),1,Population Mitochondria Different-Phenotype (%)
SALURETICACTIVITY,1,Saluretic activity
ED999,1,ED99.9
PROGRESSEDREMISSION,1,Progressed remission
ANTITUMORACTIVITY,1,Antitumor activity
BLOODGLUCOSE,1,Blood glucose
LYSOZYMERELEASE,1,Lysozyme release
LD20,1,LD20
SERUMCREATININE,1,Serum creatinine
IMMOBILITY,1,Immobility
LOGFC,1,LogFC
EFFECTIVEMOLARITY,1,Effective molarity
REDUCTIONINVIRUSTITER,1,Reduction in virus titer
DPDT20,1,dP/dt20
CONCENTRATIONINSERUM,1,Concentration in serum
CLEARANCEBLOOD,1,Clearance_blood
MECHANISMBASEDINHIBITION,1,mechanism based inhibition
THERAPEUTICINDICES,1,Therapeutic indices
KI'UNCOMP,1,Ki' uncomp
%MAX,1,%max
AUCLASTDOSE,1,AUClast/dose
PID50,1,pID50
KDPPH,1,kDPPH
AED,1,AED
DELTACPP,1,Delta CPP
PRESSORRESPONSE,1,Pressor response
KINACTKIAPP,1,kinact/KIapp
SKINRESPONSE,1,Skin response
DILICONCERN,1,DILI_Concern
AWC,1,AWC
LOAD,1,Load
AGONISTICACTIVITY,1,Agonistic activity
CFR,1,CFR
CORR,1,Corr
DOSECONVERTED,1,Dose converted
UTEROTONICACTIVITY,1,Uterotonic activity
MAXUTEROTONICRESPONSE,1,Max uterotonic response
INJECTEDDOSEORGAN,1,Injected dose/organ
TOXTOTAL,1,tox/total
TOXDSURV,1,ToxD/Surv
CONNECTIVITYDENSITY,1,Connectivity density
%DOSE,1,% dose
ERYTHEMAINDUCTION,1,Erythema induction
INHIBITION(ATCONCENTRATIONM),1,Inhibition (at concentration M)
CO2,1,CO2
INCREASEINCAMP,1,Increase in cAMP
POTENCYMEAN,1,Potencymean
HEPSEHEPATICFAILURE,1,HepSE_hepatic failure
RBLOODPLASMA,1,Rblood_plasma
FC,1,FC
RELATIVEINTRINSICACTIVITY,1,Relative intrinsic activity
CONTROLDMSOMITOTICCELLS(%),1,Control DMSO Mitotic Cells (%)
LOG1ED50,1,Log 1/ED50
FRS50,1,FRS50
SALDIURETICACTIVITY,1,Saldiuretic activity
BUNCHANGEBY,1,BUN_CHANGE_BY
EXPERIMENTALDPM,1,Experimental DPM
PRIMARYRESPONSE,1,Primary response
DELTAHR,1,Delta HR
CELLPROTEIN,1,Cell protein
KD(APP),1,Kd(app)
KIAH,1,KiAH
VMAX,1,Vmax
CELLKILL,1,Cell kill
MSTINCREASE,1,MST increase
C70,1,C70
MLD50,1,MLD50
HEMATOTOXICITY,1,Hematotoxicity
INFI,1,In/Fi
TRNAPEAKEXCLUSION,1,tRNA peak exclusion
DELTAH-V,1,Delta H-V
FPDC,1,FPDc
ELECTROLYTEEXCRETION,1,Electrolyte excretion
PAPPATOB(MEAN),1,Papp A to B (mean)
TMPDECREASE,1,TMP.decrease
AMBULATIONSCORE,1,Ambulation score
ASCITESVOLUME,1,ascites volume
P24,1,p24
IA50,1,IA50
PHOSPHORYLATIONRATE,1,Phosphorylation rate
TIMEAFTERDOSE,1,Time after dose
DRUGUPTAKEDOSE,1,Druguptake/dose
TOTALPERIPHERALRESISTANCE,1,Total peripheral resistance
NOOFMICERECEOVERED,1,No. of mice receovered
RELATIVERATEOFDECOMPOSITION,1,Relative rate of decomposition
%ACTIVITY,1,% activity
MEDIAAREA,1,Media area
MEANTOTALRESORPTION,1,Mean total resorption
VIGOURINDEX,1,Vigour_index
LOGTGI,1,Log TGI
RATE,1,Rate
RECEPTORSTATE,1,Receptor state
IC30,1,IC30
IC50RELATIVE,1,IC50 relative
MELANOTROPICACTIVITY,1,Melanotropic activity
KIK0KI,1,kik0/Ki
RATEACCELERATION,1,Rate acceleration
MTD4,1,MTD/4
INHIBITORYPOTENCY,1,Inhibitory potency
NOOFCURED,1,No. of cured
